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Abstract 
Asthma is characterized using the spirometry measurement of the forced expiratory volume 
in one second (FEV1).  Simple and inexpensive, FEV1 provides a global estimate of lung 
function but this metric cannot regionally identify airways responsible for airflow 
limitation, asthma symptoms or control.  Work that brought about an understanding that 
airway abnormalities are heterogeneously distributed within the lung in asthma patients 
has motivated the development of pulmonary imaging approaches, such as hyperpolarized 
helium-3 (3He) and xenon-129 (129Xe) magnetic resonance imaging (MRI).  These methods 
provide a way to visualize and quantify lung regions accessed by gas during a breath-hold, 
as well as those not accessed, referred to as “ventilation defects.”  Despite the strong 
foundation for the use of MRI in asthma clinical care, clinical translation has been inhibited 
in part due to the current limited clinical and physiological understanding of ventilation 
defects.  Accordingly, our objective was to better understand the structural determinants 
and clinical consequences of MRI ventilation defects observed in asthma and to provide a 
foundation for imaging to guide clinical decisions and asthma therapy.  We evaluated the 
effect of gas properties on ventilation defects.  In asthmatics, we compared hyperpolarized 
3He and 129Xe MRI before and after bronchodilator administration and showed greater gas 
distribution abnormalities using 129Xe compared to 3He before bronchodilation.  The 
temporal behavior of asthma ventilation defects was then investigated by generating 
personalized temporal-spatial pulmonary function maps from 3He MR images acquired on 
three occasions.  Persistent and intermittent defects were visualized and quantified using 
this tool and were recognized as potential intermediate endpoints or targets for treatment.  
We then evaluated clinical and emerging computed tomography-derived airway 
morphology measurements in asthmatics with and without defects.  Ventilation defects 
were observed in two-thirds of well-controlled asthmatics who had worse lung function, 
increased airway inflammation, airway hyperresponsiveness and greater airway wall 
thickness than asthmatics without ventilation defects.  Acknowledging that asthma control 
is the primary goal of asthma treatment, we investigated the relationship, and established a 
link between worse ventilation and poor control.  These findings provide a better 
understanding of asthma ventilation defects and strongly support their potential as a novel 
treatment target. 
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CHAPTER 1 
Asthma is a chronic and phenotypically heterogeneous disease of intermittent respiratory 
symptoms and airflow limitation triggered by various stimuli, and is characterized by 
bronchial hyperresponsiveness and airways inflammation.1,2  
1 INTRODUCTION 
1.1 Motivation and Overview  
Asthma is the most common chronic respiratory disease in Canada, accounting for 
approximately 80% of chronic respiratory disease,3 affecting 8.1% or 2.4 million 
Canadians in 2014 (Figure 1-1).4   
Adapted from Life and Breath: Respiratory Disease in Canada 2008.5 
 
Asthma is most common during childhood and affects more than 13% of Canadian 
children.  In 2014, 9.2% of females and 7.0% of males were diagnosed with asthma.4  In 
2009, 228 asthma-related deaths were reported in Canada.  Internationally, an estimated 
300 million people currently have asthma and this is expected to increase to 400 million 
by 2025.6  Asthma is estimated to account for one in 250 deaths worldwide.6  Due to its 
high prevalence, asthma has an enormous economic and healthcare burden for the patient 
and society, with high rates of healthcare resource utilization that vary widely with respect 
to age and disease severity.  Asthma is also a major cause of hospitalization and repeat 
hospitalization in Canada (Figure 1-2).  Annually, the number of patients hospitalized for 
asthma is comparable to hospitalization due to chronic obstructive pulmonary disease 
Figure 1-1  Proportion of all respiratory diseases due to specific conditions in Canada. 
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(COPD) and angina.7  However, in contrast to COPD and angina, asthma-related 
hospitalizations are much more common under the age of 19, accounting for approximately 
65% of all asthma admissions.7  Asthma was a contributing factor in approximately 10% 
of hospital admissions for children under the age of 5 and 8% for those aged 5 to 14 years.5  
In 1990, the estimated cost for asthma in Canada was $504 to $648 million, of which $306 
million were direct costs.8  A study by Ismalia and colleagues indicated that the annual 
direct cost per asthma patient in Canada ranges from $366 to $647.9  
 
 
Figure 1-2  Repeat hospitalizations and hospitalization cases by age and condition in 
Canada.  
The left plot shows the number of patients with a single hospitalization, one repeat 
hospitalization and two or more repeat hospitalization by condition at first admission.  The 
right plot shows the distribution of hospitalization cases by condition and age.  Adapted 
from the Canadian Institute for Health Information’s (CIHI) publication entitled Health 
Indicators 2008.7 
 
Despite decades of active research and the staggering societal burden of asthma described 
above, the mechanism of disease and its distribution within the asthmatic lung are still not 
fully understood.  Imaging and post-mortem evidence allude to the possibility that airway 
abnormalities in asthma are heterogeneously distributed within the lung.  Currently, 
however, airways disease worsening and response to therapy in asthma are commonly 
evaluated using the forced expiratory volume in one second (FEV1) – a simple and 
inexpensive measurement of airflow obstruction.  As a result, current and newly-developed 
asthma therapies are mainly directed towards improvements in FEV1, but it is well-known 
that this global measurement does not capture the regional heterogeneity of airway 
abnormalities that may be responsible for asthma control and future risk of exacerbations 
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and lung function decline.  In other words, using current clinical tools, there is no way to 
measure regional lung abnormalities in asthma, making it difficult if not impossible to 
develop, test and guide regional asthma therapies.  Satisfying the uncertain notion that all 
airways in asthma are equally abnormal and exhibit the same temporal behavior, current 
therapies are geared to all airways.   
Pulmonary functional magnetic resonance imaging (MRI), using inhaled helium-3 (3He) 
and xenon-129 (129Xe) gas, provides a way to quantify gas distribution in vivo and it has 
the advantage that it shows exactly where functional abnormalities, termed “ventilation 
defects,” are located in the asthmatic lung.  In spite of this potential, medical imaging has 
played a very limited role in asthma research, treatment development and patient care, and 
for a variety of reasons, the numerous advantages of imaging have not been translated to 
clinical use.  Regardless of the gas used for imaging, the exact etiology of ventilation 
defects in asthma is poorly understood.  A clear understanding of ventilation defects is 
absolutely necessary prior to the clinical translation of hyperpolarized gas imaging 
methods.  Armed with such an understanding, there is the potential to use functional MRI 
to guide asthma treatment, predict treatment outcomes, identify new treatment targets and 
better understand the asthmatic lung regionally and its response to asthma treatment.  With 
the challenges impeding clinical translation in mind, the overarching objective of this thesis 
was to better understand the underlying structural determinants and clinical consequences 
of MRI ventilation defects observed in asthma and to provide a foundation for imaging to 
guide clinical decisions and asthma therapy.   
In this Chapter, the relevant background knowledge necessary to understand and motivate 
the original research presented in Chapters 2 to 5 will be summarized.  It will begin with a 
general overview of the respiratory system’s structural and functional responsibilities (1.2) 
before focusing on the pathophysiology and underlying disease mechanisms of asthma 
(1.3).  Subsequently, standard clinical measurements of asthma (1.4), diagnosis and 
classification schemas (1.5) and standard of care treatment regimens (1.6) will all be 
introduced.  The benefits and limitations of currently available imaging techniques will be 
discussed with respect to their influence on better understanding the asthmatic lung and 
contribution of imaging biomarkers that can be used to guide asthma treatment (1.7).  
Finally, the specific hypotheses and objectives of this thesis will be introduced (1.8).  
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1.2 The Respiratory System: Structure and Function 
Similar to all organ systems, the functions of the respiratory system are multifaceted and 
range from protection against inhaled pathogens to gas exchange.  While the respiratory 
system includes the oral and nasal cavities, the lungs, the airways and the muscles 
responsible for facilitating breathing, here I will elaborate on the structure and function of 
the airways and the alveoli.  The airways are a pipeline which connect the external 
environment with the alveoli where gas exchange can occur across the blood-gas interface.  
By the process of ventilation, the main function of the airways and the alveoli is to deliver 
oxygen and remove carbon dioxide from the blood to maintain normal partial pressure of 
oxygen and carbon dioxide levels in the arterial blood.  
1.2.1 The Airways: Conducting and Respiratory Zones 
Inhaled air enters the respiratory system via the nasal or oral passages which converge on 
the pharynx followed by the larynx.  Beyond the upper airways, as shown in Figure 1-3, 
the lower airways are divided into the conducting zone and the respiratory zone based on 
their structural and functional characteristics.  The conducting zone is responsible for 
carrying inhaled air to the respiratory zone where gas exchange can occur. 
Conducting Zone  
The conducting zone consists of the first sixteen airway generations, beginning with the 
trachea (generation zero) and ending with the terminal bronchioles (generation 16).10  It is 
important to emphasize that conducting zone airways do not directly participate in gas 
exchange, but instead their sole function is to conduct and humidify air.  Due to its function, 
this zone is considered anatomic deadspace - approximately 150 mL of air resides here.10  
The trachea is a long, cartilaginous and muscular conduit that follows the larynx that 
directly supplies air to lungs and bifurcates asymmetrically into the left and right main 
bronchi that supply the left and right lung respectively.  Subsequently, the main bronchi 
divide into the lobar bronchi that supply the five lobes of the lung, three of which are in 
the right lung (upper, middle and lower) and two of which are in the left lung (upper and 
lower).  The lobar bronchi then divide into the segmental bronchi that supply air to their 
corresponding bronchopulmonary segment that is structurally and functionally 
independent.  Bronchi are not individually named distal to the segmental bronchi where 
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they become narrower, shorter and more numerous as they branch dichotomously to reach 
all areas of the lung.  Secondary lobules or lung sub-segments are supplied by the small 
bronchi.  It is at this point where important structural changes occur.  Beyond the small 
bronchi, the air passages no longer contain cartilage but become embedded in the lung 
parenchyma for structural support.  Terminal bronchioles are the smallest category of air 
passages without alveoli and are the final conduit of the conducting zone.   
 
 
Figure 1-3 Characteristics of the air passages. 
Adapted from Lumb A. Nunn’s Applied Respiratory Physiology, Fifth edition.11   
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Respiratory Zone  
The respiratory zone is the last seven generations (generations 17-23) of the airway tree.10  
In contrast to the conducting zone, the air passages of the respiratory zone contain alveoli 
which facilitate gas exchange.  As shown in Figure 1-3, the respiratory bronchioles begin 
the respiratory zone and have an increasing number of alveoli budding from their muscular 
walls before giving rise to the alveolar ducts which precede the alveolar sacs that are 
completely lined with alveoli.  A pulmonary acinus is considered a single anatomical unit 
consisting of a terminal bronchiole and its subsequent respiratory bronchioles, alveolar 
ducts and sacs.  The average human lung contains 30,000 acini,12 each containing 
approximately 10,000 alveoli which together make up most of the lung volume, ranging 
from approximately 2.5 to 3 L at rest.10  
1.2.2 Site of Gas Exchange: The Alveoli 
The alveoli are the site of gas exchange and are the terminal ends of the airway tree found 
on the respiratory bronchioles, alveolar ducts and alveolar sacs.  It has been estimated that 
480 million (range: 274-790 million) alveoli exist in the average human lung and that the 
average size of a single alveolus is 4.2x106 µm3 (range: 3.3-4.8 µm3) or 200 µm in 
diameter.13  The blood-gas interface of the alveoli is comprised of two layers: the alveolar 
epithelium and the capillary endothelium, which facilitates the movement of oxygen and 
carbon dioxide between the alveolar airspace and capillary plasma.  This interface is 
extremely thin (0.2-0.3 µm) with a large surface area (50-100 m2), making it well-suited 
for efficient exchange of oxygen and carbon dioxide by passive diffusion, according to the 
principles of Fick’s law.   
1.2.3 Ventilation 
Gas reaches the blood-gas interface by the process of ventilation, which is the exchange of 
air between the external environment and the alveoli by bulk flow.10  During ventilation, 
air flows because of pressure gradients that exist between the atmosphere and alveoli.  
Inspiration occurs when the inspiratory muscles actively contract and alveolar pressure 
decreases; whereas expiration occurs when the inspiratory muscles passively relax and 
alveolar pressure increases.  The total amount of air that enters the lungs and resides in the 
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conducting and respiratory zones upon inspiration is termed tidal volume (VT) and is 
approximately 0.5 L.  As shown in Equation 1-1, total ventilation is the total volume of 
air leaving the lungs each minute and is calculated as the ventilation rate multiplied by VT.   
Equation 1-1 
Total ventilation [L/minute] = Ventilation rate × VT 
As discussed above, with each exhalation, approximately 0.15 L of “stale” air from the 
respiratory zone remains in the conducting airways and is first to commute back to the 
alveoli upon subsequent inspiration.  As shown in Equation 1-2, alveolar ventilation 
represents the amount of “fresh” air that reaches the alveoli to participate in gas exchange 
and it is therefore used to more accurately quantify ventilation efficiency by taking into 
account the dead space volume (VD).   
Equation 1-2 
Alveolar ventilation [L/minute] = Ventilation rate × (VT − VD) 
For a healthy adult, the ventilation rate, VT and VD are 12-20 breaths/minute, 0.5 L and 
0.15 L respectively.14  At 15 breaths/minute, the total ventilation is 7.50 L/minute and the 
alveolar ventilation is 5.25 L/minute.  This means that although 7.5 L of fresh air enters 
the respiratory system, only 5.25 L actually reach the alveoli.    
1.3  Pathophysiology of Asthma 
The word “asthma” originated from the Greek word aazein, meaning “to breathe with open 
mouth or to pant” generalizing that any patient experiencing dyspnea was asthmatic.15   
Given that asthma is as old as antiquity, it is not surprising that the definition and our 
understanding of the disease has evolved significantly from initial accounts as evidenced 
by the quotes below.  Today, with nearly 300 million asthmatics globally, confusion and 
controversy continue to surround the definition of asthma.16 
“Asthma is the inability to breathe without making noise.” 
Aulus Cornelius, 1st Century BC 
“If from running, gymnastic exercises, or any other work, the breathing becomes difficult, 
it is called Asthma.” 
Aretaeus the Cappodocian, 2nd Century AD 
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“Asthma is paroxysmal dyspnea of a peculiar character, generally periodic, with intervals 
of healthy respiration between attacks.” 
Henry Hyde Salter, 1860 
“Asthma is a special form of inflammation of the small bronchioles.” 
Sir William Osler, 1892 
“Asthma is a disease characterized by an increased responsiveness of the trachea and 
bronchi to various stimuli and manifested by widespread narrowing of the airways that 
changes in severity either spontaneously or as a result of therapy. 
American Thoracic Society, 1962 
 
1.3.1 Definition of Asthma 
In the 2015 Global Initiative for Asthma (GINA) report, the Global Strategy for Asthma 
Management and Prevention,1 asthma is defined as: “A heterogeneous disease usually 
characterized by chronic airway inflammation.  It is defined by a history of respiratory 
symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over 
time and in intensity, together with variable expiratory airflow limitation.”  This definition 
consists of four components: symptoms, variable airflow obstruction, airway 
hyperresponsiveness and airway inflammation.17  As described in the literature, this 
relatively broad and non-specific definition encompasses many different asthma 
phenotypes identified according to environmental triggers, inflammatory processes and 
clinical features.  In a recent review highlighting the heterogeneity of asthma, common 
clinical phenotypes were classified as trigger-induced phenotypes (occupational asthma, 
cigarette smoke induced asthma, air pollution induced asthma and exercise induced 
asthma), symptom-based phenotypes (exacerbation-prone, persistent airflow limitation, 
cough-variant, adult-onset and the obese asthma) and biomarker-based phenotypes 
(eosinophilic and neutrophilic asthma).18  Phenotyping of asthma is becoming more 
important than ever due to the development of targeted and phenotype specific approaches 
to asthma therapy.   
1.3.2 Causes and Risk  
There is no single gene or environmental exposure that causes asthma,19 although the onset 
most commonly begins in childhood.  Instead, it is widely accepted that host and 
environmental factors interact to cause asthma.19  Unfortunately this interplay is complex 
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and poorly understood.  Numerous host factors have been identified that influence the risk 
of asthma; these include genetic polymorphisms,20,21 family history of asthma,22 sex,23 
race24 and obesity.25  Similarly, numerous environmental factors have been identified that 
influence the risk of asthma; these include aeroallergen sensitization,26 respiratory 
viruses,27,28 early life microbial exposures,29,30 cigarette smoke,31 air pollution,32 vitamin D 
deficiency,33 antioxidants34 and stress.35      
1.3.3 The Asthmatic Lung 
Asthma is considered a chronic disorder that is confined to the airways and involves a 
complex interaction of airflow obstruction, airway hyperresponsiveness and inflammation 
that results in symptoms.2  As shown in Figure 1-4, as compared to a healthy airway, the 
airway lumen of an asthmatic is narrowed and obstructed, restricting airflow into and out 
of the lungs.  Characteristic structural abnormalities throughout the airway walls of 
asthmatics include goblet cell hyperplasia,36 subepithelial layer thickening,37 smooth 
muscle hyperplasia and hypertrophy,38 submucosal gland hyperplasia and hypersecretion39 
and angiogenesis.40  Together, these structural abnormalities, in conjunction with 
inflammatory changes, lead to bronchial thickening and edema as well as increased mucus 
production and bronchoconstriction, all of which contribute to the airflow obstruction 
typically found in asthma.  The mechanisms that are responsible for airflow obstruction in 
asthma include bronchoconstriction by airway smooth muscle; luminal obstruction by 
mucus and debris; and inflammation and remodeling of the airway wall.  
Bronchoconstriction occurs due to smooth muscle contraction, which results in a reduction 
in airway caliber by epithelial folding, ultimately increasing airflow resistance.  
Bronchoconstriction may occur in response to various stimuli that include allergens or 
irritants such as exercise and cold air. Airway hyperresponsiveness is an “exaggerated” 
bronchoconstrictor response to various stimuli such as those mentioned above.  While 
airways throughout the bronchial tree can be involved, the magnitude of airway narrowing 
and resultant airflow obstruction is temporally intermittent but may become persistent.41   
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Figure 1-4  Airway pathology in a healthy and an asthmatic airway. 
Histological (sectioned and stained using Movat’s pentachrome stain) and corresponding 
schematic representation of airway structures in healthy and asthmatic airways.  The 
asthmatic airway has structural remodeling, including goblet cell hyperplasia, subepithelial 
fibrosis and increased smooth muscle. 
Adapted from JV Fahy Nature Reviews 2015.42   
 
Airway inflammation has a fundamental role in the pathophysiology of asthma and 
involves the interaction of many cell types and mediators.  Although the cellular 
mechanisms behind airway inflammation are beyond the scope of this thesis, important 
inflammatory cells include lymphocytes, mast cells, eosinophils, neutrophils, dendritic 
cells, macrophages and epithelial cells.  Additionally, important inflammatory mediators 
include chemokines, cytokines, cysteinyl-leukotrienes and nitric oxide.  Immunoglobulin 
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E (IgE) is the antibody responsible for activation of allergic reactions and is important in 
the development of persistent inflammation.  
1.4  Clinical Measurements of Asthma 
Clinical measurements of asthma play an important role in diagnosis, categorizing disease 
severity and evaluating the effectiveness of medications to manage disease.  Currently, no 
single clinical tool can be used to adequately diagnose and manage asthma.  Instead, an 
integrated approach is employed which combines objective measurements of pulmonary 
function, bronchial responsiveness, airway inflammation and subjective symptom and 
quality-of-life questionnaires.  
1.4.1 Global Measurements of Pulmonary Function 
In a physician’s office and hospital pulmonary function laboratory, various aspects of lung 
function can be evaluated by performing cost-effective pulmonary function testing.  Global 
spirometry measurements and lung volumes play an important role in the diagnosis and 
management of asthma.  It is important to acknowledge that pulmonary function tests are 
dependent on patient effort, limiting their use in children and cognitively impaired 
populations.  With appropriate coaching by a trained pulmonary function technologist, the 
majority of patients can perform adequate pulmonary function manoeuvres for which 
acceptability and reproducibility criteria have been published.   
1.4.1.1 Spirometry 
Spirometry, the gold standard measurement of lung function, is an important diagnostic 
and disease monitoring test that measures volume and flow of air during inhalation and 
exhalation manoeuvres.  As shown in Figure 1-5, spirometry is often performed using a 
hand-held spirometer (Figure 1-5A) and the most commonly performed manoeuvre is the 
forced exhalation manoeuvre (Figure 1-5B).  This is performed by having a participant 
breathe normally and then inspire fully, filling their lungs completely, followed by a hard 
and fast forced exhalation.  It is important that the participant exhale as hard and as fast as 
they can and that they continue exhaling until they cannot expel any more air.  At this point, 
the end of test criteria has been met.  The duration of exhalation may extend well beyond 
15 seconds, depending on the severity of the participants airflow obstruction.  The most 
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widely reported indices derived from the forced exhalation manoeuvre are the forced vital 
capacity (FVC), the FEV1 and the ratio of FEV1 to FVC (FEV1/FVC).  As shown in Figure 
1-5B, FVC is a measure of the total volume of air that can be forcefully exhaled from full 
inspiration, whereas FEV1 is a measure of the maximum volume of air that can be forcefully 
exhaled in the first second of the manoeuvre.  Both FVC and FEV1 are measured in litres 
and are also commonly expressed as a percentage of the reference value based on the 
patient’s age, height, sex and ethnicity.  Extensive spirometry standardization criteria have 
been compiled by the ATS/ERS Task Force and are now widely applied.43  
 
 
Figure 1-5  Handheld spirometer and typical volume-time spirogram tracing. 
FEV1=forced expiratory volume in one second; FVC=forced vital capacity.  
 
1.4.1.2 Lung Volumes and Capacities 
Static lung volumes and capacities are identified on a typical volume-time spirogram 
tracing as shown in Figure 1-6B.  While the majority of these can be directly measured by 
spirometry (tidal volume (TV), inspiratory reserve volume (IRV), expiratory reserve 
volume (ERV), vital capacity (VC) and inspiratory capacity (IC)), this tes0t cannot 
determine the functional residual capacity (FRC), residual volume (RV) or total lung 
capacity (TLC).  All lung volumes are defined as follows:  TV is the volume of gas 
exchanged at mouth during a normal inhalation or exhalation during tidal breathing; IRV 
is the volume of gas that can be inhaled from the end of a normal inhalation during tidal 
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breathing; ERV is the volume of gas that can be exhaled from the end of a normal 
exhalation during tidal breathing; VC is the volume of gas exchanged at the mouth between 
a full inspiration and full exhalation; IC is the volume of gas that can be inhaled from the 
end of a normal exhalation while tidal breathing; FRC is the volume of gas remaining in 
the lungs at the end of a normal exhalation while tidal breathing; RV is the volume of gas 
remaining in the lungs at the end of a full exhalation; and TLC is the volume of gas in the 
lungs at the end of a full inhalation. 
As previously alluded to, alternative nitrogen washout, gas dilution or body 
plethysmography techniques are required to measure FRC, from which RV and TLC can 
subsequently be derived by performing “linked” spirometry manoeuvres.44  As shown in 
Figure 1-6A, a body plethysmograph is an airtight chamber that can accommodate the 
patient comfortably inside.  Briefly, the linked manoeuvre is performed by having the 
participant breathe normally and then perform a series of gentle pants against a closed 
shutter initiated at FRC.  After sufficient panting has been achieved the shutter will open 
and the participant can then resume tidal breathing followed by a full inhalation and slow 
full exhalation from which ERV and IVC can be measured.  FRC is obtained by applying 
the principles of Boyle’s law relating pressure and volume in an isothermal environment.44  
RV can then be calculated as FRC minus ERV, and TLC can be calculated as the sum of 
FRC and IC. 
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Figure 1-6  Body plethysmograph and typical volume-time spirogram tracing identifying 
lung volumes. 
TV=tidal volume; IRV=inspiratory reserve volume; ERV=expiratory reserve volume; 
VC=vital capacity; IC=inspiratory capacity; FRC=functional residual capacity; 
RV=residual volume; TLC=total lung capacity. 
 
1.4.1.3 Airway Resistance  
Airway resistance (Raw) is a measure of the resistance to flow within the airways and is 
defined in Equation 1-3 as the ratio of the driving force of airflow (difference in alveolar 
and mouth pressure) to the flow rate (measured at the mouth) and can be quantified using 
several techniques.  Raw is influenced by resistance in the mouth, pharynx, larynx, large 
airways and small airways11 and is most commonly indirectly quantified using whole body 
plethysmography.45  Raw can be derived from the specific airway resistance (sRaw) and 
FRC as shown in Equation 1-4, both of which can be directly measured using 
plethysmography.  sRaw is a corrected index that describes airway resistance regardless of 
lung volume.46  Following open shutter panting, the inverse slope of the plot of flow rate 
versus box pressure is sRaw.  In healthy adults, Raw typically falls within 0.6-2.4 
cmH2O·s·L
-1.47  Both Raw and sRaw are increased in the presence of inflammation, mucus 
secretion, and bronchoconstriction.47   
Equation 1-3 
Airway resistance (Raw) [cmH2O·s·L
-1]=
Alveolar pressure - Mouth pressure [cmH2O]
Flow rate (V̇) [L·s-1]
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Equation 1-4 
Airway resistance (Raw) [cmH2O·s·L
-1]= 
Specific airway resistance (sRaw) [cmH2O·s]
Functional residual capacity (FRC) [L]
 
1.4.1.4 Inert Gas Washout 
Single-breath48 and multiple-breath49 inert gas washout techniques (SBW and MBW, 
respectively) were first employed more than 65 years ago to measure lung volumes and 
ventilation heterogeneity.  Although both tests are relatively simple, the MBW test is more 
informative and has been more commonly used.  MBW involves measuring the washout 
concentration of an inert tracer gas from the lungs during normal tidal breathing.  The tracer 
gas can be endogenous, such as nitrogen (N2), and washed-out of lungs by breathing 100% 
oxygen.  Alternatively, if the tracer gas is exogenous, such as sulfur hexafluoride (SF6) or 
helium (He), it must be washed-in prior to being washed out of the lung by breathing room 
air.  As shown in Figure 1-7, with each tidal breath of the washout phase, there is a decrease 
in the concentration of the exhaled tracer gas (N2 in this example) and when the gas 
concentration has decreased to 1/40th of the starting concentration, the test is complete.  
The manoeuvre is generally completed with the participant sitting upright and breathing 
through a mouthpiece while wearing nose clips.  
 
Figure 1-7  Example of a typical inert gas washout machine and inert gas multiple breath 
washout tracing. 
The MBW tracings display tidal volume (lower plot) and the corresponding nitrogen gas 
(N2) concentration (upper plot).  With each breath there is a decrease in the peak expiratory 
N2 concentration.  
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The most commonly reported MBW derived measurement is the lung clearance index 
(LCI), which is thought to be representative of whole lung ventilation heterogeneity.50  LCI 
is the number of FRC lung turnovers needed to clear the lungs of the inert marker gas and 
it is calculated as the cumulative expired gas volume (CEV) divided by FRC.51  Additional 
metrics that reflect ventilation heterogeneity in the conductive and acinar lung zones 
(Scond and Sacin, respectively) can be derived using sophisticated phase III slope analysis 
of the MBW tracing.52  Additional outcomes include FRC, trapped gas volume and closing 
capacity.  
Inert gas washout measurements are becoming particularly attractive due to their feasibility 
in the pediatric population53,54 and increased sensitivity to early disease changes55,56 while 
offering complementary information to standard pulmonary function tests.  Taken together, 
MBW indices of ventilation heterogeneity in asthmatics are elevated in comparison to 
healthy controls;57-59 are independent determinants of airway hyperresponsiveness;60 
improve with bronchodilation57,61 and inhaled corticosteroids;62,63 and worsen during 
exacerbations.64  Unfortunately, these measurements cannot regionally localize the site of 
functional abnormalities. 
1.4.2 Bronchial Responsiveness 
Reversibility of airflow obstruction and bronchial hyperresponsiveness are features of 
asthma airway pathophysiology that can be objectively evaluated.  The assessment of these 
disease characteristics are important for diagnosing asthma, categorizing disease severity 
and evaluating the effectiveness of asthma medications to manage disease. 
1.4.2.1 Assessing Bronchodilator Reversibility 
Evidence of reversible airflow obstruction is a key consideration when establishing a 
diagnosis of asthma.  The primary objective of reversibility testing is to determine whether 
a participant’s lung function is improved following bronchodilation, assessed by 
performing spirometry pre- and post-bronchodilator administration.  Baseline spirometry 
is performed after the participant has withheld their medications for an appropriate duration 
as advised by the ATS/ERS Task Force.43  Subsequently, an inhaled short-acting beta-
agonist (four 100μg doses of albuterol/salbutamol) is delivered to the participant prior to 
performing post-bronchodilator spirometry 15 minutes later.  Reversibility is commonly 
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expressed as the absolute change in FEV1 and FVC or as a percent of the pre-bronchodilator 
value, as shown in Equation 1-5.  It is generally accepted that a clinically-relevant positive 
bronchodilator response is warranted when the post-bronchodilator increase in FVC and/or 
FEV1 is ≥ 12% and 200mL from baseline.65    
Equation 1-5 
% reversibility= [
(Post-bronchodilator value) − (Pre-bronchodilator value)
(Pre-bronchodilator value)
] × 100 
 
 
1.4.2.2 Assessing Airway Hyperresponsiveness 
In addition to bronchodilator reversibility, airway hyperresponsiveness is another defining 
characteristic of asthma.66  Methacholine and exercise challenge testing are two of the most 
widely used methods to assess airway hyperresponsiveness for which standardized 
guidelines have been published.67   
Methacholine Challenge  
Methacholine induces bronchoconstriction by acting on airway smooth muscle receptors.  
Similar to reversibility testing, a methacholine test (MCT) should be performed after the 
participant has withheld their medications for an appropriate duration as advised by ATS 
guidelines.67    Aerosolized methacholine is inhaled through a nebulizer and the MCT is 
completed according to the established two-minute tidal breathing or five-breath dosimeter 
protocol described in detail by ATS.67  Briefly, baseline spirometry is first performed to 
assess pre-MCT FEV1 and subsequently the diluent or first dose of methacholine 
(0.03mg/mL) is administered.  After the nebulization has been completed, spirometry is 
repeated.  If FEV1 has not declined by 20%, the next highest concentration of methacholine 
should be delivered.  This procedure is repeated with increasing concentrations of 
methacholine until FEV1 has declined by more than 20% of baseline or until the highest 
concentration of methacholine (16mg/mL) has been reached.  
The primary outcome measure for the MCT is the provocative concentration of 
methacholine that causes a 20% decrease in FEV1 (PC20), from which the degree of airway 
hyperresponsiveness can be interpreted clinically.  Calculated according to Equation 1-6,   
PC20 ≥16mg/mL is indicative of normal airway hyperresponsiveness, whereas a PC20 
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≤4mg/mL is indicative of abnormal airway hyperresponsiveness.67  Intermediate values (< 
16 and >4 mg/mL) indicate borderline airway hyperresponsiveness and should be 
interpreted with caution.67   
Equation 1-6 
PC20 [mg/mL]=antilog [logC1+
(logC2-logC1)(20-R1)
R2-R1
] 
C1 = second-to-last methacholine concentration; C2 = last methacholine concentration; 
R1 = percent fall in FEV1 after C1; R2 = percent fall in FEV1 after C2. 
 
Exercise Challenge  
Exercise induces bronchoconstriction in approximately 80% of asthmatics.68  In contrast 
to methacholine, exercise is an indirect activator of smooth muscle constriction induced by 
airway dehydration and subsequent mediator release.69  Exercise challenge testing is 
preferentially performed using a treadmill or cycle ergometer as described in detail by 
ATS, although the protocols are not well standardized or uniformly implemented.67  
Briefly, 6-8 minutes of exercise (4-6 minutes at a pre-determined target intensity) should 
be completed while breathing cool (<25ºC) dry air.  The primary outcome measure for an 
exercise challenge is FEV1.  A post-exercise decreased in FEV1 >10% is considered 
abnormal and a decrease >15% is indicative of exercise-induced bronchoconstriction.  
1.4.3 Inflammation 
1.4.3.1 FeNO 
Nitric oxide (NO) is produced in the lungs and can be detected in the exhaled breath of 
humans, as first described in 1991.70  Although the exact pathophysiological role of NO in 
the lung is complex and poorly understood, its production increases in the presence of 
inflammation.71  The relationship between NO and eosinophilic airway inflammation has 
been extensively studied and has been correlated with blood eosinophils and eosinophils 
present in induced sputum, bronchoalveolar lavage and biopsies.72-77  Fractional exhaled 
nitric oxide (FeNO) is a well-established, simple, noninvasive and highly reproducible 
quantitative biomarker of eosinophilic airway inflammation that is ideally suited for serial 
monitoring of patients with airways disease.  Among the most important clinical 
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applications of FeNO are its ability to aid in the diagnosis of eosinophilic asthma and to 
predict corticosteroids-responsiveness.  Asthmatics have higher levels of NO in their 
exhaled breath as compared to healthy controls.78,79  Although not all asthmatics have 
eosinophilic inflammation, those who do tend to have elevated FeNO levels and are much 
more likely to benefit from inhaled corticosteroid (ICS) therapy than those with normal 
FeNO levels.80  According to the 2011 ATS recommendations, FeNO < 25 ppb indicates 
that eosinophilic inflammation and responsiveness to corticosteroids are unlikely, whereas 
FeNO > 50 ppb indicates that eosinophilic inflammation and responsiveness to 
corticosteroids is likely.81  Intermediate values (≥ 25 and ≤ 50 ppb) should be interpreted 
with caution.  Currently, a clinically important difference in FeNO levels has not been 
determined.  Standardized for clinical use, ATS/ERS guidelines for the measurement of 
FeNO have been published.82,83  
1.4.4 Validated Questionnaires 
1.4.4.1 Asthma Control Questionnaire 
The Asthma Control Questionnaire (ACQ)84 was designed to measure asthma control and 
the change in asthma control over time or in response to treatment.  It has been widely 
adopted as a clinical trial endpoint.85-87  The questionnaire evaluates control during the 
previous week and contains five symptom-related questions (night awakenings by 
symptoms, symptoms on waking, activity limitation, dyspnea and wheeze), pre-
bronchodilator FEV1%pred and daily rescue bronchodilator use, each scored on a seven-
point scale.  The ACQ score is calculated as the mean of five, six or seven questions to 
generate the ACQ-5 score (pre-bronchodilator FEV1%pred and daily rescue bronchodilator 
use omitted), ACQ-6 score (pre-bronchodilator FEV1%pred omitted) and ACQ-7 score 
respectively.  Scores range from zero (totally controlled) to six (severely uncontrolled).  
Asthmatics whose score ranges from 0.0 to 0.75 are considered well-controlled and those 
whose score is >1.5 are poorly-controlled.88  The cross-over point between well-controlled 
and poorly-controlled asthma is near 1.0, therefore asthmatics whose score ranges from 
0.75 to 1.5 fall into a ‘grey zone’ and should be interpreted with caution.88  The minimum 
clinically-important difference is 0.5.89   
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In addition to the ACQ, there are numerous additional questionnaires used to evaluate 
asthma control.  Some of the more common questionnaires are the Asthma Control Test 
(ACT), the Asthma Control Scoring System (ACSS), the Asthma Therapy Assessment 
Questionnaire (ATAQ), the 30-Second Asthma Test and Lara Asthma Symptom Scale 
(LASS).  
1.4.4.2 Standardized Asthma Quality of Life Questionnaire  
The Standardized Asthma Quality-of-Life Questionnaire (AQLQ(S))90 was designed to 
measure asthma-related quality-of-life.  The questionnaire evaluates quality-of-life during 
the previous two weeks and consists of 32 questions encompassing four subscore domains 
(12 questions on symptoms; 11 questions on activity limitation; 5 questions on emotional 
function and 4 questions on exposure to environmental stimuli).  A range of matters are 
assessed including activity limitation, amount of discomfort due to chest tightness, concern 
about having asthma, fear of not having access to asthma medication and symptoms from 
exposure to cigarette smoke.  Four different seven-point Likert-type response scales are 
used, ranging from one (totally limited/a very great deal/all of the time/severely limited, 
most not done) to seven (not at all limited/none/none of the time/not limited, have done 
all).  The AQLQ total score is calculated as the mean of all 32 questions and the domain 
subscores are the mean of the questions in the domain.  The minimum clinically-important 
difference is 0.5,91 although the validity of this threshold is still being discussed.  
Importantly, the AQLQ(S) has been widely adopted as a clinical trial endpoint.92 
The AQLQ preceded the AQLQ(S) and there are now additional variations including the 
Mini Asthma Quality of Life Questionnaire (Mini AQLQ) and Acute Asthma Quality of 
Life Questionnaire (Acute AQLQ).  In addition to the various AQLQ instruments, there 
are numerous additional questionnaires used to evaluate asthma-related quality-of-life.  
Some of the more common questionnaires are the Asthma Bother Profile (ABP), Asthma 
Impact Survey (AIS-6), Living with Asthma Questionnaire (LWAQ), Modified Asthma 
Quality of Life-Marks (M-AQLQ-Marks), Asthma Short Form (ASF), St. George’s 
Respiratory Questionnaire (SGRQ) and Airways Questionnaire-20 (AQ-20). 
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1.4.4.3 Dyspnea 
Dyspnea is a common symptom of asthma and the Modified Medical Research Council 
(mMRC)93 and Borg dyspnea scales94 are commonly used to assess it severity.  The 
Modified Medical Research Council dyspnea scale is one of the most commonly used 
questionnaires to assess dyspnea.  It uses a simple five-point scale which assesses the 
impact or burden of dyspnea on the patient.  Scores range from zero (breathless with 
strenuous exercise) to four (too breathless to leave the house, or breathless when dressing).  
Similarly, the modified 0-10 Borg dyspnea scale assesses how patients perceive their 
severity of dyspnea using a simple 10-point scale, with scores ranging from zero (nothing 
at all) to ten (maximal).   
1.5  Diagnosis and Classification of Asthma 
Asthma is particularly challenging to diagnose and classify due to its multiple overlapping 
pathologies that are heterogeneous between individuals (Figure 1-8).95  Although 
spirometry is most often employed to diagnose asthma, it is difficult to use spirometry to 
further classify asthma into respective phenotypic categories. With the advent of novel 
biomarkers, such as FeNO, accurate classification of asthma sub-phenotypes is possible.95  
As depicted schematically in Figure 1-8, a multifaceted approach and a gamut of 
biomarkers is required to accurately diagnose and subsequently classify asthma.96   
 
 
Figure 1-8  Asthma is a heterogeneous disease consisting of several overlapping pathologies 
necessitating multiple biomarkers to accurately diagnose and phenotype patients. 
Adapted from SJ Wadsworth, J Asthma Allergy 2011.  
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1.5.1 Asthma Diagnosis 
A history of variable respiratory symptoms, the presence of airflow obstruction or 
hyperresponsiveness, reversibility of obstruction and exclusion of alternative diagnoses 
constitutes a positive diagnosis of asthma.1,2  Respiratory symptoms indicative of asthma 
include a combination of wheeze, dyspnea, chest tightness and cough that are temporally 
intermittent and tend to worsen at night.1,2  In reality, asthma is still commonly diagnosed 
on the basis of symptoms alone.  In Ontario, Canada, only 43% of asthmatics diagnosed 
by a physician performed spirometry.97  Failure to include objective assessments in the 
diagnostic process is likely contributing to  overdiagnosis; evidence of this was observed 
in a longitudinal study across eight Canadian cities that concluded approximately 33% of 
individuals with a physician diagnosis of asthma did not have asthma when objectively 
assessed.98  Ideally, a diagnosis should be rendered through evaluation of the patient’s 
respiratory symptoms, medical history, physical examination and spirometry.1,2  
Independently, symptoms, medical history and physical exams cannot accurately exclude 
and/or confirm a diagnosis of asthma.  Spirometry is absolutely required to objectively 
assess airflow obstruction, its severity and reversibility.96  Accordingly, spirometry should 
be performed prior to and following inhalation of a short-acting bronchodilator to indicate 
the degree of obstruction and reversibility according to ATS/ERS standards.65  
Common differential diagnoses include chronic obstructive pulmonary disease, alternative 
upper airway diseases (e.g. rhinitis) and obstructions involving the large (e.g. vocal cord 
dysfunction) and small airways (e.g. bronchiolitis).2   
1.5.2 Asthma Control 
Asthma control refers to the extent that symptoms of asthma can been reduced or removed 
by treatment.17  Control encompasses two domains: current clinical control and future risk 
of exacerbations and lung function decline.17  Symptom control is gauged by evaluating 
the frequency of day-time symptoms, night-time symptoms, short-acting beta-agonist 
(SABA) use and activity limitation.  Risk is gauged by evaluating the frequency and 
severity of previous exacerbations.  Taken together, a patient’s asthma is considered to be 
well-controlled if he/she is symptom free without activity limitation or exacerbations and 
does not experience variable lung function.  As described above, multiple standardized 
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questionnaires have been designed to assess the degree of asthma control.  Some of the 
most commonly used questionnaires are the ACQ and ACT.  There is no general consensus 
between national and international guidelines regarding degrees of asthma control.  For 
example, the GINA report of 2015 used categories of “well-controlled,” “partly-
controlled” and “uncontrolled;”1 whereas the National Heart, Lung, and Blood Institute 
(NHLBI) ERP3 used “well-controlled,” “not well-controlled” and “very poorly-
controlled.”2  Regardless, the primary goal of asthma treatment is the achievement and 
maintenance of disease control.  
1.5.3 Asthma Severity 
Asthma severity can be defined by the intensity of treatment required to control asthma.17,99  
Severity can be classified as intermittent, mild, moderate and severe according to the lowest 
level of treatment required to achieve asthma control.  Shown below in Table 1-1, 
intermittent, mild, moderate and severe asthma is asthma that is well-controlled while 
receiving the indicated treatment regimen.  The indicated treatment regimens can be 
extrapolated to reflect the six-step and five-step treatment strategies proposed by the 
NHLBI100 and GINA,1 respectively.  Severe asthma is defined as asthma which requires 
treatment with high dose ICS and LABA (and/or OCS) to achieve asthma control, or 
asthma that remains uncontrolled despite maximum therapy.101  As defined, asthma 
severity can only be assessed after a patient has been on regular controller treatment for 
several months.  
Table 1-1  Classification of asthma severity. 
 Intermittent Mild Moderate Severe 
Lowest level of 
treatment required 
to achieve control  
SABA as 
needed 
Low-dose ICS or 
other low intensity 
treatment 
Low- to moderate-
dose ICS and 
LABA 
High dose ICS 
and LABA ± 
OCS 
Treatment strategy Step Allocation 
NHLBI EPR3100 1 2 3 or 4 5 or 6 
GINA1 - 1 or 2 3 4 or 5 
NHLB, Expert Panel Report 3 of the National Heart, Lung and Blood Institute; GINA, 
Global Initiative for Asthma; ICS, inhaled corticosteroids; LABA, long acting beta-
agonists; OCS, oral corticosteroids.  Adapted from DR Taylor, Eur Respir J 2008.99   
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1.6  Treating Asthma 
Similar to the majority of chronic lung diseases, no existing asthma treatments are 
preventative or curative.  Accordingly, the primary goal of asthma treatment is the 
achievement and maintenance of disease control while minimizing the risk of future 
exacerbations or lung function decline.  The majority of asthma can be well-controlled 
using a SABA for rescue during acute onset bronchoconstriction and ICS for chronic 
control.  However, as asthma severity is increased, treatment becomes more complex and 
requires personalized, phenotype-specific additive therapies.  
Towards the goal of asthma treatment, evidence-based stepwise approaches have been 
developed by the NHLBI100 and GINA1 (Figure 1-9) to guide treatment decisions. Both 
guidelines suggest that a continuous control-based management cycle (Figure 1-9), 
consisting of iterative patient assessment, treatment and review is necessary to ensure 
asthma is adequately treated.  Following each assessment, treatment can be “stepped-up” 
when asthma in not well-controlled and “stepped-down” when asthma is well-
controlled.102  The breadth of asthma medications can be categorized as controllers, 
relievers and add-on therapies.  Corticosteroids, beta-agonist bronchodilators, 
theophylline, leukotriene receptor antagonists, immunomodulators and bronchial 
thermoplasty are briefly described below. 
 
25 
 
 
Figure 1-9  2015 GINA stepwise approach to asthma treatment. 
ICS, inhaled corticosteroids; SABA, short-acting beta2-agonists; LABA, long-acting beta-
agonists; OCS, oral corticosteroids; anti-IgE, anti-immunoglobin E therapy; theoph, 
theophylline; LTRA, leukotriene receptor antagonists.  
Adapted from GINA Global Strategy for Asthma Management and Prevention, 2015.1 
 
1.6.1 Controller & Reliever Treatment  
1.6.1.1 Corticosteroids 
Corticosteroid anti-inflammatory therapy is the most effective therapy for asthma.1,2  
Corticosteroids block various inflammatory pathways, suppressing cytokine production, 
recruitment of eosinophils and the release of inflammatory mediators.41  In the 1990s, their 
efficacy was evidenced by their ability to safely reduce airflow obstruction, symptoms, 
emergency department visits, hospitalizations and asthma-related deaths, to improve 
asthma control and quality-of-life and to decrease airway hyperresponsiveness and 
exacerbation frequency.103-107  Response to this treatment is variable between asthmatics 
and is related to the type of underlying inflammation.  Asthmatics with neutrophilic 
predominant inflammation are commonly corticosteroid-resistant;108 whereas asthmatics 
with eosinophilic predominant inflammation are predominantly corticosteroid-responsive.  
As an independent controller medication, ICS demonstrate superiority over other controller 
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medications in placebo-controlled trials.109,110  Commonly used ICS include 
beclomethasone, budesonide, ciclesonide, fluticasone, mometasone and triamcinalone.   
As many as 30% of severe asthmatics require daily oral systemic corticosteroids (OCS) as 
additive maintenance therapy, with 50% requiring more than three bursts of OCS 
annually.111  Due to the well-documented negative side-effects of chronic OCS use, they 
are only recommended as an add-on treatment for severe asthmatics who remain poorly 
controlled despite high-dose ICS and long-acting beta-agonists (LABA).1,2  OCS are more 
commonly used in short bursts (3-7 days) during an exacerbation to gain control of 
symptoms as they speed the resolution and prevent relapse of exacerbations.112,113  
1.6.1.2 Beta-agonist Bronchodilators  
Short-acting and long-acting beta-agonists (SABA and LABA, respectively) are the most 
commonly used bronchodilators for treating asthma.  SABAs, such as salbutamol, are a 
highly-effective reliever of acute bronchoconstriction in mild, moderate and severe asthma.  
LABAs, salmeterol and formoterol, cause bronchodilation for greater than 12 hours114 and 
are used in combination with ICS for long-term control in moderate and severe asthma.  
The clinical benefit of monotherapy therapy with SABA and LABAs is inferior to that of 
ICS and has been linked to adverse outcomes,115 accordingly LABAs are rarely used 
independently.  When used in combination with ICS, LABAs have an additive effect, 
improving lung function and symptom control.116,117  The effects of beta-agonists are the 
result of their binding to beta-adrenoceptors, present on airway smooth muscle, epithelial 
and inflammatory cells.  Its major mechanism of action is initiated when beta-
adrenoceptors on the airway smooth muscle are stimulated, increasing cyclic AMP, which 
causes the smooth muscle to relax.  The variable rate of onset and the duration of effect 
between SABAs and LABAs is due to their hydrophilic and lipophilic characteristics that 
govern their interaction with beta-adrenoceptors.114 
1.6.2 Add-on Treatments  
1.6.2.1 Theophylline  
Low-dose theophylline, is a relatively weak bronchodilator that may have an anti-
inflammatory and immunomodulatory effect.41  Due to the availability of safer and more 
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effective treatments, such as ICS and beta-agonists, theophylline is considered an 
alternative controller option or add-on treatment.1,2,118  The clinical benefit of adding 
theophylline to ICS treatment was found to only minimally improve lung function.119  The 
clinical utility of theophylline is complicated due to its toxicity and associated side-effects 
at effective doses, which is particularly problematic as its bronchodilator effect is dose-
dependent.  Despite guideline recommendations, theophylline is one of the most prescribed 
medications for asthma internationally because of its low cost.  This relates to its use in 
developing nations where access to superior and more expensive alternatives is limited.  
1.6.2.2 Leukotriene Receptor Antagonists (LTRAs)  
LTRAs reduce bronchoconstriction and inflammation in response to various stimuli; they 
are considered an alternative first-line therapy, but are most commonly used as add-on 
treatment.1,2  Leukotrienes are biochemical mediators that are released from inflammatory 
cells such as mast cells, eosinophils and macrophages in response to various stimuli.41,120 
Binding of cysteinyl-leukotrienes to cysteinyl-leukotrienes receptors results in smooth 
muscle constriction, mucus secretion, edema and inflammation.41,120 For the treatment of 
asthma, montelukast (Singulair) is the most commonly used LTRA, blocking the effect of 
cysteinyl-leukotrienes receptors.  LTRAs are considered an alternative first-line therapy as 
they are less effective than ICS when used independently.121  In a multicentre, randomized, 
double-blind, placebo-controlled trial, montelukast improved airway obstruction, 
exacerbations, control and blood eosinophils in stable asthma.122  In a subsequent trial, the 
clinical benefit of adding montelukast to ICS treatment was found to be as effective as 
doubling the ICS dose.123  Multiple studies have concluded that adding LTRA to ICS 
results in comparable124 or worse outcomes125,126 than achieved by adding LABA to ICS.127  
1.6.2.3 Anticholinergic bronchodilators 
Anticholinergic bronchodilators are considered a clinically valuable add-on treatment for 
the treatment of asthma.  Anticholinergic agents inhibit cholinergic activity by competing 
with acetylcholine at muscarinic receptors to permit dilation of the airways.41  
Acetylcholine, which acts through muscarinic receptors, is a key player in the regulation 
of airway smooth muscle tone and mucus gland secretion.128  Studies evaluating the 
efficacy of Tiotropium Bromide (Spiriva), a long-acting muscarinic antagonist, reported 
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improved lung function and symptoms, reduced frequency of SABA use and reduced risk 
of future exacerbations in asthmatics taking ICSs and LABAs.129-131    
1.6.2.4 Immunomodulators  
Immunomodulator is an umbrella term used to encompass many different pharmaceutical 
agents aimed at modulating cell signalling and the immunologic responses in asthma.  
Omalizumab, a monoclonal antibody that interrupts the allergic cascade by binding free 
immunoglobulin E (IgE), is considered a phenotype-guided add-on treatment for allergic 
asthma that cannot be well-controlled with ICS.1,2  In patients with moderate-to-severe 
allergic asthma, large-scale clinical trials have proven omalizumab reduces exacerbations 
and symptoms, improves quality-of-life and has a steroid-sparing effect.132-135  In 
subsequent trials, adding omalizumab to ICS treatment was proven clinically beneficial 
due to further improved lung function and a reduction in exacerbations.  While omalizumab 
is the only immunomodulator currently integrated into treatment guidelines, numerous 
clinical trials have emerged to evaluate novel pharmaceutical agents engineered to target 
various pathways important to the pathogenesis of asthma.  Potential new treatments 
include: anti-interleukin 5 (IL-5) antibodies, mepolizumab136 and reslizumab;87 anti-IL-13 
antibodies, lebrikizumab137 and tralokinumab;138 anti-TNF-α antibody, golimumab;139 
tyrosine kinase inhibitor, masitinib;140 IL-2Rα antibody, daclizumab;141 and CXCR2 
antagonist, SCH527123.142    
1.6.2.5 Bronchial Thermoplasty 
Bronchial thermoplasty is a novel nonpharmacological outpatient treatment procedure for 
severe asthma.  During three bronchoscopy sessions, radiofrequency energy is delivered to 
all of the bronchopulmonary segments to disrupt bronchial smooth muscle.143  The effect 
of this procedure is a reduction in airway smooth muscle mass in the treated airways, 
resulting in a reduced potential for bronchoconstriction.144,145  The safety and efficacy of 
bronchial thermoplasty have been evaluated in numerous clinical trials, including a multi-
centre, randomized, double-blinded, sham-controlled trial, that together demonstrated 
improved asthma control, quality-of-life, and decreased exacerbation frequency, 
hospitalizations and ED visits following treatment.86,146,147  The long-term effectiveness 
was recently evaluated and reduced hospitalizations and exacerbation frequency were 
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shown to persist five years after treatment.148,149  Despite its excellent safety and efficacy 
profile, the worldwide literature consists of only about 200 patients who have received this 
treatment.  
1.7  Imaging Asthma 
Currently, the clinical use of imaging in asthma is minimal and largely confined to chest 
radiography and x-ray computed tomography (CT).  Through research initiatives, novel 
imaging biomarkers of lung structure and function have been developed, many of which 
have the potential to impact asthma diagnosis, management and evaluation of treatment 
effect.  X-ray CT, single photon emission computed tomography (SPECT), positron 
emission tomography (PET) and MRI based techniques can be used to non-invasively 
evaluate regional ventilation.  Imaging has provided valuable insight into the underlying 
disease mechanisms of asthma, and will be discussed below.  
1.7.1 Plain X-ray 
The chest radiograph (Figure 1-10) is the oldest and most common type of image used to 
evaluate the lung as it is relatively inexpensive and fast.  Unfortunately, the utility of chest 
radiographs is limited as they are two-dimensional projection images of the three-
dimensional anatomy and are therefore limited by tissue superimposition.  A posterior-
anterior chest radiograph is obtained with the patient standing upright, with the x-ray 
source positioned behind them so that the x-ray beam enters from the posterior side and 
exits the anterior side of the patient.150  Different anatomical structures absorb x-rays to 
different extents and this is termed attenuation, the principle behind the contrast in an x-
ray image.150  Highly attenuating tissues such as bone absorb many x-rays and appear white 
on an x-ray image.  In contrast, low attenuating tissues such as lung parenchyma absorb 
very few x-rays and therefore appear black on an x-ray image.  The radiation dose 
associated with a typical posterior-anterior chest radiograph is 0.01 mSv,151 approximately 
equivalent to 0.6% of the annual background radiation in Toronto, Canada (1.6 mSv).    
Chest radiographs are rarely useful in the diagnosis and management of asthma as they are 
often normal.  However, their strength lies in the ability to reveal complications or 
alternative causes of “asthma-like symptoms.”  A study by Paganin and colleagues 
concluded that only 38% of chest radiographs were abnormal in adults with chronic 
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asthma.152  Radiographic findings associated with asthma are generally subtle and they 
include increased lung volume, increased lung lucency and bronchial wall thickening.153  
Increased lung volume or hyperinflation is the most common radiographic observation and 
is seen as increased lung length and flattening of the diaphragm (Figure 1-10).41  The 
prevalence of bronchial wall thickening identified on chest radiographs has been related to 
asthma severity.152  
 
Figure 1-10  Representative posterior-anterior chest radiograph of a healthy volunteer and 
an asthmatic subject. 
In asthma, diaphragm flattening is indicative of hyperinflation.  Healthy case courtesy of 
Dr. Usman Bashir, Radiopaedia.org, rID: 18394; Asthma case courtesy of Dr. Garth 
Kruger, Radiopaedia.org, rID: 21812. 
 
1.7.2 X-ray Computed Tomography 
Since its advent in the 1970s, x-ray CT has become the imaging modality of choice for the 
evaluation of pulmonary disease.  Through technological advancements, the entire lung 
volume can now be captured with sub-millimetre isotropic spatial resolution in a single 
breath-hold using multiple-row detector CT scanners.154  This increased spatial resolution 
and the potential for isotropic voxels permit multi-planar and three-dimensional 
reconstructions.155  Similar to plain radiography, the attenuation properties of tissues 
govern image contrast in x-ray CT.  In CT however, attenuation values are measured in 
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Hounsfield units (HU) and range from -1000 HU for air, 0 HU for water and to 
approximately 700 HU for bone.155   
CT of asthmatic subjects have shown abnormal findings such as bronchial wall thickening, 
bronchial wall dilation, luminal narrowing, bronchiectasis, mosaic lung attenuation, mucus 
plugging and atelectasis (Figure 1-11).152,156  In asthma research studies, CT has been used 
extensively to directly evaluate the large airways and to indirectly evaluate the small 
airways (<2mm).  As detailed below, CT-derived metrics are correlated with clinical 
symptoms and are highly sensitive to treatment response.  Gupta and colleagues used CT 
to evaluate 185 severe asthmatics and reported that abnormalities were present in 80% of 
study participants.157   
 
 
Figure 1-11  Axial CT of the right lower lobe in two representative asthmatics. 
At baseline (panel A), after inhalation of methacholine (panel B) and then salbutamol 
(panel C) there are visually obvious variations in bronchial lumen diameters (highlighted 
by white arrow) consistent with bronchoconstriction and subsequent bronchodilation.158  In 
a separate asthmatic (panel D) mosaic attenuation due to air-trapping is observed.159 
Reproduced with permission from Beigelman-aubry et al (2002)158 and Sung et al 
(2007).159  
 
The architecture of the large airways is assessed by quantifying metrics similar to those 
employed in histological studies such as the airway wall area percent (Equation 1-7), 
airway wall thickness percent (Equation 1-8) and airway lumen area.  Initial airway 
quantification techniques relied on manual tracing; however, due to the obvious limitations 
of this approach, semi-automated and automated computer-based approaches have since 
been developed.  Three-dimensional approaches enable up to ten generations of the airway 
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tree to be segmented, and reliable quantification can be achieved for first to sixth generation 
airways.154,160  Furthermore, automated three-dimensional approaches allow for the 
identification of airways using standardized clinical nomenclature, as demonstrated in 
Figure 1-12.160   Awadh and colleagues were the first to quantify airway wall thickness in 
the segmental and sub-segmental airways of asthmatics and healthy controls using a 
manual approach.  They reported that asthmatics had a greater airway wall thickness as 
compared to controls and that wall thickness was increased with increasing asthma 
severity.161  Subsequent investigations have compared airway measurements in normal and 
asthmatic subjects using various quantification techniques and their results support the 
initial findings by Awadh et al.162-167  Furthermore, CT airway measurements have been 
correlated with asthma severity,167-169 airflow obstruction,162,164,167,168,170 airway 
hyperresponsiveness163,168,171 and pathology.168  Following interventions such as deep 
inspiration,172 methacholine challenge166 and ICS therapy,165,173,174 the airways have been 
shown to behave in the expected direction.  
Equation 1-7 
Wall Area Percent [%] = 
Airway wall area
Total airway area
×100 
Equation 1-8 
Wall Thickness Percent [%] = 
Airway wall thickness
Airway outer diameter
×100 
   
 
Figure 1-12  Three-dimensional quantitative CT of the lungs and airways in asthma.  
Coronal CT (left panel) and the corresponding three-dimensional rendering of the lung and 
airway tree using Pulmonary Workstation 2.0 (VIDA) (middle panel). The trachea, left 
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main bronchus and left upper lobe bronchus pathway is highlighted (in blue) and the 
segmental LB3 airway is quantified (right panel).  In cross-section, the pathway and LB3 
airway boundaries are outlined in red.   
 
The small airways (<2mm) cannot be directly evaluated using CT as they are beyond the 
current spatial resolution limit of the technique.  However, air trapping in asthma is thought 
to be an indirect measure of small airway obstruction and can be visualized as 
heterogeneous regions of low attenuation on CT (Figure 1-11).  As expected, regions of 
low attenuation are more apparent on expiratory as compared to inspiratory scans. Various 
metrics have been used to quantify the extent of air trapping on CT and these include 
scoring systems, threshold and percentile techniques and lung density expiratory to 
inspiratory ratios.  Threshold techniques use a specific threshold of HU (e.g. -950 HU, -
910 HU, -856 HU) and the percentage of the lung less than this threshold is calculated.175  
Percentile techniques require a specific percentile point (e.g. lowest 15th percentile) to be 
selected and the HU value for the corresponding percentile is determined.175  Using various 
CT-derived gas trapping metrics, investigators have observed significantly elevated gas 
trapping in asthmatics over healthy controls.158,176  Other investigators correlated CT 
measurements of gas trapping in asthma with asthma severity,177 airflow 
obstruction,170,176,178 airway hyperresponsiveness and disease duration.178  Zeidler and 
colleagues performed a double-blinded, cross-over study to compare the effect of 
montelukast versus placebo on small airway function in mild-to-moderate asthma.  
Compared to placebo, montelukast resulted in significantly less air trapping on CT.179  
Moreover, other interventional studies have shown that air trapping on CT worsens 
following methacholine158 and improves following treatment with ICS.180,181  These studies 
similarly concluded that CT is a more sensitive method to assess treatment response in the 
small airways than conventional lung function tests.  
In addition to providing rich qualitative and quantitative structural information regarding 
the airways and lung parenchyma, functional assessments of ventilation and perfusion are 
also possible with novel CT techniques.  Introduced in the late 1980s, xenon ventilation 
CT182 is a technique used to non-invasively measure regional pulmonary ventilation in lung 
diseases.  CT is performed after the participant inhales radiodense xenon and ventilation 
can in turn be assessed because the airspaces that contain xenon have increased CT density 
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in comparison to those that do not.183  However, this technique is limited as xenon 
enhancement is poor and this has motivated xenon ventilation imaging using a dual-energy 
CT based approach.  Using dual-energy CT, Chea and colleagues observed ventilation 
defects in 80% of stable asthmatics who had significantly worse airflow obstruction and 
thicker airway walls than asthmatics without defects.183  Using the same approach, another 
group of investigators observed an increase in xenon ventilation defects following 
methacholine that resolved following salbutamol inhalation.184  
Despite the rich qualitative and quantitative structural and functional information that CT 
can provide, it is disadvantaged due to its use of ionizing radiation.  The radiation dose 
associated a clinical chest CT is approximately 8 mSv,151 equivalent to roughly five years 
of background radiation in Toronto, Canada (1.6 mSv) or 400 plain chest radiographs.  This 
becomes a major concern in asthma research and patient care as serial imaging capabilities 
are necessary for disease management and the evaluation of response to treatment or 
intervention.
 
 
1.7.3 Nuclear Medicine 
Gamma Scintigraphy & Single Photon Emission Computed Tomography (SPECT) 
Scintigraphy and SPECT can be used to regionally evaluate perfusion and ventilation in 
the lungs.  Following the injection or inhalation of a radionuclide tracer, gamma radiation 
is used to form an image of radioactivity within the body.  Radionuclide tracers emit 
gamma rays at a specific energy that can be detected by a gamma camera that converts 
absorbed energy into an electrical signal that can be displayed as an image.  Accordingly, 
regions of high radionuclide concentration appear as hot spots on the image.  Similar to 
how x-ray CT compares to plain x-ray, SPECT compares to scintigraphy.185  Scintigraphy 
uses gamma radiation to form two-dimensional images of radioactivity within the body, 
whereas SPECT offers a three-dimensional image.   
A tracer that is radioactive itself or labelled with a radionuclide is required.185  For regional 
imaging of ventilation, radioactive gases, radioactively-labelled aerosols and Technegas 
can be used.185  The most commonly used radioactive gases are xenon-133 (133Xe) and 
krypton-81m (81mKr).  The radionuclide technetium-99m (99mTc) is used as 99mTc-
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diethylene-triamine pentaacetate (DTPA) aerosol and Technegas.185  The inhaled 
deposition of Technegas has been shown to be similar to the distribution of inhaled 133Xe 
gas, and is preferred as its deposition within the lungs remains unchanged for more than 20 
minutes.186 
Scintigraphy using inhaled 133Xe gas was the first method to identify regional ventilation 
abnormities in asthma.187,188  Engel and colleagues were the first investigators to show the 
effect of methacholine-induced bronchoconstriction on regional ventilation.189  Nearly ten 
years later, the effect of histamine-induced bronchoconstriction on ventilation was 
observed.190  In the late 1990s, King and colleagues began to measure ventilation in asthma 
using SPECT and an inhaled bolus of Technegas.  As hypothesized based on previous 
scintigraphy studies, ventilation was compromised in asthmatics compared to healthy 
controls.191  Using the same technique, the investigators subsequently observed increased 
ventilation abnormalities following methacholine challenge in asthma.192  Importantly, the 
team demonstrated a link between ventilation defects and peripheral airways disease 
measured by MBNW.192  Not necessarily representative of ventilation, SPECT has been 
used extensively in research to investigate the regional deposition of inhaled aerosols when 
labelled with the radionuclide 99mTc.193,194  
Similar to x-ray based imaging methods, an obvious limitation of SPECT is its 
radionuclide-dependent radiation exposure.  A lung ventilation-perfusion study using 
99mTc exposes the subject to an effective dose of 2-3mSv.185  Furthermore, SPECT suffers 
from poor spatial resolution (~15mm) and motion artifact due to long acquisition times.  
Positron Emission Tomography (PET) 
Similar to SPECT, PET offers three-dimensional images of radioactivity and requires the 
injection or inhalation of a positron-emitting radioisotope.  As the radioisotope decays 
within the patient, positrons are emitted and then quickly annihilated when they come into 
contact with an electron.  As a result, two photons are emitted approximately 180º to one 
another.195  The emitted photons can be detected and a three-dimensional map of 
radioactivity can be reconstructed to generate a PET image.195    
Regional ventilation, perfusion and ventilation/perfusion matching can be assessed with 
nitrogen-13 (13NN) PET following bolus injection or inhalation of 13NN.  13NN has a half-
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life of ten minutes and is not soluble in blood or tissue.195  The bolus injection technique is 
used to deliver 13NN to the lung via the bloodstream.  Accordingly, unventilated lung 
regions, termed ventilation defects, retain the tracer due to gas trapping whereas the tracer 
is quickly washed out of ventilated lung regions.  Conversely, when the alternative 
inhalation technique is used, the tracer does not reach poorly-ventilated regions of the 
lungs.  Intravenous bolus injection of 13NN was used by Venegas and colleagues in a study 
evaluating the effect of methacholine-induced bronchoconstriction on regional ventilation 
in mild-to-moderate asthmatics.196  Following bronchoconstriction, the investigators 
observed regions of poor ventilation.196  Using the same technique, similar results were 
observed in mild asthmatics but in a subsequent study, lung perfusion was shown to 
redistribute away from ventilation defects.197  The effect of omalizumab treatment on 
ventilation and ventilation/perfusion matching metrics was assessed in a small group of 
uncontrolled allergic asthmatics but no effect was observed.198   
18F-fluorodeoxyglucose (FDG) is the most commonly used PET tracer in clinical practice 
due to its high uptake by metabolically active cells, such as cancer cells.154  Interest has 
surrounded the utility of FDG-PET as a biomarker of eosinophilic and neutrophilic 
inflammation in the lungs of asthmatics.199,200  Future work is required to determine the 
utility of this approach in asthma.  
1.7.4 Magnetic Resonance Imaging 
MRI does not require ionizing radiation and, due to this obvious advantage, the past 25 
years have seen an accelerated development of pulmonary MRI.  However, conventional 
1H MRI has numerous inherent limitations that have motivated the development of 
alternative inhaled gas contrast methods since the 1990s.  Oxygen-enhanced, fluorinated 
gas and hyperpolarized gas MRI are capable of imaging lung structure and function.  Of 
these techniques, hyperpolarized gas MRI has been most widely applied in pulmonary 
research; however, despite its utility, clinical translation has been slow.   
1.7.4.1 Conventional 1H MRI 
Conventional 1H MRI is challenging due to the lung’s inherent properties.  Primarily 
consisting of air, the density of the human lung is approximately 0.1 g/cm3, making it the 
least dense organ in the body201.  Accordingly, the lungs inherently low 1H density 
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translates to low 1H MRI signal intensity.  Furthermore, the lung consists of millions of 
alveoli or air-tissue interfaces.  These numerous air-tissue interfaces create significant local 
magnetic field inhomogeneities referred to as susceptibility artifacts, further inducing 1H 
MRI signal loss.201  Finally, due to cardiac and respiratory motion, the images are highly 
susceptible to motion artifacts.  Due to these limitations, as shown in Figure 1-13, the lungs 
appear as black holes and resultantly healthy and asthmatic lungs are relatively 
indistinguishable using conventional 1H MRI sequences.    
 
Figure 1-13  Representative coronal conventional 1H MRI of a healthy volunteer and an 
asthmatic subject. 
Due to the low 1H density within the lung, 1H MRI cannot visually distinguish structural 
abnormalities inherent to the asthmatic lung.   
 
Despite these shortcomings, alternative and potentially more sensitive 1H MRI techniques 
such as ultra-short echo time (UTE),202 oxygen-enhanced203 and Fourier decomposition204 
methods have been developed.  Advantageously, both oxygen-enhanced and Fourier 
decompositions methods provide functional information, offering insight into ventilation 
and perfusion characteristics.  Even with the advent of these alternative techniques, the 
application of 1H MRI in asthma has been limited.  Static and dynamic oxygen-enhanced 
MRI methods have been used to assess oxygen delivery, uptake and washout in asthma.205-
208  Oxygen-enhanced MRI metrics are sensitive to asthma severity205-207 and correlate with 
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FEV1.
207  Most recently, the oxygen transfer function has been shown to decrease in asthma 
subjects after a segmental endobronchial allergen challenge and was correlated with 
bronchoalveolar lavage eosinophil counts.208  Although yet to be evaluated in asthma, 
Fourier decomposition MRI allows lung perfusion and ventilation to be assessed, and 
preliminary studies have demonstrated excellent feasibility and reproducibility in healthy 
volunteers and subjects with respiratory disease.204,209-211  Similarly, UTE methods have 
not been evaluated in subjects with asthma.  However, in a murine asthma model UTE 1H 
MRI was used to quantify peribronchial eosinophilic inflammation that correlated with 
lung function parameters.212    
1.7.4.2 Inhaled Gas MRI 
Over the past two decades, MRI using inhaled hyperpolarized and fluorinated gases has 
been used to investigate lung function and structure in healthy volunteers and subjects with 
pulmonary disease.  Thus far, the field of inhaled gas MRI has been dominated by 
hyperpolarized gas techniques, using 129Xe and 3He.  Unlike conventional 1H MRI, 
specialized polarizer equipment and multinuclear radio-frequency hardware are necessary.  
Furthermore, this approach requires the subject to inhale an anoxic gas mixture and 
perform a short breath-hold (8-14 seconds) during image acquisition.  The field slowly 
began to take shape following the seminal investigation by Albert and colleagues who 
produced the first hyperpolarized 129Xe MR images of excised mouse lungs.213  Using spin-
exchange optical pumping, Albert and colleagues recognized that the longitudinal 
polarization of 3He and 129Xe gas nuclei could be increased by approximately 100,000 
times.214  This strong signal makes it possible to acquire data from the hyperpolarized gas 
itself once inhaled by the patient. 
The process of polarization is achieved by spin-exchange optical pumping, circularly 
polarized light bombards a glass cell housing rubidium and a noble gas situated within a 
helmholtz coil.215  The circularly polarized light is absorbed by the rubidium atoms, 
resulting in spin-polarization of its valence electrons.  Subsequent collisions between the 
noble gas and polarized rubidium atoms result in the transfer of angular momentum from 
rubidium electrons to the noble gas nucleus, thereby increasing its nuclear-spin 
polarization.215   
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While initial investigations used hyperpolarized 129Xe gas, the field quickly transitioned to 
hyperpolarized 3He gas due to its three-fold higher nuclear gyromagnetic ratio (129Xe: 
11.78 MHz/T; 3He: 33.43 MHz/T) and greater achievable polarization (129Xe: 8-25%; 3He: 
30-40%) – both of which contribute to the greater MRI signal achieved with 3He than 129Xe 
gas.215  More recently, the limited quantity and resultant high cost of 3He gas has motivated 
the field to shift its focus back towards 129Xe gas as it is widely available and a less 
expensive alternative.216,217  Notably, advances in polarizer technology have resulted in 
improved 129Xe polarization that has improved the overall MRI signal.  It is important to 
acknowledge that excellent safety and tolerability of both 3He and 129Xe MRI has been 
demonstrated in healthy volunteers and subjects with pulmonary disease.218,219  Studies 
have shown no clinically significant adverse effects of 3He or 129Xe inhalation.218,219  With 
this method, regional ventilation, lung microstructure and gas exchange have been 
qualitatively and quantitatively evaluated in clinical research.  
Ventilation Imaging  
Spin density imaging of hyperpolarized 3He or 129Xe, acquired during breath-hold, provides 
an opportunity to visualize with high spatial resolution those areas of the lung that 
participate in gas distribution and those that do not.  As shown in Figure 1-14, in healthy 
young adults, inhalation of hyperpolarized gas results in homogeneous signal suggesting 
that all areas of the lung are participating equally in ventilation.  In contrast, characteristic 
regions of signal void are observed in asthma (Figure 1-14), corresponding to areas of the 
lungs that are not ventilated within the time-course of a breath-hold scan.  Regions of signal 
void, termed ventilation defects, have also been observed in cystic fibrosis, COPD, 
bronchiectasis, lung cancer and the healthy elderly. 
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Figure 1-14  Representative coronal centre slice hyperpolarized 3He MRI of a healthy 
volunteer and an asthmatic subject.   
3He MRI gas distribution (in blue) registered to the 1H MRI of the thorax (in grey-scale). 
Unlike the representative healthy volunteer, the asthmatic subject has visually obvious 
ventilation defects.   
 
The presence of ventilation abnormalities were initially quantified using visual scoring and 
manual segmentation, but semi-automated220,221 and automated222 segmentation 
approaches are now more commonly employed.  Quantitative MRI-derived metrics include 
the ventilation defect volume,223,224 ventilated volume,225 ventilation coefficient of 
variation226,227 and the ventilation defect percent (VDP).  VDP is a measure of the 
ventilation defect volume normalized to the thoracic cavity volume, as shown in Equation 
1-9.  VDP is now a widely disseminated biomarker220,221,225 due to its demonstrated 
reproducibility,220 relation to standard measurements of lung function228 and its sensitivity 
to disease severity and treatment response.229 
Equation 1-9 
Ventilation Defect Percent (VDP) [%]=
Ventilation defect volume
Thoracic cavity volume
×100 
Many clinical research studies using hyperpolarized gas MRI have been performed in 
asthma to evaluate ventilation heterogeneity.224,226,230-239  In 2001, Altes and colleagues 
were the first to observe heterogeneous ventilation in non-symptomatic asthmatic adults 
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with normal lung function using hyperpolarized 3He MRI.235  In addition to this seminal 
study, numerous others have observed worse ventilation in asthmatics compared to healthy 
controls (Figure 1-14).226,233,235,237  While the majority of investigational studies to date 
have evaluated adults, a recent study by Cadmen and colleagues imaged asthmatic children 
for the first time.239 Similar to previous observations in adults, a greater number and larger 
size of ventilation defects were observed in children with asthma than those without 
asthma.239  In one of the largest studies evaluating 58 asthmatics with varying disease 
severity, ventilation worsened with the increase of disease severity.233  With respect to lung 
function, the number of ventilation defects224,236 and the number of ventilation defects per 
slice232,233 were inversely correlated with FEV1, but not ventilation volume
234 or VDP.237  
VDP was, however, correlated with airways resistance, FeNO and dyspnea.237  
Without ionizing radiation, there is enormous potential for serial and longitudinal treatment 
evaluation studies using hyperpolarized gas MRI.  Accordingly, and for obvious reasons, 
interest has surrounded the temporal variability of focal MRI ventilation defects in asthma.  
In a 30-minute scan-rescan study, all defects were found to be persistent.235  Another study 
concluded that approximately 75% of defects remained in the same location when 
evaluated twice in the same day.231  Over longer periods of time (7-476 days) many 
ventilation defects were persistent or reoccurred in the same location.230-232  Similarly, 
following repeat bronchoconstriction on separate days, the majority of defects were also 
induced in the same locations.232  With methacholine226,232,236,237 and exercise230,236 induced 
bronchoconstriction, numerous new ventilation defects and more heterogeneous 
ventilation patterns have been observed.  Alternatively, salbutamol-induced 
bronchodilation has been shown to improve, but not completely reverse, induced 
ventilation abnormalities.232,234,236,237  Figure 1-15  shows the ventilation distribution for a 
representative asthmatic at baseline, post-methacholine challenge and post-salbutamol 
inhalation.  A double-blinded, placebo-controlled, multi-institutional study assessed the 
response of 3He MRI ventilation to montelukast therapy in exercise-induced 
bronchoconstriction.234  Following exercise, the authors observed a larger drop in 
ventilation volume while receiving placebo than while receiving treatment.234  These 
studies demonstrate the sensitivity of MRI ventilation to bronchoconstriction and 
treatment.         
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Figure 1-15  Representative coronal centre slice hyperpolarized 3He MRI of an asthmatic 
subject at baseline, post-methacholine and post-salbutamol.   
3He MRI gas distribution (in blue) registered to the 1H MRI of the thorax (in grey-scale). 
Ventilation abnormalities are present at baseline that become worse following 
methacholine-induced bronchoconstriction.  Post-salbutamol, ventilation is improved but 
abnormalities are not completely resolved.   
 
It is probable that ventilation defects in asthma are the result of gas trapping and airway 
obstruction, although their etiology remains to be investigated.  In an attempt to evaluate 
the structural determinants of ventilation defects in asthma, Fain and colleagues evaluated 
3He MRI in conjunction with CT and bronchoalveolar lavage.224  It was concluded that 
global metrics of ventilation volume were not related to inflammatory markers.  However, 
subsequent regional analysis suggested that ventilation defects may be associated with 
abnormal inflammation as poorly-ventilated lobes had elevated neutrophils as compared to 
well-ventilated lobes in the same patient. 224  Furthermore, in the same asthmatics, a spatial 
relationship between ventilation defects and CT hyperlucency was observed.224  
Taken together, these studies suggest that in asthma, ventilation defects are related to 
airways disease, are regionally heterogeneous, temporally variable and responsive to 
therapy and provocation.  MRI ventilation defects vary in size, ranging from tiny focal 
hypo-ventilated spots to lobar in nature, and are often observed in asthmatics despite 
normal lung function.  Most importantly, these studies suggest that asthma is a disease that 
involves selected airways focally rather than diffusely, a concept that could revolutionize 
asthma management and treatment. With the field’s imminent transition to 129Xe MRI, 
asthma has yet to be evaluated using this alternative approach.  While it can be 
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hypothesized that the knowledge gained from 3He MRI investigations will be transferable, 
direct comparisons are required.     
Diffusion-weighted Imaging  
Another type of hyperpolarized gas MR image that has been commonly acquired uses 
diffusion-weighted MRI, providing a sensitive and rapid approach for evaluating the lung 
microstructure.240  Within the lungs, movement of gas atoms is restricted by tissue 
boundaries.  Therefore, a quantitative apparent diffusion coefficient (ADC) map can be 
generated that is representative of airspace size.241  While both 3He and 129Xe ADC 
measurements have been obtained in the lung, 3He ADC has been more extensively studied 
demonstrating high reproducibility242-244 and correlation with histology measurements of 
airspace size.245  For obvious reasons, ADC studies have been most commonly employed 
in COPD, while to date there have only been a few investigations in asthma.237,239,246,247  
While heterogeneous gas diffusion coefficients have been observed throughout the 
asthmatic lung, contradiction surrounds the differences in whole lung microstructure 
between asthmatics and healthy controls.  One study has shown increased gas diffusion 
coefficients in asthma compared to healthy controls,246 whereas another study observed no 
difference.237  In the only study evaluating gas diffusion in asthmatic children, Cadmen and 
colleagues reported a greater degree of restricted diffusion in children with asthma 
compared to children without asthma.239  In the only treatment study, ADC in asthma was 
quantified at baseline, post-methacholine challenge and following salbutamol inhalation.237  
An increased ADC was observed following methacholine, indicative of gas trapping, which 
was subsequently reduced followed salbutamol inhalation.237  A recent study indicated 
ADC in asthma is related to the acinar component of ventilation heterogeneity due to its 
relationship with the MBNW derived metric Scond.  The same authors also observed that 
ADC was strongly related to FVC and a CT marker of gas trapping.247  
1.8 Thesis Hypotheses and Objectives 
The overarching objective of this thesis was to develop and apply novel pulmonary imaging 
methods to better understand asthma and to provide a foundation for functional imaging to 
guide clinical decisions and treatment in patients with asthma.  The specific objectives and 
hypotheses tested in each chapter of this thesis are introduced below.  
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In Chapter 2, our objective was to quantitatively compare hyperpolarized 3He and 129Xe 
MRI within a five-minute period before and after bronchodilator administration in a small 
group of well-controlled asthmatic adults.  We wanted to understand the effect of the gas 
physical properties on ventilation defects in asthma.  The transition from 3He to 129Xe gas 
is a necessary step to facilitate broad clinical integration of hyperpolarized gas MRI.  Due 
to the higher density and viscosity of 129Xe gas, we hypothesized that 129Xe MRI would 
reveal more ventilation abnormalities pre-bronchodilator than 3He MRI and that these 
differences would be diminished post-bronchodilator.   
In Chapter 3, our objective was to exploit the inherent temporal and spatial pulmonary 
function information provided by hyperpolarized 3He MRI and develop image processing 
methods to regionally identify temporally persistent and intermittent ventilation defects 
that could be used to measure, optimize and guide asthma treatment.  In this proof-of-
concept study, seven asthmatic subjects underwent MR imaging at three timepoints over a 
two-week period.  We hypothesized that patient-specific temporal-spatial pulmonary 
function maps could be generated from 3He MRI to visualize and quantify temporally 
persistent and intermittent ventilation defects. 
In Chapter 4, our objective was to determine the underlying structural and clinical 
determinants of asthma ventilation defects by evaluating well-established clinical and 
emerging imaging (hyperpolarized 3He MRI and CT) measurements in healthy volunteers 
and subjects with well-controlled asthma.  In addition to evaluating the relationship 
between airway structure and lung function, we asked the question: Are asthmatics with 
ventilation defects different from asthmatics without ventilation defects?  We hypothesized 
that there would be a quantitative and spatial relationship between MRI ventilation defects 
and abnormal airways and that ventilation defects would be related to well-established 
clinical measurements of asthma. 
In Chapter 5, our objective was to evaluate the relationship between MBNW and MRI 
measurements of ventilation, and to better understand their link to asthma control.  
Multiple-breath gas washout studies have previously demonstrated a link between poor 
asthma control and increased ventilation abnormalities, and this led to the questions: What 
is the relationship between in vivo ventilation defects quantified using MRI and asthma 
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control? Can ventilation defects serve as an intermediate endpoint of outcomes like 
exacerbations, quality-of-life and asthma control?  We wanted to understand this 
relationship because the primary goal of asthma treatment is the achievement and 
maintenance of disease control.  Accordingly, we hypothesized that MRI and MBNW 
measurements of ventilation would be related, and contribute to poor asthma control. 
In Chapter 6, an overview and summary of the important findings and conclusions of 
Chapters 2-5 will be provided.  The study specific limitations as well as general limitations 
of the hyperpolarized gas MRI studies presented will be discussed, and some potential 
solutions will be offered.  The thesis ends with a roadmap for future studies that could build 
on the foundation of knowledge generated by this work.  
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CHAPTER 2 
To better understand ventilation defects in asthma, here we quantitatively compared 
hyperpolarized 3He and 129Xe MRI in a small group of well-controlled asthmatics before 
and after bronchodilator administration.  
The contents of this chapter were previously published in the Journal of Magnetic 
Resonance Imaging: S Svenningsen, M Kirby, D Starr, D Leary, A Wheatley, G Maksym, 
DG McCormack and G Parraga.  Hyperpolarized 3He and 129Xe Magnetic Resonance 
Imaging Differences in Asthma prior to Bronchodilation. J Magn Reson Imaging 2013; 
38(6):1521-1530.  Permission to reproduce this article was granted by John Wiley & Sons 
and is provided in Appendix A.   
2 HYPERPOLARIZED 3HE AND 129XE MRI: DIFFERENCES IN 
ASTHMA BEFORE BRONCHODILATION 
2.1 Introduction 
Asthma – a chronic inflammatory disease of the airways is characterized by acute 
intermittent attacks of airflow limitation resulting in symptoms of dyspnea, cough, chest 
tightness, and wheeze.1,2  Reversible airflow obstruction occurs in response to external 
stimuli that trigger acute effects such as bronchoconstriction, plasma exudation, edema and 
mucus hypersecretion.  It is believed that untreated chronic airway inflammation leads to 
airway remodeling, resulting in numerous physiological and functional consequences 
including airflow limitation and ventilation abnormalities.3,4  The diagnosis and monitoring 
of asthma are commonly performed using the spirometry measurement5,6 of the forced 
expiratory volume in 1s (FEV1) -a global measure of airflow limitation that is relatively 
insensitive to changes in small airway structure and function.7,8  
Multiple-breath-nitrogen washout (MBNW) studies have clearly shown that ventilation is 
heterogeneous in asthma9,10 and that this heterogeneity is likely related to airway hyper-
responsiveness,11 although similar to FEV1, MBNW measurements cannot provide 
regional information.  Imaging studies including those using nuclear medicine 
scintigraphy,12-14 positron emission tomography15 and x-ray computed tomography (CT)16-
18 have provided a regional picture of heterogeneous ventilation abnormalities in asthma.  
Additionally, at our site19 and other centres,20-25 magnetic resonance imaging (MRI) using 
hyperpolarized helium-3 (3He) has shown regional ventilation heterogeneity20,21,25 and the 
surprising spatial-temporal persistence of ventilation abnormalities or defects22,23 in 
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asthma.  Moreover, in asthma, hyperpolarized 3He ventilation defects have been correlated 
with disease severity21 and ventilation defects become larger and/or more numerous after 
methacholine challenge and exercise.19,24,25   
Hyperpolarized 3He MRI remains a specialized imaging research tool, primarily because 
the restricted quantity and unpredictable cost of 3He gas26 has limited uptake in pulmonary 
medicine.  These issues do not pertain to hyperpolarized 129Xe MRI, an alternative contrast 
agent27 that was used to obtain the first reported MR ventilation images.28,29  With recent 
advances in polarization physics,30-33 129Xe MRI has been further developed to provide 
high resolution measurements of both 129Xe pulmonary ventilation and diffusion.28,29,32,34-
41  The safety and tolerability38,42 of 129Xe MRI was recently evaluated and a direct 
quantitative comparison with 3He MRI was reported in COPD and healthy subjects.43  This 
previous work showed significantly greater 129Xe as compared to 3He ventilation defects 
in COPD subjects, although in healthy volunteers there were no differences observed.43  
Similarly, previous work qualitatively compared 3He and 129Xe MRI gas distribution in 
subjects with cystic fibrosis (CF) and showed 3He and 129Xe ventilation defects were in 
good agreement for some subjects, but in other subjects, 129Xe ventilation defects were 
larger and/or more numerous.44  Although it is unclear what the structural determinants or 
mechanisms are behind the differences between 3He and 129Xe gas distribution, such 
differences are believed to reflect differences in the physical properties of the inspired 
gases and their interaction with pulmonary abnormalities that are not present in healthy 
volunteers.  A potential mechanism responsible for the differences in 3He and 129Xe gas 
distribution is the effect of gas density and viscosity on flow resistance in the airways, 
which is dependent on airway lumen dimensions.45  Structural narrowing of the airway 
lumen is a common feature in asthma and COPD, resulting in increased resistance to flow 
in the airways.  Thus, the higher density and viscosity of 129Xe gas may result in greater 
resistance to flow through narrowed airways, contributing to greater 129Xe MRI as 
compared to 3He MRI ventilation defects.      
To our knowledge, the direct comparison of 129Xe and 3He MRI has not been performed in 
asthmatics.  Accordingly, here we quantitatively compared hyperpolarized 3He and 129Xe 
MRI within a short 5-minute period before and 25-30 minutes after salbutamol 
administration in a small group of well-controlled asthmatic adults. 
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2.2     Materials and Methods 
2.2.1 Subjects and Study Design 
All subjects provided written informed consent to the study protocol approved by the local 
research ethics board and Health Canada, and the study was compliant with the Personal 
Information Protection and Electronic Documents Act (PIPEDA, Canada) and the Health 
Insurance Portability and Accountability Act (HIPAA, USA).  Seven subjects were 
enrolled between the ages of 18 and 60 years of age (mean age=47±7 years; n=4 males) 
with a physician diagnosis of asthma and FEV1 ≥ 60%pred (Table 2-1).  Before salbutamol 
administration, vital signs were recorded, pulmonary function tests completed, and MRI 
was performed.  Post-bronchodilator imaging and pulmonary function tests were 
performed 25-30 minutes after administration of 200µg salbutamol (Apo-Salvent CRC 
Free Inhalation Aerosol; Apotex, Toronto, Ontario, Canada) delivered through a 
pressurized metered dose inhaler and AeroChamber Plus valved holding chamber (Trudell 
Medical International, London, Canada).   
Spirometry and plethysmography were performed pre- and post-salbutamol using a 
MedGraphics Elite Series plethysmograph (MedGraphics, St. Paul, MN, USA).  All 
manoeuvres were performed according to the American Thoracic Society (ATS) 
guidelines.46  All subjects also underwent a previous imaging session 326±199 days prior 
to this study.  At this time, hyperpolarized 3He MRI and thoracic CT were performed prior 
to methacholine challenge and 3He MRI was repeated following methacholine, as 
previously described.19 
2.2.2 Image Acquisition 
MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric Health 
Care, Milwaukee, WI, USA) MRI system with broadband imaging capability as previously 
described.47  Subjects were instructed to inhale a gas mixture from a 1.0L Tedlar® bag 
(Jensen Inert Products, Coral Springs, FL, USA) from functional residual capacity (FRC), 
and image acquisition was performed in 8-15s under breath-hold conditions.  To minimize 
the potential for differences or bias in the levels of inspiration between 3He and 129Xe MRI, 
extensive coaching was performed and the order of 3He and 129Xe MRI acquisition was 
75 
 
randomized.  Conventional 1H MRI was performed prior to hyperpolarized 3He and 129Xe 
MRI with subjects scanned during 1.0L breath-hold of ultrahigh purity, medical grade 
nitrogen (N2) (Spectra Gases, Alpha, NJ) using the whole body radiofrequency (RF) coil 
and 1H fast spoiled gradient-recalled-echo sequence (10s data acquisition, TR = 4.3ms, TE 
= 1.2ms, flip angle = 20 degrees, field of view (FOV) = 40cm x 40cm; matrix, 128 x 128; 
14-17 slices; slice thickness = 15mm, 0mm gap) as previously described.47   
Hyperpolarized 3He MRI was enabled using a linear bird-cage transmit/receive chest coil 
(RAPID Biomedical GmbH, Wuerzburg Germany).  A turn-key system (HeliSpin™) was 
used to polarize 3He gas to 30—40% and doses (5mL/kg body weight) were administered 
in 1.0L Tedlar® bags diluted with N2.  
3He MRI coronal static ventilation images were 
acquired using a fast gradient-recalled echo method (9s data acquisition, TR = 3.8ms, TE 
= 1ms, flip angle = 1 degree, FOV = 40cm x 40cm; matrix, 128 x 128; 14-17 slices; slice 
thickness = 15mm, 0mm gap) as previously described.47 
Hyperpolarized 129Xe MRI was enabled using a custom-made, unshielded quadrature-
asymmetric bird-cage coil model tuned to 35.34MHz, as previously described.48,49  129Xe 
gas (86% enriched) was polarized to 10—60% using a turn-key polarizer (XeBox-E10, 
Xemed LLC, New Hampshire, USA).  Doses of hyperpolarized 129Xe gas were dispensed 
directly into the pre-rinsed 1.0L Tedlar® bags pre-filled with 4He to generate a 50/50 
mixture.  129Xe MRI coronal static ventilation images were acquired using a 3D fast 
gradient-recalled-echo sequence with centric phase-encoding ordering in the y direction 
and normal sampling in the z direction during a breath-hold of the 1.0L 129Xe/4He mixture 
(14s data acquisition, TR = 6.7ms, TE = 1.5ms, flip angle = variable, FOV = 40cm × 40cm; 
matrix, 128 x 128; 14-17 slices; 15mm slice thickness, 0 gap) as previously described.43  
Thoracic CT was performed using a 64-slice Lightspeed VCT scanner (GEHC, Milwaukee, 
WI USA) using a detector configuration of 64×0.625mm, 120 kVp, 100 effective mA, tube 
rotation time of 500ms and a pitch of 1.0.  In order to reduce the radiation dose delivered 
to each subject, CT images were acquired for 56 (versus a total of 400 possible) 1.25mm 
thick slices in a region-of-interest (ROI) spatially identified by 3He MRI to contain 
ventilation defects.  In order to spatially register CT and 3He MRI breath-hold volumes and 
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anatomy, CT was acquired similar to MRI with subjects in breath-hold after inhalation of 
a 1.0L Tedlar® bag of N2 from FRC. 
2.2.3 Image Analysis 
3He and 129Xe MRI semi-automated segmentation was performed to quantify lung volumes 
using custom software generated using MATLAB R2007b (The Mathworks Inc., Natick, 
MA, USA), as previously described.50  To compare the distribution of both 3He and 129Xe 
gases within the lung, we segmented the 3He and 129Xe images based on pixel signal 
intensity.  Briefly, 3He and 129Xe static ventilation images were segmented using a K-means 
approach that classified voxel intensity values into five clusters ranging from signal void 
(cluster 1 (C1) or ventilation defect volume (VDV)) and hypo-intense (cluster 2 (C2)) to 
hyper-intense signal (cluster 5 (C5)), and therefore generating a gas distribution cluster-
map.  For delineation of the ventilation defect boundaries, a seeded region-growing 
algorithm51  was used to segment the 1H MRI thoracic cavity for registration to the cluster-
map.  3He and 129Xe VDP were generated using VDV normalized to the thoracic cavity 
volume.  Similarly, for the remaining ventilation clusters, the segmented 1H thoracic cavity 
volume was used to generate a cluster percentage representing a normalized cluster volume 
for the lung.  All measurements were performed by the same observer (S.S.) with two years 
of experience performing semi-automated 3He MR image segmentation.  The 
reproducibility of the semi-automated method was previously determined50 on the basis of 
intra-observer variability of five repeated 3He MRI VDP measurements for five asthmatic 
subjects.  
The signal-to-noise ratio (SNR) was calculated for each 3He and 129Xe static ventilation 
slice and then averaged to obtain a single SNR value for each subject image.  Briefly, SNR 
was determined by calculating the mean voxel value within a 5 x 5 cm2 voxel region of 
interest (ROI) for four representative ROI within the lung parenchyma, and dividing by the 
standard deviation of the voxel values for four representative ROI of the same size in the 
image background where there was no lung structure, as previously described.43   
Ventilation heterogeneity was estimated according to previously described methods25 
using the coefficient of variation (COV).  Briefly, a ventilated lung ROI was defined as gas 
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distribution cluster-map clusters C2-C5.  For each voxel within the ventilated lung ROI a 
local ventilation heterogeneity value was calculated by computing the coefficient of 
variation of the signal intensity in the voxels 5 x 5 neighborhood.  Mean COV for each 
slice was calculated for each 3He and 129Xe static ventilation slice and then averaged to 
obtain a single COV value for each subject. 
Partial CT image analysis was performed using software (Pulmonary Workstation 2.0, 
VIDA Diagnostics; Iowa City, IA, USA) to generate wall area percent (WA%) and lumen 
area (LA).  An automated airway tree segmentation algorithm (VIDA) was applied, 
however, a manual component was introduced to the algorithm if the trachea and main 
bronchus were not present in the image. Seed-points were manually placed within the 
lumen of the airway of interest to initiate manual segmentation of the airway.  To confirm 
the spatial relationship between a ventilation defect and the corresponding airway of 
interest, the partial CT was manually registered to the corresponding MR image using 3D 
Slicer manual registration software (http://www.slicer.org).52  
2.2.4 Statistical Analysis  
In order to determine the statistical significance of the difference between pulmonary 
function tests and MRI measurements pre- and post-salbutamol we performed a 
multivariate analysis of variance (MANOVA) and repeated measures analysis of variance 
(ANOVA) using SPSS 20.0 (IBM, Armonk, NY, USA).  Furthermore, in order to 
determine if the change observed following salbutamol inhalation using 129Xe MRI was 
significantly greater than the change observed using 3He MRI, we performed a three-way 
mixed-design repeated measures ANOVA, using SPSS 20.0.  In this analysis subject was 
treated as a between-subjects factor, and treatment (pre- and post-salbutamol) and gas (3He 
and 129Xe) was treated as a within-subjects factor.  Finally, because 3He MRI often has 
higher SNR than 129Xe MRI, there is the potential for regions of reduced signal intensity 
to appear as ventilation defects in low SNR 129Xe images.  Therefore, Pearson correlations 
(r) were performed to determine the relationship between the difference in 3He and 129Xe 
VDP with the difference between 3He and 129Xe SNR using GraphPad Prism version 4.00 
(Graphpad Software Inc, San Diego, CA, USA).  In all statistical analyses, results were 
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considered statistically significant when the probability of making a Type I error was less 
than 5% (p < 0.05). 
2.3 Results 
Table 2-1 shows demographic characteristics, pulmonary function, and MRI 
measurements for seven mild-to-moderate asthma subjects (four males) pre- and post-
salbutamol.  For all subjects, mean age was 47±7 years and mean body mass index was 
27±4 kg/m2.  Pre-bronchodilator mean FEV1 was 76±6%pred and mean FVC was 
91±12%pred.  All subjects were considered to be well-controlled with ≤ 1 asthma 
exacerbation resulting in hospitalization in the calendar year prior to the study visit.    
Table 2-1 Subject demographic characteristics, pulmonary function and MRI 
measurements. 
 Pre-Salbutamol 
(n=7)  
Post-Salbutamol 
(n=7) 
Significance of 
Difference (p)* 
Subject Demographics 
Age yrs (±SD) 47 (7) - - 
Male Sex  4 - - 
BMI kg/m2 (±SD) 27 (4) - - 
Pulmonary Function Test 
FEV1 %pred  (±SD) 76 (6) 83 (10) 0.01 
FVC %pred (±SD)   91 (12) 93 (13) 0.35 
FEV1/FVC % (±SD) 67 (7) 71 (6) 0.01 
TLC %pred (±SD) 104 (8) 103 (10) 0.41 
RV %pred (±SD) 136 (16) 123 (12) 0.17 
RV/TLC (%)(±SD) 40 (8) 37 (6) 0.15 
IC %pred (±SD) 101 (16) 112 (18) 0.02  
FRC %pred (±SD) 108 (17) 95 (16) 0.003  
Raw %pred (±SD) 184 (72) 133 (56) 0.04  
MRI Measurements    
3He VDP % (±SD) 6 (5) 4 (3) 0.001 
129Xe VDP % (±SD) 8 (5) 5 (4) <0.0001 
3He COV (±SD) 0.282 (0.018) 0.269 (0.024) <0.0001 
129Xe COV (±SD) 0.309 (0.028) 0.296 (0.036) 0.002 
SD=Standard Deviation, BMI=Body Mass Index, FEV1=Forced Expiratory Volume in 
1s, %pred=Percent Predicted, FVC=Forced Vital Capacity, TLC=Total Lung Capacity, 
RV=Residual Volume, IC=Inspiratory Capacity, FRC=Functional Residual Capacity, 
Raw=Airway resistance, VDP=Ventilation Defect Percent, COV=Coefficient of 
Variation.   
*Significance of difference (p<.05) determined using a multivariate analysis of variance. 
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Figure 2-1 shows for two representative asthmatics (subject A and B), 3He and 129Xe MRI 
coronal slices before and after bronchodilator administration as well as signal intensity 
cluster maps and COV maps.  For both subjects, there were visibly obvious regional 
ventilation abnormalities in the MRI and cluster maps.  As shown, 129Xe gas distribution 
was qualitatively more heterogeneous (COV maps) compared to 3He MRI, with regions of 
patchy signal void (cluster and COV maps).  As shown in Figure 2-1, following salbutamol 
administration, for both 129Xe and 3He MRI, some ventilation abnormalities disappeared 
whereas others persisted. 
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Figure 2-1  3He and 129Xe MRI pre- and post-salbutamol. 
Hyperpolarized 3He and 129Xe MRI for two representative subjects (Subjects A and B) pre- 
and post-salbutamol.  Static ventilation MRI, corresponding cluster maps and coefficient 
of variation (COV) maps are shown for:  
A) 43 yr old male, baseline FEV1=82%pred, baseline FEV1/FVC=69%;  
B) 50 yr old female, baseline FEV1=71%pred, baseline FEV1/FVC=68%.   
C1 = cluster 1, C2 = cluster 2, C3 = cluster 3, C4 = cluster 4, and C5 = cluster 5.  
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As shown in Table 2-1, for all subjects there was a significant improvement in mean 
FEV1%pred (p=0.01), FEV1/FVC (p=0.01), IC %pred (p=0.02), FRC %pred (p=0.003), and 
airways resistance (Raw %pred p=0.04) after the administration of salbutamol.    Pre-
bronchodilator 129Xe VDP (8 ± 5%) was significantly greater than 3He VDP (6 ± 5%, 
p=0.003); post-bronchodilator 3He (4 ± 3%) and 129Xe VDP (5 ± 4%) were not significantly 
different.  SNR was significantly lower for 129Xe MRI compared to 3He MRI both pre- 
(3He: 46±21, 129Xe: 22±8, p=0.02) and post-bronchodilator (3He: 36±16, 129Xe: 22±10, 
p=0.005), importantly however, the difference between 3He and 129Xe VDP pre-
bronchodilator (r=0.02, p=0.96) was not related to image SNR.  The COV for 129Xe MRI 
ventilation was significantly greater than for 3He MRI ventilation, both pre- (p<0.0001) 
and post-bronchodilator (p<0.0001).  
In Table 2-1 and shown in more detail in Figure 2-2, there was a significant improvement 
post-salbutamol for 3He (p=0.001) and 129Xe MRI VDP (p<0.0001) with the improvement 
in 129Xe MRI VDP significantly greater than for 3He MRI VDP (p=0.008).  Post-
salbutamol, both 3He (p<0.0001) and 129Xe (p=0.002) COV were significantly decreased.  
There was no relationship for the difference in VDP post-salbutamol with SNR (3He MRI, 
r=-0.30, p=0.51; 129Xe MRI, r=-0.32, p=0.49).  A subject listing of all MRI measurements 
is provided in Table 2-2.   
 
Figure 2-2  Bronchodilator response using hyperpolarized 3He and 129Xe MRI. 
Mean hyperpolarized 3He and 129Xe ventilation defect percent (VDP) and ventilation 
coefficient of variation (COV) pre- (white) and post-salbutamol (grey).  Values are means 
for all subject slices, and error bars are ± SD. *p ≤ 0.01, **p ≤ 0.001, ***p ≤ 0.0001. 
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Table 2-2  Pre- and post-salbutamol hyperpolarized 3He and 129Xe MRI measurements. 
Pre – Salbutamol 
 3He MRI 129Xe MRI 
Subject VDP 
(%) 
C2 
(%) 
C3 
(%) 
C4 
(%) 
C5 
(%) 
VDP 
(%) 
C2 
(%) 
C3 
(%) 
C4 
(%) 
C5 
(%) 
1
‡
 3 12 40 29 16 4 9 35 36 16 
2 1 10 37 33 19 3 9 28 40 21 
3
§
 17 11 32 26 15 18 9 26 28 20 
4
*
 6 12 39 29 15 8 15 19 36 23 
5
†
 6 12 37 35 10 7 11 35 34 14 
6 6 12 40 29 12 7 13 33 34 14 
7 5 11 40 30 14 8 11 30 38 14 
Mean (±SD) 6 (5) 11 (1) 38 (3) 30 (3) 14 (3) 8 (5) 11 (2) 29 (6) 35 (4) 17 (4) 
Post – Salbutamol 
 3He MRI 129Xe MRI 
Subject VDP 
(%) 
C2 
(%) 
C3 
(%) 
C4 
(%) 
C5 
(%) 
VDP 
(%) 
C2 
(%) 
C3 
(%) 
C4 
(%) 
C5 
(%) 
1
‡
 2 10 44 30 14 2 9 32 40 17 
2 1 10 41 30 18 1 6 17 45 31 
3
§
 12 12 31 31 14 13 12 21 34 20 
4
*
 4 10 35 32 19 4 10 27 37 23 
5
†
 3 9 40 33 14 4 9 31 38 18 
6 6 12 42 28 12 8 17 25 35 15 
7 4 11 39 31 15 4 14 29 42 12 
Mean(±SD) 4 (3) 11(1) 39(4) 31(2) 15(2) 5 (4) 11(4) 26(5) 39(4) 19(6) 
VDP=ventilation defect percent (C1=Cluster 1), C2 =Cluster 2, C3=Cluster 3, 
C4=Cluster 4, C5=Cluster 5, SD=standard deviation.  † Subject A, ‡ Subject B, § Subject 
C, * Subject D 
 
To further investigate the difference in 3He and 129Xe gas distribution detected prior to 
salbutamol inhalation we evaluated the spatial relationship of airways and ventilation 
defects using thoracic CT.  All subjects underwent a previous imaging session, 326±199 
days prior to this study when hyperpolarized 3He MRI and thoracic CT were acquired as 
previously described.19  In Figure 2-3, we show the centre coronal slice 3He and 129Xe MRI 
and the corresponding centre slice 3He MRI following methacholine challenge19 for 2 
subjects: Subject C, a 41yr old male, FEV1=75% pred; and Subject D, a 36 year old female, 
FEV1=86%pred.  As shown with arrows in Figure 2-3, for Subject C, a large sub-segmental 
ventilation defect distal to the apical bronchus of the right upper lobe (RB1) was visualized 
using 129Xe MRI and also using 3He MRI but only after provocation with methacholine, at 
the PC20.  Thoracic CT for this subject revealed a 4
th generation apical sub-segmental 
bronchus of the right upper lobe as the airway that was spatially proximal to this specific 
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ventilation defect.  The CT-derived WA% and LA for this 4th generation airway were 78% 
and 2.9 mm2 respectively, both of which are worse than previously reported values for a 
group of older asthmatic men (WA%=55-80% and LA=5-15mm2).53  For Subject D, there 
was no evidence of a right upper lobe ventilation abnormality and CT-derived 
measurements WA% and LA were 69% and 3.8 mm2 respectively for the same 4th 
generation apical sub-segmental bronchus.  
 
Figure 2-3  MRI and CT for two asthmatic subjects. 
Hyperpolarized 3He and 129Xe MRI and post-methacholine 3He MRI for two subjects (C 
and D)  
C) 41 yr old male, FEV1=75%pred, FEV1/FVC=66%.  White arrows identify a right upper 
lobe ventilation defect visible using 129Xe MRI, and for 3He MRI, only post-methacholine 
at PC20. Regional CT is shown with the apical segmental bronchus of the right upper lobe 
in red which is proximal to the 129Xe and 3He post-methacholine ventilation defect.  The 
cross-sectional slice of the airway is shown and the airway of interest is identified in a 
schematic of the bronchial tree. 
D) 36 yr old female, FEV1=86%pred, FEV1/FVC=73% with no ventilation defect in the right 
upper lobe.   
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2.4 Discussion 
Hyperpolarized 3He MRI of asthma has been performed over the last 2 decades19-25,54,55 
and across numerous studies, asthma ventilation defects have been shown to be spatially 
and temporally persistent,22,23 and some of these ventilation defects partially or fully 
resolve following inhaled or systemic therapy.19,20,24,25  Unfortunately, we still do not have 
a full understanding of the structural or physiological determinants of such asthma 
ventilation abnormalities,56 although armed with such an understanding there is the 
potential to use functional MRI to guide asthma therapy, to identify new therapeutic targets 
or at least, better understand regional pulmonary response to asthma therapy.  A recent 
pilot study that compared 3He and 129Xe MRI in older healthy and COPD subjects43 showed 
greater 129Xe MRI ventilation defects in COPD suggesting that 129Xe MRI may provide 
enhanced sensitivity to airway abnormalities in obstructive lung disease.  In COPD there 
are multiple mechanisms that may be responsible for 3He and 129Xe ventilation differences 
including increased airways resistance and the presence of emphysema and the effects of 
collateral ventilation.43,57  To try to get a better understanding of the structure-function 
relationships in the asthmatic lung, and to tease out the different contributing etiological 
factors that result in ventilation defects in asthma, here we directly compared 
hyperpolarized 3He and 129Xe MRI ventilation defects before and after salbutamol 
inhalation.  We made a number of important observations: 1) 129Xe VDP and COV were 
significantly greater than 3He MRI VDP and COV before salbutamol inhalation, 2) there 
were significantly greater post-salbutamol improvements in 129Xe MRI VDP such that 3He 
and 129Xe MRI were not significantly different post-salbutamol, and, 3) a remodeled sub-
segmental airway was shown to be spatially related to a sub-segmental 129Xe MRI 
ventilation defect that was not visible using 3He MRI, except at PC20, after methacholine 
administration. 
First, we directly compared hyperpolarized 3He and 129Xe MRI acquired within 
approximately five minutes of one another and observed that 129Xe MRI VDP and COV 
were both qualitatively and quantitatively greater than 3He MRI-derived VDP and COV.  
We note that in this study, the differences between 3He and 129Xe MRI VDP were not large 
– much smaller in fact than previously reported in COPD.43  Although VDP was not large, 
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qualitatively, there certainly was evidence of increased 129Xe ventilation heterogeneity 
compared to 3He and these differences were quantified using the 3He and 129Xe ventilation 
COV.  We note that SNR was lower for 129Xe as compared to 3He MRI, and therefore there 
is the potential for regions of the lung with reduced signal intensity to appear as ventilation 
defects in low SNR 129Xe images.  However, we observed that the difference between 3He 
and 129Xe SNR was not significantly correlated with the difference between 3He and 129Xe 
VDP.  Therefore, VDP and COV differences might well reflect other differences in the 
physical properties of the inspired gases and perhaps their interactions with airway 
abnormalities present in the asthmatic lung.  For example, in asthma, like COPD, the small 
airways (<2mm) are the major site of airflow obstruction and are believed to result in 
increased airways resistance.58  129Xe gas has both a greater density and viscosity than 3He 
(pure 129Xe gas has approximately 40 times greater density and 1.5 times greater viscosity 
than pure 3He gas)57 and this has an effect on resistance to both turbulent and laminar flow 
in the airways, as previously described.45  Importantly, we have previously estimated the 
density and viscosity of the inspired 3He-N2 (40/60) and 
129Xe-4He gas mixtures (50/50).57  
The estimated density of the inspired 3He-N2 gas mixture and 
129Xe-4He gas mixture was 
0.61kg/m3 and 2.65kg/m3, respectively, and the estimated viscosity of the 3He-N2 mixture 
and 129Xe-4He mixture was 1.99x10-4P and 2.55x10-4P, respectively.57  The increased 
density of 129Xe gas would tend to increase the gas Reynold’s number, thereby increasing 
the probability for turbulent flow with higher airflow resistance; laminar flow resistance 
would also increase proportionately to the change in viscosity according to Poiseulle’s 
equation.45  The increased density and viscosity of 129Xe gas could lead to slower filling or 
decreased access to lung units distal to narrowed or obstructed airways, amplifying 
ventilation differences arising from airway abnormalities between the gases.   
In COPD, emphysema may be an additional factor responsible for the differences in 3He 
and 129Xe MRI ventilation and may account for the larger 129Xe/3He MRI differences 
previously observed in COPD43 compared to asthma.  In emphysematous lung tissue, 
resistance to flow through collateral channels is low whereas in normal lung tissue, flow 
resistance through collateral channels is very high.59  Regardless, the results observed here 
in asthma support further interrogation using dynamic imaging approaches such as recently 
reported in COPD.60  It is also important to note that previous work has also shown that the 
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mixture of 129Xe/4He gas administered during image acquisition performed here better 
approximates the self-diffusion coefficient of room air in the lung,43 as compared to 3He/N2 
or 3He/4He gas mixtures, supporting the notion that 129Xe gas distribution might provide a 
better estimate of “ground truth” ventilation abnormalities.   
Second, and as might be expected, we observed a significant regional improvement in both 
3He and 129Xe MRI VDP following salbutamol administration, with the 129Xe MRI 
improvement significantly greater than 3He MRI.  Regional improvements in ventilation 
have previously been reported following salbutamol inhalation using xenon-enhanced 
dual-energy CT in asthma.61  However, to our knowledge this is the first study to report a 
change in 129Xe MRI ventilation abnormalities following inhaled salbutamol.  Beta-2 (β2) 
adrenergic receptor agonists promote smooth muscle relaxation and dilation, increasing 
airway caliber with concomitant decreased resistance to flow.  Post-salbutamol, for all 
subjects, the global measurement of airways resistance was significantly decreased and this 
may have resulted in the improved and more similar regional distribution of 3He and 129Xe 
gas post-salbutamol.  This suggests that increased airway caliber following bronchodilator 
administration allows for similar access of 3He and 129Xe to lung regions, as previously 
reported in healthy subjects.43 
Finally, in a single asthmatic, we showed that a relatively large sub-segmental ventilation 
defect that was visualized using 129Xe MRI, was also visible using 3He MRI, but only after 
methacholine challenge at the PC20.  Thoracic CT acquired within a year of this study and 
contemporaneous to the methacholine challenge was used to locate the airway proximal to 
this defect.  A 4th generation apical segmental bronchus of the right upper lobe was 
identified as the significantly remodeled airway that was spatially related to this ventilation 
defect.  Furthermore, in another asthmatic with a normally ventilated right upper lobe, the 
same 4th generation airway showed more “normal” airway morphology.  It is clear that 
airway diameters and wall thicknesses vary among individuals and we acknowledge that 
we do not believe that one defect in one subject confirms our hypothesis.  However, these 
results support the hypothesis that in asthma, 3He gas may penetrate lung regions through 
partially obstructed airways that 129Xe gas cannot access during a short breath-hold scan; 
in other words 3He MRI may mask clinically relevant airway abnormalities in asthma.  This 
interesting finding warrants further investigation in a larger group of asthmatic subjects to 
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determine whether there is indeed a relationship between abnormal airway 
pathophysiology and the differences between 3He and 129Xe gas distribution.   
We acknowledge that this work was limited by the small number of subjects evaluated and 
therefore caution should be exercised in generalizing these results to a more general asthma 
population.  Indeed, the reported VDP in this small group of asthmatics was low and may 
be related to the nearly normal FVC for these subjects, reflecting the fact that these subjects 
(who were enrolled from a tertiary care asthma centre) were receiving optimal asthma 
therapy.  The low baseline VDP also suggests that the differences in 3He and 129Xe VDP 
reported here might provide a conservative estimate of the differences that would be 
observed in a larger, less specialized asthma subject group.  What is clear though, is that 
salbutamol effectively negated the differences observed between 3He and 129Xe VDP.  
Future studies should aim to evaluate a large group of healthy volunteers and asthmatic 
subjects with varying disease severity.  Additionally, clinical tests such as dyspnea scores 
and measurements of exercise performance should be performed.  The clinical relevance 
of the difference in 3He and 129Xe gas distribution detected could then be determined by 
direct comparison with established measures that are patient-centred and clinically 
relevant.  
Over the last two decades, an international imaging physics research effort has been 
undertaken to develop non-invasive MRI methods, with the promise of direct and serial 
structure-function measurements of the lung without radiation burden or risk.  Yet, the 
treatment and monitoring of patients with asthma is still mainly based on spirometry and 
some emerging inflammatory biomarkers.62  Certainly, low accessibility and the 
high/unpredictable cost of 3He gas has also limited its development and use.26  It is 
important to note that the relatively low and predictable cost of 129Xe gas provides the 
potential for greater accessibility of pulmonary functional imaging for research and patient 
care.  One advantage of 129Xe gas is that it is capable of passive transmembrane diffusion 
and it is soluble in tissues and blood.  Hyperpolarized 129Xe MRI dissolved phase imaging 
has shown good spatial agreement with the corresponding ventilation image.34.  The 
differences between 3He and 129Xe MRI gas distribution shown here are unlikely to be 
related to transmembrane diffusion of 129Xe gas as it has been estimated that only 1-2% of 
the inhaled 129Xe gas dose is dissolved in the tissues and blood, during the 10-15s breath-
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hold.21  Regardless of the gas used for imaging, we think that the lack of a clear 
understanding of the clinical or physiological meaning of MRI ventilation defects will also 
impede its development as a clinical tool, necessitating more detailed physiological and 
modeling studies.  In this study, we observed small but significant differences between 
129Xe and 3He MRI VDP before salbutamol inhalation that suggested 129Xe MRI may be 
more sensitive to airflow obstruction in asthma that is responsive to salbutamol.  It is not 
clear which one of the currently available pulmonary functional MRI methods (including 
oxygen-enhanced MRI)63,64 provides ventilation estimates that are closest to ground truth 
(ie. ventilation that occurs with molecular oxygen mixed in air).   The availability of 
oxygen-enhanced and 129Xe MRI will certainly facilitate the research that still needs to be 
done to investigate the fundamental anatomical and morphological determinants that 
govern the occurrence and location of a ventilation defect, including bronchoscopy with 
biopsy and histological assessment.  MRI can be considered complementary to CT and 
endobronchial biopsy because the anatomical determinants of small airway ventilation 
defects may be beyond the resolution of CT and perhaps the reach of an endoscope or 
optical coherence tomography probe65 as well.    
In conclusion, we evaluated hyperpolarized 3He and 129Xe MRI ventilation defects in a 
small group of asthmatics before and after salbutamol inhalation and reported significantly 
greater (worse) 129Xe compared to 3He VDP and COV pre-salbutamol.   We identified a 
remodeled airway that was spatially related to a sub-segmental ventilation defect visualized 
only with 129Xe MRI.  These results suggest that the higher density and viscosity of 129Xe 
gas (which is more similar to molecular oxygen in air than 3He gas) may help reveal 
ventilation abnormalities prior to bronchodilation that are not observed using 3He MRI. 
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CHAPTER 3 
Hyperpolarized 3He MRI previously revealed the temporal and spatial heterogeneity of 
ventilation defects in asthmatics, but these findings have not been used in treatment studies 
or to guide personalized treatment.  Accordingly, here we generated personalized 3He MRI 
temporal-spatial pulmonary function maps to regionally identify temporally persistent and 
intermittent ventilation defects that may be used to optimize, evaluate and guide asthma 
treatment.   
The contents of this chapter were previously published in Academic Radiology:  S 
Svenningsen, F Guo, M Kirby, S Choy, A Wheatley, DG McCormack and G Parraga.  
Pulmonary Functional Magnetic Resonance Imaging: Asthma Temporal-spatial Maps. 
Acad Radiol 2014; 21(11):1402-1410.  Permission to reproduce this article was granted 
by Elsevier and is provided in Appendix A.   
3 PULMONARY FUNCTIONAL MAGNETIC RESONANCE 
IMAGING: ASTHMA TEMPORAL-SPATIAL MAPS 
3.1 Introduction 
Asthma is a chronic pulmonary disease1 characterized by acute and predominantly 
reversible episodes of airflow limitation and airway hyperresponsiveness that leads to 
airway remodeling2,3  Currently used asthma measurements are largely dependent on 
spirometry measurements of airflow limitation made at the mouth.  Such measurements 
tend to over-estimate large airway constriction and under-estimate small airways disease4 
and these measurements cannot regionally identify the airways responsible for airflow 
limitation, asthma symptoms or control.  
Currently, pulmonary imaging techniques play a minor role in the clinical diagnosis and 
management of asthma, although quantitative measurements of regional structural and 
functional pulmonary abnormalities5 can be derived using a number of imaging methods.  
For example, x-ray computed tomography (CT) has been used to show airway remodeling 
and evidence of gas trapping in asthmatics.6,7  Single-photon emission computed 
tomography8,9 and positron-emission tomography10 have revealed the spatial distribution 
and extent of airway remodeling in asthmatics at rest and during exacerbations.  
Hyperpolarized noble gas magnetic resonance imaging (MRI), using either 3He or 129Xe, 
also provides a way to visualize and quantify lung regions that participate in ventilation 
and those that do not.11,12  Longitudinal and interventional 3He MRI studies have revealed 
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the regional and temporal nature of ventilation defects in asthma before and after 
provocation (exercise and methacholine) and therapy.13-15  Previous work also showed that 
in asthma, ventilation defects are related to disease severity,16 CT measurements of gas 
trapping17 and airway morphological abnormalities.18  Taken together, these studies 
suggest that in asthma, ventilation defects are related to airways disease, are regionally 
heterogeneous, temporally variable and responsive to therapy and provocation.19-22  
Asthma ventilation defects may be considered as therapy targets or intermediate endpoints 
as they are present in older asthmatics with more advanced or severe disease, increased 
indices of inflammation and more severely remodeled airways.18   
There is enormous potential for imaging methods to improve the efficacy or cost-
effectiveness of asthma therapy.  However until now, the presence, location and/or 
variability of such defects has not yet been used to guide or interpret the efficacy of asthma 
therapy.  The purpose of this proof-of-concept study, therefore, was to exploit the inherent 
temporal and spatial pulmonary function information provided by hyperpolarized 3He MRI 
to identify temporally persistent and intermittent ventilation defects as potential targets for 
therapy.   
3.2 Materials and Methods 
3.2.1 Study Design 
Subjects who were 18-55 years of age, with a physician diagnosis of asthma and forced 
expiratory volume in one second (FEV1) ≥ 60%pred were recruited from a tertiary care 
asthma clinic.  All subjects provided written informed consent to a study protocol that was 
in compliance with the Health Insurance Portability and Accountability Act and approved 
by the local Research Ethics Board and Health Canada.  All subjects consented to three 
study visits, each 5±2 days apart, that took place between May 2007 and May 2008.  At 
each visit, pre- and post-exercise challenge, spirometry was performed followed by 1H and 
3He MRI.   Spirometry was performed using an ndd EasyOne spirometer (ndd 
Medizintechnik AG, Zurich, Switzerland) and FEV1, forced vital capacity (FVC) and 
FEV1/FVC were obtained according to the American Thoracic Society guidelines.
23  The 
exercise challenge was performed according to American Thoracic Society guidelines.24  
Briefly the subject exercised (after a 2-minute warm-up) for 6 minutes on a treadmill, while 
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inhaling compressed, room temperature dry air, at a workload which increased the heart 
rate to 80-90% of the individual’s age predicted maximum. 
3.2.2 Magnetic Resonance Imaging 
Following spirometry, MRI was performed using a whole body 3.0 Tesla Excite 12.0 MR 
system (GE Healthcare, Milwaukee, WI, USA), as previously described.25  Subjects were 
in the supine position and all image acquisitions were performed under breath-hold 
conditions (15 sec) following inspiration of a 1.0 L gas mixture from functional residual 
capacity (FRC).  To minimize the potential for differences in the level of inspiration 
between imaging sessions, extensive coaching was performed prior to and during each 
imaging session.  To ensure that each inhalation was performed from FRC, subjects were 
instructed to take two tidal breaths before inhaling the gas mixture from the 1.0 L Tedlar® 
bag (Jensen Inert Products, Coral Springs, FL, USA).  
Hyperpolarized 3He MRI static ventilation imaging was enabled using a single-channel, 
rigid, transmit-receive elliptical chest coil (RAPID Biomedical GmbH, Wuerzburg, DEU) 
as previously described.25  Hyperpolarized 3He gas (30-40% polarization) was provided by 
a turnkey system (HeliSpinTM, GE Healthcare, Durham, NC, USA) and administered to 
subjects (dose: 5mL/kg of body weight) in a 3He/N2 mixture.
25  Hyperpolarized 3He MRI 
static ventilation images were acquired following inspiration of the hyperpolarized 3He/N2 
gas mixture using a fast two-dimensional gradient echo sequence with the following 
parameters: repetition time, 4.3 msec; echo time, 1.4 msec; flip angle, 7○; field of view, 44 
x 44 cm; matrix size, 128 x 128; slice gap, 0 mm; 14 contiguous slices; and slice thickness, 
15 mm.  Subsequent to hyperpolarized 3He MRI, conventional 1H MRI was performed 
during a 1.0 L breath-hold of 4He/N2 to mimic the 
3He MRI breath-hold manoeuvre.  For 
1H imaging, a fast spoiled gradient recalled echo sequence was applied with the following 
parameters: repetition time, 4.7 msec; echo time, 1.2 msec; flip angle, 30○; field of view, 
44 x 44 cm; matrix size, 256 x 256; slice gap, 0 mm; 14 contiguous slices; and slice 
thickness, 15 mm. 
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3.2.3 Image Analysis 
3.2.3.1 Overview of Pipeline 
Figure 3-1 provides a summary of the registration and segmentation pipeline used to 
generate whole lung, two-dimensional, temporal-spatial pulmonary function maps.  The 
inputs to the pipeline are N  3He images acquired at visits  Ni ...,2,1 , where 2N , and 
an associated 1H MR image acquired at an arbitrary visit j ,  Nj ...,2,1 .  The pipeline 
consists of four steps: 1) Registration, 2) 1H MRI Segmentation26, 3) 3He MRI 
Segmentation26 and, 4) Temporal Map Generation and was developed using 3D Slicer 4.2 
open source platform (http://www.slicer.org, Boston, MA, USA) and MATLAB R2013A 
(The Mathworks Inc. Natick, MA, USA).  In this proof-of-concept demonstration, 3He MR 
images were acquired at three visits ( 3N ), and an associated 1H MR image was 
arbitrarily chosen at visit 2 ( 2j ). 
 
Figure 3-1  Pipeline to generate whole lung, two-dimensional, hyperpolarized 3He MRI 
temporal-spatial pulmonary function maps. 
The pipeline is divided into four steps: 1) Registration, 2) 1H MRI Segmentation, 3) 3He 
MRI Segmentation and, 4) Temporal Map Generation.  The inputs to the pipeline are N  
3He MR images acquired at visits  Ni ...,2,1 , where 2N , and an associated 1H MR 
image acquired at an arbitrary visit j ,  Nj ...,2,1 . 
 
3.2.3.2 Step 1: Registration 
As shown in Figure 3-1, using 3D Slicer, 3He MR images acquired at each visit i, 3Hevisiti, 
 Ni ...,2,1 , and the 1H MR image acquired at visit j, are co-registered to 3Hevisiti=j to 
generate temporal-spatial pulmonary function maps.  3Hevisiti=j, corresponding to the same 
visit at which the 1H MR image was acquired, is used as the fixed image for each inter-
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visit 3Hevisiti-
3Hevisiti=j and intra-visit
 1Hvisitj-
3Hevisiti=j registration.  Inter-visit 
3Hevisiti-
3Hevisiti=j registration is required to correct for misalignment between two 
3He MRI scans 
acquired at visit i and j due to inter-visit patient position variability on the scanner bed.  
3Hevisiti-
3Hevisiti=j co-registration is performed using an automated non-rigid deformable (B-
spline) registration method.  Intra-visit 1Hvisitj-
3Hevisiti=j co-registration is employed using 
landmark-based affine registration with 4-7 corresponding anatomical fiducial markers, 
such the carina, trachea, primary bronchi and the diaphragm. 
3.2.3.3 Step 2: 1H MRI Segmentation 
The thoracic cavity mask, which identifies the lung boundary and intern the thoracic cavity 
volume (TCV), is generated by segmenting 1Hvisitj using a seeded-region growing 
algorithm,27 as previously described.26  There is a subsequent manual editing option 
implemented to permit user modification of the automatically generated mask.   
3.2.3.4 Step 3: 3He MRI Segmentation  
For each visit i, automated 3Hevisiti ventilation segmentation is achieved using a hierarchical 
K-means clustering method, as previously described.26  The resulting 3He cluster maps 
consist of five clusters that represent signal intensity classes ranging from no signal (cluster 
1 (C1), or ventilation defect volume (VDV)), hypo-intense signal (C2) to hyper-intense 
signal (C5).  Subsequently, 3He clusters C2-C5 are merged and thoracic cavity masking 
was performed to generate corresponding 3He ventilation masks (VM).  3He MRI 
ventilation defect percent (VDP) was quantified by normalizing VDV to the TCV, as 
previously described.28   
3.2.3.5 Step 4: Temporal Map Generation  
To convey the short-term temporal behavior of 3He gas distribution, temporal-spatial 
pulmonary function maps are generated from N 3He ventilation masks and consist of three 
clusters: 1) persistent defect, 2) intermittent defect, and 3) persistent ventilation.  Temporal-
spatial pulmonary function map voxels are deemed as “persistent defect” if the 
corresponding 3He MRI ventilation mask voxels were ventilation defect (C1) at each visit.  
Similarly, a voxel is deemed persistently ventilated if the corresponding ventilation mask 
voxels were ventilated (C2-C5) at each visit.  A voxel is deemed as “intermittent defect” if 
the corresponding voxels were not consistently ventilation (C2-C5) or ventilation defect 
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(C1) at each visit.   Persistent ventilation defect percent (VDPP), intermittent ventilation 
defect percent (VDPI) and persistent ventilation percent (PVP) were generated as the ratio 
of each volume to the 1H MRI TCV.   
3.2.4 Registration Performance Evaluation  
Registration accuracy was estimated using the target registration error (TRE),29 defined as 
the distance between corresponding fiducial points in the fixed image and the moving 
images after registration.  Distinguishing anatomical landmarks that were readily apparent 
to the human observer, including the carina, trachea, primary bronchi and the diaphragm, 
were used as fiducials.   
3.2.5 Statistical Analysis 
Repeated-measures analysis of variance (ANOVA) were performed to evaluate changes in 
spirometry measurements, 3He polarization, 3He dose and 3He MRI VDP across timepoints 
using IBM SPSS Statistics version 21.00 (SPSS Inc., Chicago, IL, USA).  Paired two-tailed 
t-tests were used for statistical comparison of temporal-spatial pulmonary function map 
(VDPP and VDPI) anterior-centre-posterior (AP) and superior-middle-inferior (SI) 
differences, as previously described,20 using GraphPad Prism version 6.02 (GraphPad 
Software, Inc., San Diego, CA, USA).  Relationships between temporal-spatial pulmonary 
function maps (VDPP and VDPI) and spirometry were evaluated using Spearman 
correlation coefficients (r) and linear regressions (r2) generated using GraphPad Prism.  The 
mean of all spirometric measurements, acquired at visit 1, 2 and 3, were used to assess 
relationships.  Results were considered statistically significant when the probability of 
making a Type I error was less than 5% (p < 0.05). 
3.3 Results 
Subject demographic characteristics are shown in Table 3-1 for seven adults with asthma 
(n=4 males, mean age=28±9 years), all of whom completed three imaging sessions with a 
mean inter-visit interval of 5±2 days.  In total there were 8 adverse events in 6 subjects.  
All adverse events were related to hypoxia, defined as a temporary decrease in SpO2 below 
88%, and these were temporally related to MRI breath-hold manoeuvres.  Table 3-2 shows 
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mean spirometry and hyperpolarized 3He measurements acquired at each visit and Table 
3-3 provides a subject listing of all measurements.   
Table 3-1  Subject demographic characteristics. 
 
Table 3-2  Repeated spirometry and hyperpolarized 3He measurements. 
 Time-point (n=7) 
(±SD) Sig of Diff (p)* 
Parameter Visit 1 Visit 2 Visit 3 
Spirometry     
 FEV1 %pred 88 (11)  86 (12) 84 (12) 0.22 
 FVC %pred 104 (10) 101 (15) 99 (14) 0.18 
 FEV1/FVC %  72 (8) 71 (7) 72 (8) 0.76 
Hyperpolarized 3He  
 Dose mL 386 (70) 380 (76) 386 (95) 0.74 
 Polarization % 13 (2)  12 (2) 12 (2)  0.31 
 MRI VDP %  4 (2)  4 (3)  4 (3)  0.93 
Sig of Diff=Significance of difference; SD=Standard Deviation; FEV1=Forced 
Expiratory Volume in 1s; %pred=Percent Predicted; FVC=Forced Vital Capacity; 
MRI=Magnetic Resonance Imaging; VDP=Ventilation Defect Percent. 
*Significance of difference (p<0.05) determined using a repeated-measures analysis of 
variance.  
 
  
 
Parameter  
Asthma (n=7) 
(±SD) [range] 
Age years  28 (9) [21-47] 
Male/Female 4/3 
BMI kg/m-2   26 (4) [21-33] 
SaO2 97 (2) [94-98] 
FEV1 %pred  88 (11) [65-99] 
FVC %pred   104 (10) [89-120] 
FEV1/FVC %  72 (8) [61-81] 
SD=Standard Deviation; BMI=Body Mass Index; SaO2=Arterial Oxygen Saturation; 
FEV1=Forced Expiratory Volume in 1s; %pred= Percent Predicted; FVC=Forced Vital 
Capacity. 
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Table 3-3  Subject listing of demographic, spirometry and hyperpolarized 3He MRI 
measurements.   
V1=Visit 1; V2=Visit 2; V3=Visit 3; FEV1=Forced Expiratory Volume in 1s; 
%pred=Percent Predicted; FVC=Forced Vital Capacity; VDP=Ventilation Defect Percent; 
VDPP=Persistent Ventilation Defect Percent; VDPI=Intermittent Ventilation Defect 
Percent; PVP=Persistent Ventilation Percent. 
 
Figure 3-2 shows representative coronal hyperpolarized 3He MRI slices, acquired at each 
visit, for each subject.  All asthmatics evaluated had visually obvious 3He MRI gas 
distribution abnormalities at one or more of their imaging timepoints and qualitative 
differences in the distribution of 3He gas were observed between visits, as shown in Figure 
3-2.  However, despite regional gas distribution differences, as shown in Table 3-2, 
spirometry (FEV1%pred, p=0.22; FVC%pred, p=0.18; FEV1/FVC%, p=0.76) and whole lung 
3He MRI VDP (p=0.93) were not significantly different between visits.  Additionally, 3He 
dose (p=0.74) and polarization (p=0.31) was not different between imaging sessions.      
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Figure 3-2  3He MRI co-registered to the corresponding 1H MRI acquired at visit 1-3, and 
the corresponding temporal-spatial pulmonary function maps for seven asthmatic subjects.  
Regional differences in the spatial distribution of 3He MRI ventilation defects are visually 
apparent between visits for each subject.  This short-term temporal 3He ventilation defect 
behaviour is shown in the corresponding two-dimensional temporal-spatial map for each 
subject. 
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3.3.1 Temporal-Spatial Pulmonary Function Maps 
Temporal-spatial pulmonary function maps were generated from 3He MR images acquired 
at three visits ( 3N ), and an associated 1H MR image was arbitrarily chosen at visit 2 (
2j ). 
3.3.1.1 Target Registration Error 
Four corresponding fiducials were marked on each image volume (3Hevisit1, 
3Hevisit2, 
3Hevisit3 and 
1Hvisit2), for a total of 168 fiducials (24 per subject).  The mean distance between 
corresponding fiducials in the 3He-3He and 1H-3He image sets was 22±12mm and 
19±10mm, respectively.  For inter-visit 3He-3He registration, the mean TRE value for all 
112 fiducials (56 pairs) was 7±5mm (range: 1mm-29mm).  For intra-visit 1H-3He 
registration, the mean TRE for all 56 fiducials (28 pairs) was 6±3mm (range: 2mm-14mm). 
3.3.1.2 Ventilation Defect Temporal Behavior 
Figure 3-2 shows temporal-spatial pulmonary function maps for each subject and these 
spatially quantified the short-term temporal behavior of 3He MRI ventilation defects.  Lung 
regions with persistent (black) and intermittent ventilation defects (blue) were identified, 
the remaining regions were persistently ventilated (cyan).  For all subjects evaluated, the 
mean persistent ventilation defect percent was low (mean VDPP=0.2±0.2%) as was mean 
intermittent ventilation defect percent (VDPI=4±2%).  Mean persistent ventilation percent 
was high (PVP=95±3%) across the three imaging sessions.   
3.3.1.3 Anatomic Differences 
As qualitatively shown in Figure 3-3 and quantitatively described in Figure 3-4, VDPP 
and VDPI were evaluated in the AP and SI regions of interest.  VDPI was significantly 
greater in the posterior as compared to the centre (p=0.02) and anterior (p=0.04) lung 
regions but VDPP was not different.  In the inferior lung region, VDPI was significantly 
greater (p=0.04) than the superior lung region, while VDPP was not different.   
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Figure 3-3  Three-dimensional 3He MRI temporal-spatial pulmonary function maps for 
three representative asthmatic subjects. 
3D 3He MRI in the coronal, axial and sagittal view to qualitatively evaluate persistent and 
intermittent ventilation defects.  Both persistent and intermittent ventilation defects are 
prominent in the gravity-dependent posterior and inferior lung regions.  
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Figure 3-4  3He MRI intermittent ventilation defect percent (VDPI) and persistent 
ventilation defect percent (VDPP) anatomical differences. 
Plots show anatomical differences in VDPI and VDPP for regions of interest in the anterior-
centre-posterior (A, B) and superior-middle-inferior directions (C, D).  Box and whisker 
plots represent: minimum, 25th percentile, median, 75th percentile, and maximum.  
Statistically significant differences between regions of interest are shown. 
 
3.3.1.4 Relationships with Spirometry 
Figure 3-5 shows correlations for VDPP and VDPI with baseline and post-exercise 
FEV1/FVC.  Both VDPP and VDPI were negatively correlated with baseline (VDPP: r=-
0.87, p=0.01; VDPI: r=-0.96, p=0.0008) and post-exercise FEV1/FVC (VDPP: r=-0.79, 
p=0.04; VDPI: r=-0.96, p=0.003). There were no significant correlations for VDPP or VDPI 
with FEV1%pred or FVC%pred.  
108 
 
 
Figure 3-5  Relationship of 3He MRI temporal-spatial pulmonary function with airflow 
obstruction at baseline and following exercise challenge. 
Baseline FEV1/FVC was significantly correlated with intermittent ventilation defect 
percent (VDPI) (r=-0.96, p=0.0008) (A), and persistent ventilation defect percent (VDPP) 
(r=-0.87, p=0.01) (B).  Post-exercise FEV1/FVC was significantly correlated with VDPI 
(r=-0.96, p=0.003) (C), and VDPP (r=-0.79, p=0.04) (D).  Dotted lines indicate the 95% 
limits of agreement.  
 
3.4 Discussion 
We aimed to exploit 3He MRI ventilation measurements to generate asthma temporal-
spatial pulmonary function maps in acknowledgement of the paucity of real-time 
visualization/quantification tools available to identify temporal changes in regional 
ventilation, especially in response to therapy.  Therefore, here we developed a registration-
segmentation pipeline to generate 3He MRI temporal maps in mild-to-moderate asthmatics 
in order to spatially quantify temporally persistent and intermittent ventilation defects.  
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First, we acquired 3He MRI in seven asthmatic subjects, in whom there were no changes 
in pulmonary function tests or 3He MRI VDP during a three-week data acquisition period.  
For most subjects however, there were visually obvious differences in the regional 
distribution of 3He ventilation defects over the three-week time period.  Previous studies 
have evaluated 3He MRI ventilation defects following bronchoconstriction13,20,21,30 and 
bronchodilation,20,22 and these studies quantitatively described changes in the size and 
number of ventilation defects.  Other studies13,14,30 have evaluated ventilation defect 
reproducibility prior to and following bronchoconstriction and bronchodilation.  These 
studies suggested that the location and the temporal occurrence of ventilation defects prior 
to broncho-provocation were heterogeneous.30  We think that this important information 
can be quantified and simplified using multiple 3He MRI time-points and that using a single 
snapshot in time would likely be insufficient to quantify the complex interactions between 
space, time and airway hyperresponsiveness.  Persistent ventilation defects represented 
regions that were always abnormal, perhaps due to remodeled, narrowed and/or collapsed 
airways that altered the time constants for lung filling beyond the timeframe for MRI 
acquisition (15 sec).  Intermittent defects may be related to a number of underlying 
physiological airway abnormalities such as variable airway lumen diameter, exposure to 
triggers of hyperresponsiveness or mucus plugging.   
MRI temporal-spatial pulmonary function maps may be used to regionally locate the 
specific airways that are proximal to persistent or intermittent ventilation abnormalities as 
potential targets for localized airway treatment such as bronchial thermoplasty.31  For 
example, as shown in Figure 3-2 and Figure 3-3, for subject 3, the map provides evidence 
of highly localized disease.  For this subject, measurements of response to therapy to 
localize treatment should be directed to the lower left lobe, and can avoid the upper left 
lobe and the right lung.    
Second, we observed that intermittent ventilation defects and persistently ventilated lung 
showed regional differences or biases.  All subjects were imaged in the supine position, 
and in the gravity-dependent lung regions (posterior and inferior) VDPI was increased.  
This suggests that ventilation defects are more variable over time in dependent lung 
regions, a finding which must be further investigated.  This finding is supported by 
previous quantitative findings in both asthmatic and healthy subjects20 that VDP is greater 
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in the dependent lung regions.  Although the physiological mechanism responsible for this 
observation is not known, airway collapse may be a plausible explanation.   
Finally, we observed correlations for airflow obstruction (FEV1/FVC) with VDPI and 
VDPP at baseline and following exercise-induced bronchoconstriction.  Due to an increased 
sensitivity of asthmatic airways to a range of constrictor agonists, bronchial 
hyperresponsiveness is often referred to as the “hallmark” of asthma.  Accordingly, 
intermittent defects were identified in an attempt to spatially identify hyperresponsive 
airways as potential therapy targets.  We hypothesized that asthmatics with intermittent 
defects would show greater response to broncho-provocation and interestingly, we did 
observe a strong relationship between intermittent defects and post-exercise FEV1/FVC 
(r=-0.96, p=0.003) in these seven asthmatics.  This lends support to the notion that 
temporal-spatial measurements may be identifying hyper-responsive lung regions or ROI 
that are more likely to constrict during an exacerbation.    
Although this preliminary demonstration provides promising proof-of-concept results, we 
must acknowledge several limitations.  Importantly, a sample size of seven is small, 
therefore, our feasibility results should be considered a conservative estimate of VDPP and 
VDPI.  In fact, the immediate application of our method may be better-suited to poorly-
controlled and more severe asthma.  Additionally, the maps generated here captured week-
to-week lung function variability and not long-term ventilation defect persistence or 
disease progression.  The temporal persistence of ventilation defects was previously shown 
to decrease with time,14 therefore a longer inter-visit interval than used here might yield 
fewer persistent defect ROIs.  Additionally, we recognize the importance of potential 
registration errors and the effect this has on map interpretation – especially on the lung 
periphery where sub-segmental defects tend to appear.  In our experience, most registration 
errors are derived from scan-to-scan variability/differences in lung inflation levels, 
potentially due to gas trapping, and we therefore implemented a deformable registration 
method to minimize this.  If the methodology developed here was extended to generate 
maps to display transient ROI in response to methacholine and/or salbutamol, the 
application of the non-rigid registration algorithm presented here would be even more 
essential to account for larger changes in lung volumes and shape.  Finally, we must 
consider our approach as a precursor to temporal-spatial pulmonary function maps 
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generated using hyperpolarized 129Xe gas22 as these will certainly play a more prominent 
role in the future.32  Clearly, prior to the clinical application of this potential pulmonary 
image-guidance tool extensive efficacy evaluations are required.  Specifically, a 
randomized two-arm evaluation comparing the efficacy of conventional and image-guided 
treatment will be necessary to determine if similar changes in asthma control and quality-
of-life can be achieved as those obtained following conventional therapy.   
By “seeing” the disease and its variability over time, we can potentially help improve 
asthma treatments and outcomes, amounting to enormous clinical value.  Therefore, this 
work must be viewed as a first necessary step towards the development of high resolution 
image-guidance maps to help target specific airway abnormalities in asthmatics who 
undergo localized asthma therapies, such as bronchial thermoplasty, that currently are not 
guided by imaging to abnormally functioning lung.  In conclusion, personalized asthma 
temporal-spatial pulmonary function maps were generated from thoracic 3He MRI to 
visualize and quantify regional ventilation defects observed over time. 
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CHAPTER 4 
Towards the goal of understanding the structural determinants and clinical consequences 
of MRI ventilation defects in asthma, we evaluated well-established clinical and emerging 
CT-derived airway morphology measurements in healthy volunteers and asthmatics with 
and without ventilation defects.   
The contents of this chapter were previously published in the journal Thorax: S 
Svenningsen, M Kirby, D Starr, HO Coxson, NA Paterson, DG McCormack and G 
Parraga.  What are Ventilation Defects in Asthma? Thorax 2014; 69(1):63-71.  Permission 
to reproduce this article was granted by BMJ Publishing Group Ltd and is provided in 
Appendix A.   
4 WHAT ARE VENTILATION DEFECTS IN ASTHMA? 
4.1 Introduction 
Asthma is typically diagnosed and characterized using the spirometry measurement1,2 of 
the forced expiratory volume in 1 second (FEV1).  Although relatively simple and 
inexpensive, spirometry measurements provide a global estimate of the morphological 
changes in the small and medium-sized airways that are believed to be related to luminal 
inflammation, airway remodeling and constriction.  We now realize using multiple breath 
nitrogen washout studies3,4 and pulmonary imaging methods, that functional abnormalities 
in asthma are in fact regionally heterogeneous,5-7 temporally persistent8-10 and that these 
abnormalities regionally respond to broncho-provocation7,11,12 and to bronchodilator 
therapy.11,13  Thoracic x-ray computed tomography (CT) has been used for over a decade 
as a non-invasive method to investigate structure-function relationships of asthmatic 
airways and has shown strong relationships between CT-derived airway measurements 
with inflammation,14,15 spirometry14-21 and disease severity.14,16,20,22  However, while these 
CT data are encouraging, they are still somewhat limited because it is well recognized that 
CT cannot resolve or measure airways beyond the 5th or 6th generation.  Moreover, even 
using new lower dose and iterative reconstruction methods,23 CT is not recommended for 
longitudinal studies and studies of young adults and children because of the potential risks 
associated with exposure to ionizing radiation.  Other pulmonary imaging methods such as 
nuclear medicine scintigraphy24-26 and positron emission tomography (PET)27 are also 
limited clinically because of inherently low spatial resolution.   
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Hyperpolarized 3He magnetic resonance imaging (MRI) has been previously used to 
visualize heterogeneous and abnormal gas distribution in asthma.  Regions of signal void 
or ventilation defects have been shown to be temporally persistent8-10 and to correlate 
significantly with spirometry,6,28,29 disease severity6 and CT measurements of gas 
trapping.28  In addition, 3He MRI also provides a way to perform intensive serial 
measurements due in part to its excellent safety profile,30 and the speed with which imaging 
can be performed.  More specifically, 3He MRI ventilation defects have been shown to 
increase from baseline following both methacholine7,11,12 and exercise12 challenge, and 
decrease from baseline following salbutamol administration.13  In asthma, the relationship 
between ventilation defects and patient outcomes such as exacerbation frequency and 
severity has not yet been evaluated, however this has been evaluated in chronic obstructive 
pulmonary disease (COPD).31  Recently, there has been growing interest in the clinical 
application of hyperpolarized gas MRI to assess treatment efficacy and furthermore to 
guide localized airway treatments in asthma.  Preliminary work in severe asthma has shown 
improved 3He gas distribution following localized bronchial thermoplasty treatment.32  
While these results provide a strong foundation for the use of MRI in asthma research and 
patient care, a major drawback has been that we do not clearly understand the etiology of 
MRI ventilation defects.33  It has been speculated that MRI ventilation defects reflect 
regional airway narrowing that may be the consequence of airway remodeling;34 however, 
to our knowledge, the direct spatial and quantitative relationship between MRI ventilation 
defects and CT airway measurements has not been reported in asthmatics.  Therefore, our 
objective was to determine the underlying structural and clinical determinants of asthma 
ventilation abnormalities by evaluating well-established clinical and emerging imaging 
(hyperpolarized 3He MRI and CT) measurements in healthy volunteers and subjects with 
asthma. 
4.2 Methods 
4.2.1 Study Subjects 
All subjects provided written informed consent to a study protocol approved by the local 
research ethics board, and the study was compliant with the Personal Information 
Protection and Electronic Documents Act (PIPEDA, Canada) and the Health Insurance 
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Portability and Accountability Act (HIPAA, USA).  Subjects were enrolled between 18 
and 60 years of age, including mild-to-moderate35 asthmatics, and healthy subjects with no 
history or diagnosis of asthma or any other chronic or current acute respiratory illness.  
Asthmatic subjects were phenotyped from health records based on disease severity and 
symptoms from a tertiary care centre (interdisciplinary Allergy and Respirology asthma 
care centre); all asthma subjects had a current physician diagnosis of asthma, were 
currently under treatment for asthma and had a positive methacholine challenge within the 
past five years.  At a single visit, spirometry, plethysmography, fractional exhaled nitric 
oxide (FeNO) breath analysis and pulmonary CT was performed within 30 minutes of MRI. 
4.2.2 Pulmonary Function Tests 
Spirometry and plethysmography were performed according to American Thoracic Society 
Guidelines36 using an ndd EasyOne spirometer (ndd Medizintechnik AG, Zurich, 
Switzerland) and a MedGraphics Elite Series plethysmograph (MedGraphics, St. Paul, 
MN, USA), respectively.  FeNO was measured using a Niox Mino (Aerocrine Inc. USA, 
New Providence, NJ, USA).  Methacholine challenge was performed as previously 
described 11 and the provocative concentration causing a 20% decrease in FEV1 (PC20) was 
determined.  Borg and modified Medical Research Council (mMRC) dyspnea scores were 
recorded. 
4.2.3 Magnetic Resonance Imaging 
MRI was performed on a whole body 3.0 Tesla Discovery 750MR (General Electric Health 
Care, Milwaukee, WI, USA) system with broadband imaging capability, as previously 
described.37  Subjects were instructed to inhale a gas mixture from a 1.0L Tedlar® bag 
(Jensen Inert Products, Coral Springs, FL, USA) from functional residual capacity (FRC), 
and image acquisition was performed in 8-15s under breath-hold conditions.  Conventional 
1H MRI was performed prior to hyperpolarized 3He MRI, both methods are previously 
described.37   
3He MR images were qualitatively and quantitatively evaluated for ventilation 
abnormalities by a single trained observer.  Upon qualitative inspection, asthmatic subjects 
were classified into two groups, 1) asthmatics with no ventilation defects (ND) and 
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asthmatics with ventilation defects (AD).  If 3He gas was homogenously distributed 
throughout the lung and there were no visible ventilation defects the subject was classified 
as belonging to the ND group.  In contrast, if 3He gas was heterogeneously distributed 
throughout the lung and/or there were visually obvious ventilation defects, the subject was 
classified as belonging to the AD group.  Quantitative evaluation of 3He MRI was 
performed to estimate ventilation defect percent (VDP) and ventilation heterogeneity using 
the coefficient of variation (COV).  3He MRI semi-automated segmentation was performed 
to quantify lung volumes using custom software generated using MATLAB R2007b (The 
Mathworks Inc., Natick, MA, USA), as previously described.38  As shown in Figure 4-1, 
3He static ventilation images were segmented using a K-means approach that classified 
voxel intensity values into five clusters ranging from signal void (cluster 1 (C1) or 
ventilation defect volume (VDV)) to hyper-intense signal (cluster 5 (C5)) to create a gas 
distribution cluster-map.  3He MRI VDP was generated using VDV normalized to the 
thoracic cavity volume.  Whole lung and regional VDP specific to the CT region-of-interest 
(ROI) were generated for each subject.  Ventilation heterogeneity was estimated according 
to previously described methods7 using the COV.  Briefly, a ventilated lung ROI was 
defined as gas distribution cluster-map clusters C2-C5.  For each voxel within the 
ventilated lung ROI a local ventilation heterogeneity value was calculated by computing 
the COV of the signal intensity in the voxels 5 x 5 neighborhood.  Mean COV for each 
slice was calculated for each 3He static ventilation slice and then averaged to obtain a single 
COV value for each subject.   
4.2.4 Computed Tomography 
Following 3He MRI, thoracic CT was performed with the same inhalation breath-hold 
volume and manoeuvre used for MRI, in order to match CT and MRI lung volume and 
anatomy.  CT imaging was performed in the supine position using a 64-slice Lightspeed 
VCT scanner (GEHC, Milwaukee, WI USA) using a detector configuration of 64×0.625 
mm, 120 kVp, 100 mA, 0.5 second gantry rotation, and a pitch of 1.25.  To reduce the 
radiation dose, CT was obtained for a 4cm axial ROI where there were visually obvious 
MRI ventilation defects.  In the case where there were no visually obvious ventilation 
defects, the CT volume was acquired in the superior region of the lung.  This approach 
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resulted in CT volumes consisting of 32-80 slices and a total effective dose ranging from 
0.37 mSv to 0.14 mSv, (generated using the CT parameters and algorithm at 
www.impactscan.org).   
CT image analysis was performed using Pulmonary Workstation 2.0, (VIDA Diagnostics; 
Iowa City, IA, USA) to generate bronchial wall area percent, wall thickness percent and 
lumen area  for all 3rd-5th generation segmental bronchi analyzed and lumen area was 
normalized to body surface area.39  As shown in Figure 4-1, an automated airway tree 
segmentation algorithm was applied with a manual seed-point in the airway lumen 
introduced if the trachea and main bronchus were not present in the image.  For each 
subject, all airway segment measurements were averaged to report whole lung means.  To 
identify potential spatial relationships between 3He MRI ventilation defects and 
corresponding airways, CT-MRI co-registration was performed using 3D Slicer 
registration software (http://www.slicer.org).40 
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Figure 4-1  Schematic for 3He MRI – Regional CT image acquisition, co-registration and 
analysis. 
A region-of-interest (ROI) (green-yellow rectangle) with ventilation defects was located 
using 3He MRI.  Following MRI, regional CT was acquired in that specific ROI. 
Ventilation defect percent (VDP) was quantified for the whole lung and the CT-derived 
ROI and an automated airway tree segmentation algorithm (VIDA) was applied to obtain 
airway measurements.  Using the carina and trachea as a landmark, the regional CT with 
rendered airways was rigidly co-registered with the corresponding MR image to confirm 
the spatial relationship between ventilation defects and corresponding airways. 
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4.2.5 Statistical Analysis 
Pulmonary function tests, MRI and CT measurements were compared between subject 
groups using unpaired Student t-tests performed using SPSS 20.0 (IBM, Armonk, NY, 
USA).  Linear regression (r2) and Spearman rank correlation coefficients (r) were 
performed using GraphPad Prism version 4.00 (Graphpad Software Inc, San Diego, CA, 
USA).  Results were considered statistically significant when the probability of making a 
Type I error was less than 5% (p < 0.05). 
4.3 Results 
We enrolled 34 subjects including 26 subjects with a clinical diagnosis of asthma and 
previous methacholine challenge results consistent with asthma, and 8 healthy volunteers.  
Table 4-1 shows subject demographic data, pulmonary function measurements, and 
dyspnea scores for the two subgroups, and a subject listing of all data is provided in the 
online supplement, Table 4-3S.  
Table 4-1 Subject demographic characteristics for asthmatics and healthy volunteers. 
SD=Standard Deviation, BMI=Body Mass Index, FEV1=Forced Expiratory Volume in 1s, 
%pred= Percent Predicted, FVC=Forced Vital Capacity, sRaw=Specific Airway Resistance, 
FeNO=Fraction of Exhaled Nitric Oxide, PC20= provocative concentration of methacholine 
sufficient to induce a 20% decrease in FEV1, mMRC=modified Medical Research Council. 
*n=1 
 
 
 
Healthy  
(n=8) 
Asthmatics 
(n=26) 
Subject Demographics 
Age yrs (±SD) 34 (11) 35 (11) 
Male/Female 4/4 12/14 
BMI kg/m2  (±SD) 23 (3) 25 (5) 
Pulmonary Function Tests 
FEV1 %pred(±SD) 102 (10) 84 (15) 
FVC %pred  (±SD) 103 (10) 93 (11) 
FEV1/FVC % (±SD)   81 (6) 74 (11) 
sRaw cmH2O·s (±SD) 3.0 (0.5) 6.9 (4.7) 
FeNO ppb (±SD) 18*  44 (45) 
PC20 mg/ml (±SD) 42.3 (19.2) 5.9 (12.3) 
Dyspnea Scores 
mMRC Score (±SD) 0 (0) 1 (1) 
Borg Score (±SD) 0 (0) 0.5 (1) 
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Upon qualitative visual inspection, nine of the 26 asthmatics had no ventilation defects 
(ND) and 17 had visually obvious asthma ventilation defects (AD).  Figure 4-2 shows 
posterior, centre and anterior 3He MRI static ventilation coronal slices (in blue) co-
registered to the 1H anatomical MRI (in grey-scale) for a representative healthy volunteer 
as well as ND and AD asthmatics with yellow arrows identifying ventilation defects.  For 
both healthy volunteers and ND asthmatics, 3He gas was homogeneously distributed 
throughout the lung whereas in contrast, AD asthmatics had visually obvious ventilation 
heterogeneity and ventilation defects.  Of the 8 healthy volunteers and 26 asthmatics 
evaluated, 2 healthy volunteers and 12 asthmatics underwent imaging across multiple 
timepoints ranging from 4 years prior, to 2 years following the study session reported here.  
In accordance with the study visit data presented here, both healthy volunteers had no 
ventilation defects at their additional timepoint.  All asthmatics who underwent multiple 
imaging timepoints were AD asthmatics and all of these subjects had ventilation defects at 
their additional timepoint and in the same spatial locations.  Moreover, for all asthmatic 
subjects with repeated imaging measurements (n=12), VDP was not significantly different 
(p=0.49) from measurements acquired and reported in this study.   
As shown in Table 4-2, AD subjects were significantly older than ND subjects (p=0.01) 
with significantly worse FEV1/FVC (p=0.0003), specific airways resistance (sRaw) 
(p=0.004), FeNO (p=0.03), PC20 (p=0.008), COV (p=0.046), wall thickness percent 
(p=0.02) and lumen area normalized to body surface area  (p=0.04), but importantly there 
was no mean difference for FEV1 (p=0.08), FVC (p=0.71) or dyspnea (mMRC: p=0.79, 
Borg: p=0.12).  As compared to healthy subjects, AD subjects had significantly worse 
FEV1 (p=0.001), FEV1/FVC (p=0.003), sRaw (p=0.003), PC20 (p<0.0001), COV (p=0.007) 
wall area percent (p=0.001), wall thickness percent (p=0.04), and lumen area normalized 
to body surface area (p=0.0003), but there was no significant difference for FVC (p=0.06).  
ND subjects had significantly worse FVC (p=0.04), PC20 (p=0.02) and wall area percent 
(0.03) compared to healthy volunteers, but no significant difference for FEV1 (p=0.09), 
FEV1/FVC (p=0.36), sRaw (p=0.36), COV (p=0.11), wall thickness percent (p=0.61) or 
lumen area normalized to body surface area (p=0.26). 
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Figure 4-2  Hyperpolarized 3He MRI of a representative healthy volunteer and asthmatic 
subjects. 
3He MRI gas distribution (in blue) registered to the 1H MRI of the thorax (in grey-scale) 
for posterior, centre and anterior coronal slices for a representative healthy volunteer, an 
asthmatic with no ventilation defects, and two asthmatics with ventilation defects.  Yellow 
arrows identify ventilation defects.  
Healthy Volunteer: 27 yr old female, FEV1=105%pred, FEV1/FVC=85%, sRaw=2.60 
cmH2O·s; Asthmatic 1 No Defects: 23 yr old female, FEV1=82%pred, FEV1/FVC=79%, 
sRaw=3.80 cmH2O·s; Asthmatic 2 Defects: 25 yr old female, FEV1=87%pred, 
FEV1/FVC=69%, sRaw=5.36 cmH2O·s; Asthmatic 3 Defects: 42 yr old male, 
FEV1=72%pred, FEV1/FVC=65%, sRaw=13.85 cmH2O·s. 
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Table 4-2 Subject demographic characteristics, pulmonary function, hyperpolarized 3He 
MRI and x-ray CT airways measurements for asthmatics and healthy volunteers. 
ND=Asthmatics with No Defects, AD=Asthmatics with Defects, SD=Standard Deviation, 
FEV1=Forced Expiratory Volume in 1s, %pred= Percent Predicted, FVC=Forced Vital 
Capacity, sRaw=Specific Airway Resistance, FeNO=Fraction of Exhaled Nitric Oxide, 
PC20= provocative concentration of methacholine sufficient to induce a 20% decrease in 
FEV1, mMRC=modified Medical Research Council, VDP=Ventilation Defect Percent, 
COV=Coefficient of Variation, WA%=Wall Area Percent, WT%=Wall Thickness Percent, 
LA=Lumen Area, BSA=Body Surface Area. *Significance of difference (p<0.05) 
determined using a t-test.  †n=1; ‡n=8; δn=13; ¥HV: n=5; ND: n=9; AD: n=9. 
  
 Healthy  
(n=8) 
Asthma  
(n=26) 
Significance of Difference*  
(p) 
  ND  
(n=9) 
AD 
(n=17) 
HV vs. 
ND 
HV vs. 
AD 
ND vs. 
AD 
Subject Demographics 
Age yrs (±SD) 34 (11) 27 (8) 39 (11) 0.19 0.29 0.01 
Male/Female 4/4 2/7 10/7 - - - 
Pulmonary Function Tests 
FEV1 %pred(±SD) 102 (10) 91 (13) 81 (14) 0.09 0.001 0.08 
FVC %pred  (±SD) 103 (10) 92 (10) 94 (11) 0.04 0.06 0.71 
FEV1/FVC % (±SD)   81 (6) 84 (7) 69 (10) 0.36 0.003 0.0003 
sRaw cmH2O·s 
(±SD) 
2.96 
(0.53) 
3.42(1.22) 8.51(4.95) 0.36 0.003 0.004 
FeNO ppb (±SD) 18† 17 (9)‡ 60 (50)δ - - 0.03 
PC20 mg/ml (±SD) 42.3 
(19.2) 
14.3(16.8) 1.4 (3.9) 0.02 <0.0001 0.008 
Dyspnea 
mMRC Score (±SD) 0.0 (0.0) 0.7 (0.7) 0.8 (1.0) 0.02 0.04 0.79 
Borg Score (±SD) 0.1 (0.2) 0.2 (0.3) 0.7 (0.8) 0.28 0.047 0.12 
3He MRI       
Whole Lung VDP% 
(±SD) 
1.22 
(0.19) 
1.31(0.32) 4.26(3.28) - - - 
Regional VDP% 
(±SD)¥ 
0.94 
(0.28) 
0.95(0.40) 2.35(0.98) - - - 
Whole Lung COV 
(±SD) 
0.22 
(0.02) 
0.23(0.01) 0.26(0.03) 0.11 0.007 0.046 
Regional CT¥       
WA% (±SD) 62 (2) 66 (3) 69 (3) 0.03 0.001 0.08 
WT%  (±SD)  24 (4) 25 (2) 29 (4) 0.61 0.04 0.02 
LA mm2 (±SD)  18 (3) 14 (6) 11 (4) 0.19 0.002 0.12 
LA/BSA mm2/m2 
(±SD)  
10 (2) 8 (3) 6 (2) 0.26 0.0003 0.04 
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Figure 4-3 shows the correlations for FEV1 and sRaw with whole lung VDP, regional VDP 
and wall area percent.  FEV1 was significantly correlated with both 
3He MRI VDP (whole 
lung: r=-0.61, p=0.0002; regional: r=-0.55, p=0.006) and wall area percent (r=-0.49, 
p=0.02).   In addition, sRaw was significantly correlated with both 3He MRI VDP (whole 
lung: r=0.77, p<0.0001; regional: r=0.81, p<0.0001) and wall area percent (r=0.48, 
p=0.02).  Additionally, FEV1 and sRaw were significantly correlated with whole lung 
3He 
MRI COV (FEV1: r=-0.49, p=0.003; sRaw: r=0.59, p=0.0003).  Figure 4-4 demonstrates 
that for all subjects wall area percent was significantly correlated with whole lung (r=0.42, 
p=0.046) and regional VDP (r=0.43, p=0.04).   
 
Figure 4-3  Relationships of MRI and CT measurements with FEV1 and airways resistance. 
(A) Negative relationship between 3He MRI VDP and FEV1%pred (WL: r=-0.61, r2=0.20, 
p=0.0002; RG: r=-0.55, r2=0.26, p=0.006). 
(B) Positive relationship between 3He MRI VDP and specific airways resistance (sRaw) 
(WL: r=0.77, r2=0.62, p<0.0001; RG: r=0.81, r2=0.75, p<0.0001). 
(C) Negative relationship between wall area percent and FEV1%pred (r=-0.49, r2=0.23, 
p=0.02).  
(D) Positive relationship between wall area percent and specific airways resistance (sRaw) 
(r=0.48, r2=0.21, p=0.02). 
WL=whole lung, RG=regional, WA%=wall area percent 
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Figure 4-4  Relationship between 3He MRI VDP and CT-derived wall area percent (WA%) 
WA% was significantly correlated with both whole lung 3He MRI VDP (r =0.42, r2=0.11, 
p=0.046) and regional 3He MRI VDP (r =0.43, r2=0.15, p=.04). 
Dashed lines represent the 95% confidence intervals of the regression line.  
 
 
Figure 4-5 shows hyperpolarized 3He MRI ventilation maps for four asthmatics with the 
3He MRI ventilation map in blue co-registered to the CT volume with the airway tree 
segmented in yellow.  The qualitative spatial relationship between ventilation defects 
(yellow arrows) and remodeled airways (white arrows) is shown. 
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Figure 4-5  Spatial relationship between ventilation defects and airways for four 
representative asthmatics with ventilation defects. 
3He MRI gas distribution (in blue) registered to the regional CT of the thorax (in grey-
scale) with the airway tree segmented in yellow.  Airway measurements are for the specific 
airway (white arrow) spatially related to the ventilation defect (yellow arrow) of interest. 
Panel A is a 29 yr old male FEV1=81%pred, regional VDP=5%, wall area=71%, lumen 
area=5mm2; Panel B is a 49 yr old male, FEV1=60% pred, regional VDP=3%, wall area 
=67%, lumen area=12mm2 ; Panel C is a 25 yr old female, FEV1=87% pred, regional 
VDP=2%, wall area =75%, lumen area=5mm2; Panel D is a 58 yr old male, FEV1=73% 
pred, regional VDP=1%, wall area=70%, lumen area=5mm
2.  
 
4.4 Discussion  
To better understand the structural and clinical determinants of MRI ventilation defects in 
asthma, and, in turn, what it might mean for an asthmatic to have ventilation defects, we 
evaluated well-established clinical measurements and emerging CT and 3He MRI 
measurements of airway structure and function.  
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We think that it is interesting that 9/26 (35%) subjects with clinical findings and 
methacholine challenge results diagnostic of asthma had a 3He MRI gas distribution that 
was qualitatively and quantitatively (VDP and COV) similar to healthy volunteers.  It is 
important to note that all of the healthy volunteers had a homogenous gas distribution with 
no visual or quantitative evidence of ventilation defects, which is in agreement with 
previous work at our centre11,41-43 and others.5,7,44  In contrast, and as expected based on 
previous investigations,5-9,11,12 the remaining 17/26 (65%) asthmatics had obvious 
ventilation abnormalities.  This observation prompted us to ask the question: Are 
asthmatics with ventilation defects different than asthmatics without ventilation defects?  
The results here suggest that asthmatics with ventilation defects are older, with worse 
FEV1/FVC, (but similar FEV1), and greater airways resistance, airway responsiveness, and 
airway inflammation/remodeling.  Such findings suggest that ventilation defects may 
reflect long-term or progressive airway remodeling in patients with a longer history of 
disease or perhaps more severe or advanced disease.  Regardless, the constellation of 
clinical and imaging findings in these asthmatics suggest that more aggressive therapy or 
compliance to therapy is required.  This is a hypothesis that can be tested in future imaging 
studies of older and/or more severe asthmatics.  
A number of studies have quantitatively investigated asthma airway structure using CT and 
showed that bronchial wall thickness was related to asthma severity, duration of disease 
and airflow obstruction.14-22  Similarly, 3He MRI has previously shown that ventilation 
defects were related to asthma severity6 and in a preliminary report,45 half of a small group 
of asthmatics (7/15) showed no obvious ventilation defects, with significantly different 
bronchial wall thickness (but not bronchial wall area) compared to asthmatics with 
ventilation defects.  Here, we prospectively acquired both MRI and CT within about 30 
minutes using the same lung volume and breath-hold manoeuvre to try to mimic the same 
airway and parenchyma dimensions using both imaging methods.  We must consider that 
because 3He gas is itself, highly diffusive and may penetrate even narrowed airways, there 
is the possibility that even when bronchial wall thickness and lumen area are abnormal, 
some 3He gas ventilation is possible.  In support of this explanation, we note the recent 
report of indirect or collateral ventilation in COPD that was directly visualized using 
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hyperpolarized 3He MRI46 – likely possible only because the timeframe for imaging was 
relatively long and 3He gas is highly diffusive.   
We also observed that regional CT airway morphology and 3He ventilation defect 
measurements were significantly correlated.  This important finding suggests that there is 
a relationship between airways that are remodeled and/or constricted and ventilation 
defects.  Previous studies have demonstrated that focal regions of hyperlucency on CT 
(likely related to gas trapping) were spatially correlated with 3He MRI ventilation defects28 
and bronchoalveolar lavage had higher total and percent neutrophils in areas of the lung 
with greater ventilation defects, suggestive of increased inflammation.  Although we 
observed significant relationships between airway dimensions and defects, these 
relationships were modest, perhaps because of the heterogeneity of asthma and the asthma 
patients evaluated here, or because of the relatively low dose partial CT region of interest 
that was utilized.  It is important to acknowledge that in asthma, the airways from the large 
bronchi to the alveolar ducts may be involved,47 thus using CT to measure airway 
dimensions has limitations because CT cannot spatially resolve the small airways (<2mm) 
sufficiently to provide accurate measurements.  In addition to small and heterogeneously 
distributed ventilation defects, some of the asthmatics evaluated here presented large 
wedge shaped defects; these have previously been reported using single photon emission 
computed tomography (SPECT) imaging with Technegas25 and are believed to be the result 
of segmental airway narrowing.  Following MRI-CT registration we were able to identify 
and quantify segmental bronchi that were spatially related to ventilation defects.  Larger 
‘segmental’ ventilation defects may be the result of proximal remodeled sub-segmental 
airways feeding these regions of signal void.  Unfortunately, due to the limitations of the 
spatial resolution of the CT images, we cannot comment on the structure of the smaller 
airways distal to the sub-segmental airways quantified here, which may further contribute 
to the abnormal gas distributions observed.   
Large and temporally persistent 3He ventilation defects, provide excellent targets for 
therapy and could potentially guide localized airway treatments such as bronchial 
thermoplasty.  Although we have focused our attention on ventilation defects, areas of 
hyper-intense signal intensity are often observed in asthmatic subjects in conjunction with 
ventilation defects.  Similar to regions of signal void, to our knowledge, the underlying 
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etiology of these regions has not been investigated.  We hypothesize that hyper-intense 
signal may be due to hyperinflation and note that investigation of these regions is warranted 
in asthma. 
We recognize and acknowledge that this work was limited by the relatively small number 
of subjects evaluated, although we note that this is the single largest prospective study that 
directly compared CT and 3He MRI in asthmatics and healthy subjects.  Furthermore, the 
subjects evaluated here were enrolled from a multi-disciplinary asthma care centre and 
therefore they represent a diverse group of asthmatics that have been mainly referred to 
improve asthma symptoms and control.  As shown in Figure 4-3, there was a single subject 
with elevated VDP as compared to the other AD subjects and we confirmed that this 42 
year old male had experienced an asthma exacerbation that required hospitalization 
approximately 5 months prior to hyperpolarized 3He MRI performed here.  This subject’s 
asthma was previously well-controlled and the exacerbation was determined to be the result 
of sudden cessation of asthma medication.  It is important to note that the relationships 
presented in Figure 4-3 remain statistically significant when this outlier is removed from 
the analysis.  Certainly, this is a hypothesis generating study and therefore marginally 
significant p-values should be interpreted with caution, and larger studies are required for 
more extensive phenotyping and characterization of asthmatics and to test the hypotheses 
generated here.  We must also acknowledge that our analysis was limited because of the 
acquisition of partial CT thoracic volumes.   
In summary, our results showed that asthmatics with 3He MRI ventilation abnormalities 
were older, with greater airway hyperresponsiveness, and worse measurements of 
FEV1/FVC and airways resistance/inflammation as well as abnormally remodeled airways 
in comparison to asthmatics without ventilation defects.  Hyperpolarized 3He ventilation 
abnormalities were spatially and quantitatively related to remodeled airways in asthmatics 
providing a better understanding of the etiology of heterogeneous ventilation abnormalities 
in asthma and the clinical meaning of these abnormalities in asthmatics with similar FEV1. 
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4.6 Supplementary Material  
Table 4-3S  Subject listing of demographic characteristics, pulmonary function and dyspnea. 
Subject Age Gender FEV1 FVC FEV1/FVC IC RV TLC sRaw FeNO PC20 mMRC Borg 
 (yrs)  (%pred) (%pred) (%) (%pred) (%pred) (%pred) (cmH2O·s) (ppb) (mg/ml)  Baseline Post-MCh 
Healthy Volunteers (n=8) 
021 27 F 105 105 85 124 107 113 2.60 18 8.5 0 0 0.0 
023 39 M 86 95 72 125 182 118 2.77 - 54.4 0 0 0.0 
027 24 M 108 110 80 113 179 121 4.00 - - 0 0.5 2.0 
030 50 F 106 107 79 134 75 110 3.08 - - 0 0 2.0 
031 26 F 97 90 93 99 109 96 3.24 - 46.1 0 0 0.5 
033 23 M 93 91 85 110 99 99 2.18 - 52.6 0 0 0.0 
034 30 M 101 108 77 111 102 109 2.81 - 49.9 0 0 0.5 
035 50 F 117 118 79 126 88 115 3.01 - - 0 0 0.5 
Mean(±SD) 34(11) - 102(10) 103(10) 81(6) 118(11) 118(40) 110(9) 2.96(0.53) - 42.3(19.2) 0(0) 0.1(0.2) 0.7(0.8) 
Asthmatics with No Defects (n=9) 
005 45 F 78 87 72 124 108 102 4.97 - 2.4 2 0.5 4 
006 23 F 96 91 92 107 104 97 1.50 8 16.9 1 1 7 
007 24 M 81 85 81 86 111 94 3.22 12 27.9 0 0.5 3 
008 34 M 82 79 84 110 105 91 2.67 16 55.2 0 0 3 
010 30 F 102 101 87 135 82 96 2.25 21 3.4 1 0 2 
017 23 F 112 102 96 128 164 122 3.95 12 13.2 0 0 3 
018 22 F 79 83 82 90 115 91 5.58 37 0.4 0 0 3 
020 23 F 82 91 79 104 69 87 3.80 17 0.3 1 0 2 
024 20 F 108 110 86 138 85 99 2.88 10 9.1 1 0 4 
Mean(±SD) 27(8) - 91(13) 92(10) 84(7) 114(18) 105(25) 98(10) 3.42(1.22) 17(9) 14.3(16.8) 0.7(0.7) 0.2(0.3) 3.4(1.4) 
Asthmatics with Defects (n=17) 
001 49 F 69 94 59 116 144 110 10.20 38 0.08 0 1 1 
002 30 M 96 105 75 122 108 109 5.11 - 0.2 0 0 4 
003 29 M 81 100 66 118 115 111 19.50 114 0.1 1 0.5 3 
004 49 F 59 75 63 84 130 96 - - 0.07 0 0 2 
011 23 F 98 93 91 101 113 95 2.93 116 0.2 1 1 3 
012 25 F 87 107 69 119 98 101 5.36 50 0.1 1 0 3 
013 37 M 77 77 81 107 135 97 10.42 31 0.1 4 1 3 
014 29 F 92 102 77 98 96 97 2.64 18 1.3 1 1 3 
015 47 M 60 82 57 99 115 94 6.51 45 0.3 0 0.5 4 
016 53 M 104 104 77 111 82 100 4.78 22 16.3 0 0 4 
019 42 M 72 88 65 110 144 108 13.85 40 0.1 1 0 1 
022 24 F 99 111 76 132 90 108 6.40 187 0.2 0 0 3 
025 58 M 73 99 56 91 121 110 8.38 29 1.0 0 0.5 0 
026 37 M 93 93 66 105 107 109 4.33 - 2.6 1 0.5 3 
028 36 F 66 92 59 129 165 113 15.74 - 0.8 1 3 3 
029 41 M 75 95 63 114 136 106 13.76 69 0.1 1 2 3 
032 49 M 69 77 70 98 98 87 6.31 23 1.0 1 0.5 3 
Mean(±SD) 39(11) - 81(14) 94(11) 69(10) 109(13) 117(22) 103(8) 8.51(4.95) 60(50) 1.4(3.9) 0.8(1.0) 0.7(0.8) 2.7(1.1) 
SD=Standard Deviation, FEV1=Forced Expiratory Volume in 1s, %pred= Percent Predicted, FVC=Forced Vital Capacity, IC=Inspiratory 
Capacity, RV=Residual Volume, TLC=Total Lung Capacity, sRaw=Specific Airway Resistance, FeNO=Fraction of Exhaled Nitric 
Oxide, PC20=provocative concentration of methacholine sufficient to induce a 20% decrease in FEV1, mMRC=modified Medical 
Research Council.  
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CHAPTER 5 
Improving asthma control is the primary treatment goal for asthmatics.  Links between 
asthma control and ventilation defects have not been ascertained so we endeavoured to 
answer the question, “What is the relationship of asthma control with in vivo ventilation 
defects quantified and regionally visualized using MRI?” 
The contents of this chapter are in preparation to be submitted to the journal Radiology: S 
Svenningsen, P Nair, DG McCormack and G Parraga.  What do Ventilation Defects Reveal 
about Asthma Control? Radiology (To be submitted December 2015).    
5 WHAT DO VENTILATION DEFECTS REVEAL ABOUT 
ASTHMA CONTROL? 
5.1 Introduction 
The primary goal of asthma treatment is the achievement and maintenance of disease 
control.  Unfortunately, approximately 50% of asthmatics remain poorly controlled with 
up-to 10% of these patients experiencing severe and life-threatening exacerbations.1  It is 
now well-understood that the clinical and pathophysiological characteristics of poorly-
controlled asthma are heterogeneous which makes treatment decisions particularly 
complex.  Because of this heterogeneity, sensitive and specific disease biomarkers are 
required to guide treatment decisions aimed at improving asthma control.  Recent studies 
using multiple-breath-gas-washout techniques have suggested that poor asthma control 
may be related to ventilation heterogeneity.2,3  Although the exact pathophysiological 
abnormalities responsible for ventilation heterogeneity are unclear, these may include 
regional variations in luminal accumulation of inflammatory cells, mucus, albumin and 
fibrin, thickening of the airway walls, smooth muscle hyperplasia and hypertrophy, sub-
epithelial fibrosis and mucus cell metaplasia.   
Ventilation heterogeneity measured using the lung clearance index (LCI), was first 
described over 65 years ago,4 and has endured as a biomarker of obstructive lung disease.  
Ventilation heterogeneity in asthmatics is elevated in comparison to healthy controls,5-7 is 
an independent determinant of airway hyperresponsiveness,8 improves with 
bronchodilation5,9 and inhaled corticosteroids3,10 and worsens during exacerbations.11  
Although this mature body of research strongly supports the notion that LCI is sensitive to 
139 
 
ventilation heterogeneity in asthma, such measurements cannot localize the site of these 
functional abnormalities. 
On the other hand ventilation defects may be regionally identified and visualized using 
pulmonary imaging methods12,13 including noble gas magnetic resonance imaging (MRI).14  
It was previously established that in well-controlled asthmatics, focal MRI ventilation 
defects are associated with worse lung function, increased airway inflammation, airway 
hyperresponsiveness and greater airway wall thickness.15  Furthermore, MRI ventilation 
defects are temporally and spatially persistent,16 worsen in response to bronchoconstriction 
and improve following bronchodilation.17  
Until now however, the relationship between ventilation defects and asthma control and 
exacerbations has not been ascertained.  Therefore, the purpose of this small study in severe 
asthmatics was to investigate MBNW and MRI measurements of ventilation heterogeneity 
to better understand their relationship with asthma control.  We hypothesized that MRI 
ventilation defects and the lung clearance index would be correlated, and that both would 
be biomarkers of poor asthma control. Given the relative lack of therapy options for severe 
asthma, this is important because regional ventilation defects and the lung clearance index 
provide endpoints that might be helpful in guiding treatment decisions aimed at improving 
asthma control.  
5.2 Methods 
5.2.1 Study Participants and Design 
Participants provided written informed consent to a study protocol approved by a local 
research ethics board, and the study was compliant with the Personal Information 
Protection and Electronic Documents Act (PIPEDA, Canada) and the Health Insurance 
Portability and Accountability Act (HIPAA, USA).  Patients between 18 and 70 years of 
age with a diagnosis of severe asthma, according to the Global Initiative of Asthma (GINA) 
treatment step criteria 18 and under the care of a respirologist were recruited from two 
academic tertiary care centres (McMaster and Western Universities, Canada). 
During a single 2-hour visit, all participants performed pre- and post-bronchodilator 
spirometry, MBNW and MRI.  Asthma-control and quality-of-life was assessed using the 
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Asthma-Control-Questionnaire (ACQ; 7-item version)19 and Standardized-Asthma-
Quality-of-Life-Questionnaire (AQLQ(S)),20 respectively.  Borg and modified Medical 
Research Council dyspnea scores were recorded.  Clinical history of severe asthma 
exacerbations, emergency department (ED) visits and hospitalizations for respiratory 
symptoms were self-reported.  As previously defined,21 a severe asthma exacerbation was 
a worsening of symptoms requiring treatment with oral or intravenous corticosteroids, OR 
a doubling of inhaled corticosteroid (ICS) dose for ≥ 3 days, OR any temporary increase 
in the dosage of oral corticosteroids (OCS) for subjects taking maintenance OCS.  
Methacholine challenge was performed within 6 months previous to the MRI visit to 
determine the provocative concentration resulting in a ≥20% decrease in FEV1 (PC20).   
5.2.2 Pulmonary Function Tests and Bronchial Challenge 
Spirometry was performed according to American Thoracic Society Guidelines 22 using a 
MedGraphics Elite Series plethysmograph (MedGraphics; St. Paul, MN, USA).  For post-
bronchodilator measurements, four 100μg doses of Novo-Salbutamol® HFA (Teva 
Novopharm Ltd.; Toronto, ON, Canada) were delivered through a pressurized meter dose 
inhaler using an AeroChamber Plus spacer (Trudell Medical International; London, ON, 
Canada).  All participants were instructed to withhold their short-acting beta-agonists 12 
hours prior to their visit (overnight).   
5.2.3 Lung Clearance Index 
The multiple breath washout manoeuvre was performed using 100% oxygen (O2) for 
nitrogen washout and the ndd EasyOne Pro® LAB system (ndd Medical Technologies; AG, 
Zurich, Switzerland) equipped with an ultrasonic flow and molar mass sensor.  With the 
volunteer seated upright and breathing through a mouth piece while wearing nose clips, the 
washout phase was initiated after several breaths of room air by switching from room air 
to 100% O2 at end expiration.  Tidal breathing of 100% O2 was performed until washout 
was complete (expired N2 concentration <2.5% of test start).  Functional residual capacity 
(FRC) was calculated from the cumulative volume of expired N2 divided by the difference 
between the end-tidal concentration at the start and end of the washout.  The cumulative 
expired volume (CEV) was the cumulative volume of expired air during the washout.  The 
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lung clearance index (LCI) was the number of FRC lung turnovers required to reach N2 
concentration<2.5% of test start and was generated as CEV divided by FRC as previously 
described.23  The washout manoeuvre was performed in duplicate and LCI was reported as 
the mean of two washout manoeuvres.  
5.2.4 Magnetic Resonance Imaging  
MRI was performed on a whole body 3.0 Tesla Discovery MR750 (General Electric Health 
Care, Milwaukee, WI, USA) system with broadband imaging capability, as previously 
described.24  Subjects were instructed to inhale a gas mixture from a 1.0L Tedlar® bag 
(Jensen Inert Products; Coral Springs, FL, USA) from FRC, and image acquisition was 
performed in 8-15s under breath-hold conditions.  Conventional 1H MRI was performed 5 
minutes prior to hyperpolarized 3He MRI and both methods were previously described.24   
Quantitative evaluation was performed by a single trained observer (S.S) using custom 
semi-automated segmentation software generated using MATLAB R2007b (The 
Mathworks Inc.; Natick, MA, USA), as previously described.25  3He MRI ventilation defect 
percent (VDP) was generated and defined as the ventilation defect volume normalized to 
the thoracic cavity volume.25 
5.2.5 Statistical Analysis 
Data were tested for normality using the Shapiro-Wilk normality test and when data were 
not normal, non-parametric tests were performed.  Univariate relationships were evaluated 
using linear regressions (r2), Pearson correlations (r) and when the data were not normal, 
Spearman correlations ().  Paired two-tailed t-tests and Wilcoxon matched-pairs signed 
rank tests were used to evaluate the effect of bronchodilator therapy on ventilation 
heterogeneity.  Unpaired t-tests and Mann-Whitney tests were performed to compare 
ventilation heterogeneity in subjects stratified by ACQ (≤2 or >2) and AQLQ scores (≥5 
or <5) and previous 6-month exacerbation history (<1 or ≥1).  All statistical analyses were 
performed using GraphPad Prism version 6.02 (GraphPad Software Inc.; La Jolla, CA, 
USA) and results were considered statistically significant when the probability of making 
a Type I error was < 5% (p < 0.05). 
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5.3 Results 
5.3.1 Study Participants 
Table 5-1 provides a summary of demographic and asthma characteristics for 18 
participants (6 males/12 females, 46±12 years) with severe asthma.   The mean duration of 
asthma was 31±15 years (range=7-57), pre-bronchodilator FEV1 was 68±24%pred 
(range=33-103%pred) and pre-bronchodilator FEV1/FVC was 65±15% (range=35-88%).  A 
participant listing provided in Table 5-3 (supplement) shows there was abnormal 
ventilation heterogeneity (both VDP and LCI) for 13 participants and there was normal 
VDP/LCI or normal VDP/abnormal LCI for five subjects.  
Table 5-1  Participant demographics and asthma measurements. 
Parameter (±SD) Severe Asthma (n=18) 
 Pre-bronchodilator Post-bronchodilator 
Age years  46 (12) - 
Male/Female 6/12 - 
Duration of asthma years  31 (15) - 
BMI kg/m2  29 (5) - 
FEV1  L 2.2 (0.8) 2.5 (0.8) 
FEV1  %pred 68 (24) 75 (26) 
FVC  L 3.5 (1.0) 3.6 (1.0) 
FVC  %pred 83 (19) 88 (17) 
FEV1/FVC  % 65 (15) 68 (16) 
PC20  mg/mL 1.4 (2.8)
* - 
Lung clearance index 10.5 (3.0) 9.5 (2.6)† 
Ventilation defect percent  %  12 (11) 8 (8) 
SD=standard deviation; BMI=body mass index; FEV1=forced expiratory volume in 1 
second; %pred=percent predicted; FVC=forced vital capacity; PC20=methacholine 
concentration for 20% decrease in FEV1. 
*n=5; †n=17  
 
Asthma medications and control parameters are summarized in Table 5-2.  A participant 
listing of these data is also provided in Table 5-4 (supplement).  Despite receiving medium-
to-high dose inhaled corticosteroids (ICS) and long-acting beta-agonists (GINA treatment 
step 4-5),18 all 18 participants had poorly-controlled disease as evidenced by mean ACQ 
score (2.3±0.9, range=1.0-4.3).  Eight (44%) participants were prednisone-dependent 
(dosage ranging from 2.5 to 50 mg/day).  One or more severe asthma exacerbations were 
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reported by nine (50%) and 15 (83%) participants in the previous 6- and 12-months 
respectively.   
Table 5-2  Asthma medication and control. 
 Severe Asthma (n=18) 
Asthma Medications  
 Inhaled corticosteroid n (%) 18 (100%) 
 Long-acting β2-agonist n (%) 18 (100%) 
 Long-acting anticholinergic n (%) 7 (39%) 
 Oral corticosteroid n (%) 8 (47%) 
 Leukotriene receptor antagonist n (%) 9 (53%) 
 Anti-immunoglobulin E n (%) 1 (6%) 
Asthma Control  
 ACQ score* 2.3 (0.9) 
 AQLQ total score* 4.6 (1.2) 
 mMRC dyspnea score* 1.3 (1.0) 
 Borg dyspnea score* 2.5 (2.3) 
 Severe exacerbation previous 6 months n (%) 9 (50%) 
 Severe exacerbation previous year n (%) 15 (83%) 
 ED visit previous 6 months n (%) 1 (6%) 
 ED visit previous year n (%) 4 (22%) 
 Hospitalization previous 6 months n (%)  0 (0%) 
 Hospitalization previous year n (%) 1 (6%) 
Values are mean (±SD) except when indicated otherwise.  ACQ=asthma control 
questionnaire; AQLQ=asthma quality-of-life questionnaire; mMRC=modified Medical 
Research Council; ED=emergency department. *n=16 
5.3.2 Ventilation Heterogeneity 
Figure 5-1 shows pre-bronchodilator coronal 3He MRI ventilation (in blue) co-registered 
to 1H anatomical MRI (in grey-scale) for six representative participants.  As shown 
qualitatively in Figure 5-1, there was a greater number and volume of 3He MRI ventilation 
abnormalities in participants with worse ACQ.  For example, in subject S17 there was a 
relatively homogeneous ventilation pattern, normal LCI and relatively good asthma control 
whereas for subjects S16, S06, S13 and S04, there was qualitatively abnormal ventilation 
that was concomitant with worse asthma control.   
Table 5-1 shows that both VDP (pre-salbutamol=12±11%, post-salbutamol=8±8%, 
p=0.008) and LCI (pre-salbutamol=10.5±3.0, post-salbutamol=9.5±2.6, p=0.02) 
significantly improved following bronchodilation.  One participant (S12) could not 
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complete the post-bronchodilator MBNW manoeuvre due to fatigue and was excluded 
from this evaluation.    
 
Figure 5-1  Hyperpolarized 3He MRI of representative patients with severe asthma. 
Centre coronal slice 3He MRI ventilation in blue co-registered to anatomical 1H MRI in 
grey-scale for six representative severe asthmatics.  S07: 55 year-old female, 
FEV1=77%pred, ACQ=1.4, LCI=9.7, VDP=2%; S17: 39 year-old female, FEV1=66%pred, 
ACQ=1.7, LCI=6.7, VDP=3%; S16: 48 year-old male, FEV1=78%pred, ACQ=2.3, LCI=8.6, 
VDP=8%; S06: 45 year-old male, FEV1=34%pred, ACQ=2.7, LCI=11.5, VDP=14%; S13: 
56 year-old male, FEV1=34%pred, ACQ=3.1, LCI=17.5, VDP=33%; S04: 60 year-old 
female, FEV1=47%pred, ACQ=4.3, LCI=14.0, VDP=35%. 
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5.3.3 Ventilation Heterogeneity and Asthma Control 
Figure 5-2 shows VDP and LCI in participants stratified by ACQ score (ACQ≤2, n=7 and 
ACQ>2, n=9), AQLQ score (AQLQ≥5, n=7 and AQLQ<5, n=9) and by the number of self-
reported exacerbations in the past 6 months (exacerbations <1, n=9 and exacerbations ≥1, 
n=9).  As shown in Figure 5-2A, there was significantly worse VDP (18±13% versus 
6±5%; p=0.04), but not LCI (11.2±3.6 versus 9.4±2.4; p=0.3), in the subgroup of 
asthmatics with ACQ scores >2.  There was also significantly worse VDP (18±13% versus 
6±5%; p=0.04), but not LCI (11.4±3.3 versus 9.1±2.6; p=0.2), in the subgroup of 
asthmatics with AQLQ scores <5.  Figure 5-2C also shows that there was a trend towards 
worse VDP (17±13% versus 8±5%; p=0.053), but not LCI (11.2±3.8 versus 9.7±1.8; 
p=0.3), in asthmatics reporting ≥1 exacerbation in the past 6-months.  There were 15 
subjects with exacerbations in the previous 12-months (VDP=13±12%; LCI=10.3±3.2).  
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Figure 5-2  Ventilation heterogeneity stratified by ACQ and AQLQ scores and self-
reported exacerbations.    
A) Significantly worse VDP (>2 ACQ, VDP=18±13%; ≤2 ACQ, VDP=6±5, p=0.04), but 
not LCI (>2 ACQ, LCI=11.2±3.6; ACQ≤2, LCI=9.4±2.4, p=0.29) for subjects with 
ACQ >2.  
B) Significantly worse VDP (AQLQ<5, VDP=18±13; AQLQ≥5, VDP=6±5, p=0.04), but 
not LCI (AQLQ<5, LCI=11.4±3.3; AQLQ≥5, LCI= 9.1±2.6, p=0.16), for subjects 
with AQLQ total scores <5.   
C) There was a trend towards greater VDP (exacerbations ≥1, VDP=17±13%; 
exacerbations<1, VDP=8±5%; p=0.053), but not LCI (exacerbations ≥1, 
LCI=11.2±3.8 exacerbations<1, LCI= 9.7±1.8; p=0.3), for subjects with ≥1 
exacerbation in past 6-months.   
Box-and-whiskers plots show minimum, 25th percentile, median, 75th percentile, and 
maximum with each individual value superimposed on the graph.  += mean.  ACQ=asthma 
control questionnaire; AQLQ=asthma quality-of-life questionnaire; LCI=lung clearance 
index; VDP=ventilation defect percent. 
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5.3.4 Relationships 
Given the different results for the ACQ and AQLQ subgroups with VDP and LCI 
measurements, we also evaluated the bilateral relationships for LCI and VDP and their 
post-salbutamol changes.  Figure 5-3 qualitatively shows some of these relationships in 
individual participants.  For example, for subjects S11, S03 and S15, there was significantly 
improved VDP, with minimal post-salbutamol change in LCI.  In contrast, for subjects 
S02, S13 and S05, there was significantly improved LCI with a minimal post-salbutamol 
change in VDP.  Figure 5-4A shows that there were strong VDP-LCI correlations pre- 
(r=0.86, r2=0.74, p<0.0001) and post-bronchodilator (r=0.93, r2=0.86, p<0.0001).  However, 
as shown in Figure 5-4B, the post-bronchodilator change in VDP was not correlated with 
the post-bronchodilator change in LCI (r=0.44, r2=0.01, p=0.08).  As shown in Figure 
5-4C and D, VDP (r=0.62, r2=0.38, p=0.01) was correlated with ACQ score and LCI 
(r=0.49, r2=0.24, p=0.052) showed a similar trend.  VDP and LCI were not related to 
AQLQ score (VDP: r=-0.34, r2=0.11, p=0.20; LCI: r=-0.22, r2=0.05, p=0.40) or 
exacerbations in the past 6 (VDP: r=0.31, r2=0.02, p=0.21; LCI: r=0.08, r2=0.0001, p=0.77) 
and 12-months (VDP: r=0.03, r2=0.003, p=0.92; LCI: r=-0.21, r2=0.06, p=0.41).  
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Figure 5-3  Pre- and post-bronchodilator 3He ventilation MRI.   
S11: 40 year-old female, ACQ=2.3, ΔLCI=-0.8, ΔVDP=-11%; S03: 61 year-old male, 
ACQ=2.1, ΔLCI=-1.4, ΔVDP=-13; S15: 42 year-old male, ACQ=1.4, ΔLCI=0.6, ΔVDP=-
4%; S02: 67 year-old male, ACQ=NA, ΔLCI=-3.8, ΔVDP=-5%; S13: 56 year-old male, 
ACQ=3.1, ΔLCI=-2.1, ΔVDP=-5%; S05: 38 year-old female, ACQ=1.9, ΔLCI=-2.2, 
ΔVDP=-1%. 
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Figure 5-4  Relationship for ventilation heterogeneity and asthma control. 
A) VDP was significantly correlated with LCI pre- (r=0.86, r2=0.74, p<0.0001, 
y=3.1x-20.0) and post-bronchodilator (r=0.93, r2=0.86, p<0.0001).  
B) The change in VDP and LCI post-bronchodilator was not correlated (r=0.44, 
r2=0.01, p=0.08). 
C) VDP was significantly correlated with ACQ (r=0.62, r2=0.38, p=0.01). 
D) There was a trend for an LCI–ACQ correlation (r=0.49, r2=0.24, p=0.052). 
Dotted lines=95% confidence intervals; ACQ=asthma control questionnaire; LCI=lung 
clearance index; VDP=ventilation defect percent. 
 
5.4 Discussion  
In an endeavour to answer the question: Are MRI ventilation defects related to asthma 
control?, we evaluated MRI and LCI measurements in 18 severe asthmatics.  We observed: 
1) abnormal VDP and LCI were strongly correlated but there were different responses to 
salbutamol, 2) there was significantly worse VDP but not LCI in asthmatics with an ACQ 
score >2 and AQLQ score <5, which was supported by a significant VDP-ACQ correlation, 
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and, 3) there was a trend towards greater VDP, but not LCI, in asthmatics with ≥1 
exacerbation in the past 6-months.  
To our knowledge, this is the first direct evaluation of MRI and LCI ventilation 
heterogeneity and their relationship with asthma control.  Similar to previous imaging17,26 
and multiple-breath washout studies27 we observed abnormally heterogeneous ventilation 
that improved post-bronchodilator.  The strong correlation for LCI and VDP was not 
surprising.  The fact that there was no relationship for the post-bronchodilator change in 
VDP and LCI was not expected, but may be explained by a number of mechanistic 
differences in the measurements themselves.   
The temporal resolution of both approaches relative to the time constants for lung segment 
filling and emptying are important to consider.  For example, inert gas washout 
measurements are made over a time-course of many minutes of normal tidal breathing and 
based on the time needed to exchange N2 with O2 in lung regions accessible to inhaled gas.  
In contrast, MRI ventilation defects are typically measured during a single 8-10s inhalation 
breath-hold; hence, inhaled-gas MRI provides a rapid visual snapshot of where the inhaled 
gas goes when inhaled from FRC.  In the case of airway narrowing or gas trapping that are 
both common in severe asthma, long time constants for lung filling and emptying are 
expected and this may explain some of the differences for VDP and LCI observed here.    
In addition to temporal resolution differences, there may be differences in the apparent 
spatial resolution of the MBNW and MRI methods used.  In principle, LCI measurements 
may be influenced by any or all of the conducting and acinar lung zones.27  For ventilation 
MRI, there is somewhat coarse spatial resolution (3x3x15mm) and this may result in an 
underestimation of very small ventilation defects.  Supporting this notion, subjects S07 and 
S14 reported relatively well-controlled disease (ACQ=1.4 and 1.0) but abnormal LCI and 
relatively homogeneous MRI ventilation.  Another explanation, previously proposed,27 
suggests that even small ventilation defects may increase LCI well beyond the upper-limit 
of normal, resulting in an overestimation of disease severity.   Supporting this view, subject 
07 had an abnormal LCI (9.7) and only a single small hypo-ventilated region (VDP=2%).  
Importantly, this 55 yr old female was prescribed oral prednisone (7.5mg/day) and ICS 
(Budesonide > 1000µg), and was relatively well-controlled (ACQ=1.4).  We also observed 
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post-bronchodilator imaging improvements in patients in whom LCI did not change, such 
as in subject S04.  This 60 year old female reported very poor control (ACQ=4.3) and 
highly heterogeneous ventilation (VDP=35%; LCI=14.0) despite high-dose OCS 
maintenance therapy (prednisone 50mg/day) and ICS (Fluticasone propionate 
dose>1000µg).  Similar VDP responses have been reported in COPD patients with little or 
no bronchodilator reversibility measured using FEV1.
28   
The most important observation stemming from this study was the finding of significantly 
worse VDP in asthmatics with ACQ>2 and AQLQ<5 and a trend toward worse VDP in 
asthmatics with more frequent exacerbations.  These findings were not observed using LCI 
measurements, perhaps because of the small sample size and/or because LCI is a less 
sensitive measure of the underlying pathophysiology responsible for asthma control.  This 
novel imaging result was also supported by a significant relationship for VDP (and a trend 
for a significant relation for LCI) with ACQ score.   It is worth noting that a previous 
ventilation imaging study using single photon emission computerized tomography 
(SPECT), reported no relationship for ACQ score and ventilation.29  This discordant result 
may stem from the inherently low spatial resolution of SPECT or small sample size, or 
perhaps because the asthmatics in the previous study were well-controlled.  Previous 
seminal studies point to the clinical importance of airflow obstruction,30 airway 
inflammation,31 respiratory system reactance32 and inert-gas washout ventilation 
heterogeneity measurements of asthma.2,3  Yet, some of these measurements underestimate 
asthma pathophysiology because of their relative insensitivity to the peripheral airway 
abnormalities directly responsible for asthma symptoms and control.  In view of the 
limitations of conventional clinical asthma measurements, we think our results strongly 
support the use of pulmonary MRI in clinical research and in the management of severe 
asthmatics in whom control is difficult to achieve.   
We recognize a number of study limitations including the small number of study 
participants.  However, pulmonary imaging measurements are quite sensitive and therefore 
significant differences may be detected using small sample sizes.  Nonetheless, caution 
should be exercised in generalizing our results to a general asthma population.  We also 
acknowledge that asthma patients were recruited from two major tertiary care centres, so 
FeNO and sputum inflammometry were not available for the majority of patients.  If these 
152 
 
were available, we could try to tease out the relative contribution of luminal inflammation 
to ventilation heterogeneity and asthma control.  Furthermore, we did not (for logistical 
reasons) evaluate a comparator group of well-controlled asthmatics or asthmatics with 
more moderate disease.  Because of this, we could not ascertain the relative contribution 
of asthma severity to ventilation heterogeneity in this study, but this relationship was 
previously explored in well-controlled patients with mild to moderate asthma.15  It is 
noteworthy that there was no difference in ventilation heterogeneity for participants 
prescribed oral prednisone versus those who were not prednisone-dependent.   Postural 
effects should also be considered when comparing MRI and MBNW measurements of 
ventilation heterogeneity because imaging was performed supine, whereas MBNW was 
performed upright.  In one previous study, gas trapping was increased in supine asthmatic 
children but this was not the case for MBNW ventilation heterogeneity measurements.33  
Regardless, to mitigate and minimize postural effects including atelectasis, imaging was 
completed within 5 minutes, limiting the time that patients remained supine, which limits 
atelectasis.34   
While there is strong evidence that poor asthma control is associated with an increased risk 
for future severe asthma events35 and exacerbations,36 biomarkers that identify the source 
and regional location of poor control are generally lacking and many are not readily 
available except in highly specialized care centres, beyond the reach of the vast majority 
of asthma patients.  In this context, we note that MBNW biomarkers are more universally 
available and previously revealed the efficacy of aerosolized ultrafine steroid particles in a 
subset of asthma patients with abnormal acinar airways.10  Moreover, emerging biomarkers 
of airway inflammation have been proposed37 and used as therapy targets to significantly 
decrease asthma exacerbations.38-40  The results of our study argue for the continued 
development and use of novel and conventional ventilation heterogeneity biomarkers and 
measurements of asthma.   
In conclusion, in a small group of poorly-controlled severe asthmatics, MRI ventilation 
defects were significantly worse in the subgroup of patients with worse asthma control and 
quality-of-life.  Hence, regional ventilation defects may be considered as intermediate 
endpoints of asthma that can be used to evaluate therapies in relatively small studies that 
target improved asthma control and quality-of-life.   
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5.6 Supplementary Material  
Table 5-3S  Participant listing of demographic and other measurements. 
 Demographics  Questionnaires and Exacerbation History  Spirometry  Ventilation heterogeneity 
 Age Sex BMI  Duration ACQ   AQLQ Scores  Dyspnea Scores  Exacerbations ED visits Hospitalizations  FEV1 FVC FEV1/FVC  LCI VDP 
Subject (yrs) (M/F) (kg/m2)  (yrs) Score  Tota Acti  mMRC Borg  (n)* (n)* (n)*  Pre/Post(L) Pre/Post(L) Pre/Post(%)  Pre/Post Pre/Post(%) 
001 34 F 40  16 -  - -  - -  0/2 0/0 0/0  2.2/2.5 3.0/3.2 74/80  9.5/8.8 12/10 
002 67 M 28  7 -  - -  - -  0/0 0/0 0/0  3.1/3.4 4.8/5.0 66/68  12.6/8.8 11/6 
003 61 M 33  7 2.1  4.6 4.6  0.0 4.0  1/3 0/0 0/0  2.7/3.4 5.0/5.8 54/59  13.4/12.1 30/17 
004 60 F 33  39 4.3  3.2 2.7  3.0 9.0  2/4 0/2 0/0  1.0/0.9 2.1/2.0 46/46  14.0/14.4 35/20 
005 38 F 30  36 1.9  5.9 6.0  1.0 1.0  0/1 0/0 0/0  1.4/1.6 1.7/2.0 82/79  11.5/9.3 7/6 
006 45 M 25  44 2.7  4.7 4.6  1.0 1.0  0/0 0/0 0/0  1.5/1.6 3.3/3.4 44/47  11.5/10.6 14/11 
007 55 F 33  20 1.4  5.0 5.1  1.0 3.0  0/1 0/0 0/0  2.1/2.3 2.9/3.1 71/76  9.7/9.3 2/3 
008 47 F 30  34 2.3  5.3 5.3  2.0 2.0  2/5 1/1 0/0  3.0/3.0 3.7/3.6 80/83  6.3/7.1 2/2 
009 21 F 20  18 2.7  3.1 3.6  2.0 5.0  0/5 0/0 0/0  3.4/3.5 3.8/3.7 88/94  7.0/7.3 1/2 
010 45 F 31  41 1.6  4.0 4.9  0.0 0.5  4/18 0/0 0/0  3.0/3.3 3.8/3.8 78/86  7.4/6.6 4/1 
011 40 F 29  27 2.3  4.8 4.7  1.0 1.0  6/12 0/0 0/0  2.1/2.4 3.3/3.4 65/72  10.6/9.8 18/7 
012 31 F 37  28 2.0  5.8 5.8  2.0 1.0  3/4 0/3 0/1  0.9/1.4 2.3/3.1 42/46  13.4/NA 15/5 
013 56 M 25  55 3.1  4.2 4.4  - -  2/3 0/0 0/0  1.5/1.5 4.4/4.2 35/37  17.5/15.5 33/29 
014 44 F 27  23 1.0  5.6 5.6  1.0 0.5  0/1 0/0 0/0  2.9/3.0 3.8/3.9 74/79  7.7/7.3 3/2 
015 42 M 33  28 1.4  4.6 5.5  1.0 2.0  0/0 0/0 0/0  2.7/3.1 4.0/4.4 67/71  9.5/10.1 8/4 
016 48 M 30  46 2.3  5.5 6.4  0.0 3.0  0/1 0/0 0/0  2.9/3.2 4.2/4.4 69/72  8.6/8.2 8/8 
017 39 F 22  36 1.7  6.1 6.2  1.0 0.5  5/7 0/0 0/0  2.2/2.4 4.0/3.9 56/62  6.7/6.1 3/2 
018 59 F 23  57 4.3  1.7 2.4  3.0 4.0  4/8 0/1 0/0  1.4/1.6 1.9/2.7 71/58  11.6/11.0 15/16 
Mean 
(±SD) 
46 
(12) 
12F/ 
6M 
29 
(5) 
 31 
(15) 
2.3 
(0.9) 
 4.6 
(1.2) 
4.9 
(1.2) 
 1.3 
(1.0) 
2.5 
(2.3) 
 9(50%)/ 
15(83%) 
1(6%)/ 
4(22%) 
0(0%)/ 
1(6%) 
 2.2(0.8)/ 
2.5(0.8) 
3.5(1.0)/ 
3.6(1.0) 
65(15)/ 
68(16) 
 10.5(3.0)/ 
9.5(2.7) 
12(11)/ 
8(8) 
SD=standard deviation; M=Male; F=Female; BMI=body mass index; ACQ=asthma control questionnaire; AQLQ=asthma quality-of-
life questionnaire; Tota=Total; Acti=Activity; mMRC=modified Medical Research Council; ED=emergency department; FEV1=forced 
expiratory volume in 1 second; BD=bronchodilator; FVC=forced vital capacity; LCI=lung clearance index; VDP=ventilation defect 
percent. *in previous 6 months/in previous year. 
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Table 5-4S  Participant listing of asthma medications. 
 SABA  LABA  LAAC  ICS  OCS  LTRA  Anti-IgE 
Subject Generic  Generic Dose(µg/d)  Generic Dose(µg/d)  Generic Dose(µg/d)  Generic Dose(mg/d)   Generic Dose(mg/d)  Generic  Dose(mg) 
001 Salbutamol  Formoterol 12  -- --  Budesonide 400  Prednisone 4  -- --  -- -- 
002 Salbutamol  Formoterol 24  -- --  Budesonide 800  Prednisone 12.5  -- --  -- -- 
003 Salbutamol  Formoterol 24  Tiotropium 18  Budesonide 800  Prednisone 20  Montelukast 10  -- -- 
004 Salbutamol  Salmeterol 100  Tiotropium 18  Fluticasone 2500  Prednisone 50  Montelukast 10  -- -- 
005 Salbutamol  Formoterol 36  -- --  Budesonide/Beclometasone 1200/800  Prednisone 2.5  -- --  -- -- 
006 Salbutamol  Formoterol 20  Tiotropium 18  Mometasone furoate/Fluticasone 800/1000  -- --  Montelukast 10  -- -- 
007 Salbutamol  Formoterol 24  Tiotropium 18  Budesonide 1600  Prednisone 7.5  -- --  -- -- 
008 Salbutamol  Salmeterol 100  -- --  Fluticasone 1000  -- --  Montelukast 10  -- -- 
009 Terbutaline  Formoterol 24  -- --  Budesonide 800  -- --  Montelukast 10  -- -- 
010 Salbutamol  Salmeterol 100  -- --  Fluticasone 1500  -- --  Montelukast 10  -- -- 
011 Salbutamol  Formoterol 24  -- --  Budesonide/Ciclesonide 800/800  Prednisone 7.5  Montelukast 10  -- -- 
012 Salbutamol  Salmeterol 100  Tiotropium 18  Fluticasone/Ciclesonide 1000/400  Prednisone 3  Montelukast 10  -- -- 
013 Salbutamol  Salmeterol 100  Tiotropium 18  Fluticasone 1000  -- --  -- --  -- -- 
014 Salbutamol  Formoterol 24  -- --  Budesonide 800  -- --  -- --  -- -- 
015 Salbutamol  Formoterol 24  -- --  Budesonide 1200  -- --  -- --  -- -- 
016 Salbutamol  Formoterol 24  -- --  Budesonide/Ciclesonide 800/800  -- --  -- --  Omalizumab 150 
017 Salbutamol  Formoterol 24  -- --  Budesonide 800  -- --  Montelukast 10  -- -- 
018 Salbutamol  Formoterol 20  Aclidinium bromide 800  Mometasone furoate/Ciclesonide 800/800  -- --  -- --  -- -- 
SABA=Short-acting beta-agonist; LABA=Long-acting beta-agonist; LAAC=Long-acting anticholinergics; ICS=Inhaled 
Corticosteroids; OCS=Oral corticosteroids; LTRA=Leukotriene Receptor Antagonists; Anti-IgE=Anti-immunoglobulin E.
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CHAPTER 6 
6 Conclusions and Future Directions 
The final chapter of this thesis revisits our rationale and research objectives and provides 
a summary of the important findings and conclusions of Chapters 2-5.  Subsequently, study 
specific limitations, general limitations and potential solutions are presented.  Finally, a 
roadmap for future studies in asthma motivated by the work presented in this thesis will be 
outlined.   
6.1 Overview of Rationale and Research Questions 
The forced expiratory volume in one second (FEV1) currently plays an important role in 
the diagnosis and management of asthma; and it is also universally used as a primary 
endpoint of lung function in the majority of asthma clinical trials.1,2  However, FEV1 is a 
global measurement made at the mouth that cannot be used to ascertain regional lung 
function and it is relatively insensitive to subtle changes and peripheral airway pathology 
in asthma.3  For decades, the concept of regionally heterogeneous airway abnormalities in 
asthma has been acknowledged.  This regional heterogeneity was first noted in cadavers 
using post mortem ex vivo gross sections and histology.4  Shortly after, single-breath and 
multiple-breath washout studies in living patients were also indicative of ventilation 
heterogeneity in asthma, but due to the limitations of this technique, the regional site of 
functional abnormalities could not be ascertained.5  Accordingly, beyond specialized 
academic centres, it has been difficult to investigate asthmatics based on the suggested 
regional nature of their underlying pathology.  There has therefore been an urgent need for 
non-invasive and quantitative imaging methods to regionally evaluate asthma.   
In response to this demand, numerous imaging methods have been developed and are 
currently available to non-invasively evaluate asthma regionally,6 however, they are not all 
well-suited for serial and longitudinal investigations.  While CT is widely available and 
provides high spatial and temporal resolution images of lung structure7,8 and function,9 it 
is burdened by radiation exposure, a particular concern when evaluating asthmatic children 
and young adults.  Similarly, nuclear medicine methods are burdened by ionizing radiation 
exposure and are further limited by relatively poor spatial resolution.10-12    
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In contrast, functional MRI using hyperpolarized 3He and 129Xe is not limited by radiation 
exposure.  The recent development of this approach has demonstrated promise for 
functional imaging of asthma13 as it provides an opportunity to visualize, with high spatial 
and temporal resolution, those areas of the lung that participate in gas distribution and those 
that do not.  In healthy young adults, inhalation of hyperpolarized gas results in 
homogeneous signal suggesting that all areas of the lung are participating equally in 
ventilation.14-17  In contrast, characteristic ventilation defects are observed in asthma, 
corresponding to areas of the lung that are not ventilated within the time-course of a breath-
hold scan.13,18-27  Previous work using this technique provides a strong foundation for its 
use in asthma research and patient care; however, a major drawback is that the clinical and 
physiological meaning of MRI-derived ventilation defects is poorly understood.  
Furthermore, the heterogeneity of asthma is under appreciated by the medical community.  
Regardless of the gas used for imaging, a clear understanding of ventilation defects is 
absolutely necessary prior to the clinical translation of hyperpolarized gas imaging 
methods.  Therefore, in spite of the well-demonstrated potential for pulmonary imaging to 
provide a better understanding of the regional aspects of asthma, it currently takes on an 
insignificant role in asthma clinical care and treatment evaluation and guidance.    
Accordingly, the overarching objective of this thesis was to develop and apply novel 
pulmonary imaging methods to better understand asthma and to provide a foundation for 
functional imaging to guide clinical decisions and therapy in patients with asthma.  The 
specific research questions investigated here included: 1) Do the different properties of 
129Xe and 3He gas result in significant differences in 129Xe compared to 3He gas distribution 
before and after bronchodilator administration in well-controlled asthmatics? (CHAPTER 
2); 2) Can the inherent temporal and spatial pulmonary function information provided by 
hyperpolarized 3He MRI be used to visualize and quantify temporally persistent and 
intermittent ventilation defects as potential targets for therapy? (CHAPTER 3); 3) Are 
asthmatics with 3He MRI ventilation defects different from asthmatics without ventilation 
defects with respect their airway structure and standard clinical measurements of disease? 
(CHAPTER 4) and, 4) What is the relationship of asthma control with ventilation defects 
quantified and regionally visualized using 3He MRI? (CHAPTER 5).  
161 
 
6.2 Summary and Conclusions 
In Chapter 2, we quantitatively compared hyperpolarized 3He and 129Xe MRI in a small 
group of seven asthmatics before and after salbutamol inhalation.  Prior to salbutamol 
inhalation, 129Xe VDP (8±5%) was significantly greater than 3He VDP (6±5%, p=0.003).  
Post-salbutamol, there was a significant improvement in both 129Xe (5±4%, p<0.0001) and 
3He (4±3%, p=0.001) VDP, but the improvement in 129Xe VDP was significantly greater 
(p=0.008).  For a single asthmatic, a sub-segmental 129Xe MRI ventilation defect that was 
visible only prior to salbutamol inhalation but not visible using 3He MRI was spatially 
related to a remodeled airway (WA%=78%, LA=2.9 mm2).  These results indicate that 
hyperpolarized 129Xe MRI may help reveal ventilation abnormalities prior to 
bronchodilation that are not observed using hyperpolarized 3He MRI. 
In Chapter 3, we exploited the temporal and spatial information inherent to 3He MRI to 
generate pulmonary ventilation temporal-spatial maps that could be used to measure, 
optimize and guide asthma therapy.  In this proof-of-concept study, seven asthmatics 
underwent spirometry and 3He MRI on three occasions, each 5±2 days apart.  A registration 
and segmentation pipeline was developed to generate temporal-spatial pulmonary function 
maps.  This enabled the regional mapping of temporally persistent and intermittent 
ventilation defects that were normalized to the 1H MRI thoracic cavity volume to generate 
VDPP and VDPI.  Persistent and intermittent ventilation defects were identified and were 
strongly correlated with FEV1/FVC (VDPP: r=-0.87, p=0.01; VDPI: r=-0.96, p=0.0008). 
These findings suggest that temporal-spatial pulmonary maps generated from 3He MRI can 
be used to quantify temporally persistent and intermittent ventilation defects as asthma 
intermediate endpoints and targets for therapy.  
In Chapter 4, we evaluated well-established clinical as well as 3He MRI and x-ray CT 
airway measurements in eight healthy and 26 asthmatic subjects to better understand the 
determinants of 3He MRI ventilation defects in asthma.  Prior to broncho-provocation, 17 
asthmatics (17/26=65%) had visually obvious evidence of ventilation defects and nine 
asthmatics had no ventilation defects (9/26=35%).  Asthmatics with defects were older 
(p=0.01) with worse FEV1/FVC (p=0.0003), airways resistance (p=0.004), FeNO (p=0.03), 
lower PC20 (p=0.008), and wall thickness percent (p=0.02), compared to asthmatics without 
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defects.  We also identified a moderate correlation for wall area percent with VDP (r=0.43, 
p=0.04).  These results indicate that asthmatics with 3He MRI ventilation defects are older 
with significantly worse airway hyperresponsiveness, inflammation and airway 
remodeling in comparison to asthmatics without defects; and that hyperpolarized 3He 
ventilation abnormalities are spatially and quantitatively related to abnormally remodeled 
airways.   
In Chapter 5, we evaluated MBNW and MRI measurements of ventilation heterogeneity 
and their relationship with asthma control in 18 severe asthmatics.  Mean VDP was 
12±11% and LCI was 10.5±3.0 with both VDP (p=0.008) and LCI (p=0.02) improving 
post-bronchodilator.  While VDP was strongly correlated with LCI (r=0.86, p<0.0001), the 
post-bronchodilator change in VDP and LCI was not correlated (p=0.08).  There was 
significantly worse VDP but not LCI in asthmatics with ACQ >2 (p=0.04) and AQLQ<5 
(p=0.04).  Notably, VDP (but not LCI, p=0.052) was correlated with ACQ score (r=0.62, 
p=0.01).  MRI ventilation defects were significantly worse in severe asthma patients with 
poor asthma control and poor quality-of-life.  This is important, because as an intermediate 
endpoint, ventilation defects may be used to target therapy to improve clinically-important 
asthma outcomes.   
In summary, we have provided: 1) evidence that hyperpolarized 129Xe MRI may be more 
sensitive than 3He MRI to ventilation abnormalities; 2) a new method to quantify 
temporally persistent and intermittent ventilation defects that may be used as intermediate 
endpoints and targets for therapy; 3) evidence that asthmatics with 3He ventilation defects 
are older with significantly worse airway hyperresponsiveness, inflammation and airway 
remodeling in comparison to asthmatics without defects; and, 4) evidence that ventilation 
defects are significantly worse in severe asthmatics with poor asthma control and poor 
quality-of-life. 
6.3 Limitations 
In this section, some of the most significant limitations of the studies presented in Chapters 
2-5 are discussed.  It should be noted that a description of the study specific limitations are 
also presented within the discussion section of the respective Chapters.  In addition to 
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Chapter specific limitations, this section includes a description of general limitations 
common to Chapters 2-5. 
6.3.1 Study Specific Limitations 
Hyperpolarized 3He and 129Xe MRI: Differences in Asthma before Bronchodilation 
(Chapter 2) 
In the study presented in Chapter 2, thoracic CTs were not contemporaneously acquired 
and this limited our ability to investigate the relationship between lung structure and 
function.  However, for two of the seven asthmatics evaluated, partial thoracic CTs were 
acquired approximately one year before 3He and 129Xe MRI.  In a single asthmatic, we 
observed a large wedge shaped ventilation defect at baseline using 129Xe MRI but not using 
3He MRI; the defect was spatially related to a partially obstructed airway.  This 
serendipitous finding led us to hypothesize that 3He gas may penetrate lung regions through 
partially obstructed airways that 129Xe gas cannot access during a short breath-hold scan.  
Unfortunately, without whole lung thoracic CTs for all seven subjects we were unable to 
further investigate, and statistically evaluate, the relationship between abnormal airway 
pathophysiology and the differences between 3He and 129Xe gas distribution.   
Another limitation was that ventilation abnormalities, quantified as VDP, for the small 
group of mild-to-moderate asthmatics with well-controlled disease evaluated in this study 
were not large.  The mean pre-salbutamol VDP was low as compared to a previous study 
of asthma,22 but importantly was higher than previously reported values observed for 
healthy volunteers of a similar age.22  Accordingly, the differences in 3He and 129Xe 
ventilation defects reported here might be a conservative estimate of the differences that 
would be observed in a larger group of asthmatics with a range of disease severity.  Ideally, 
a range of mild, moderate and severe asthmatics would have been evaluated to ascertain if 
the differences observed between the two gases were dependent on disease severity.   
Similarly, we were unable to ascertain the clinical relevance of the improvement in both 
3He and 129Xe VDP following salbutamol inhalation.  This endeavor was not possible as 
clinically-relevant measurements such as dyspnea or exercise capacity were not collected 
at the time of study.  Importantly, however, the smallest detectable difference (SDD), 
defined as the smallest difference that can be measured with prospectively determined 
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confidence not due to measurement error (variability) has been previously calculated for 
3He MRI and the mean change in the 3He (0.11L) and 129Xe MRI (0.14L) ventilation defect 
volume measured in this study was greater than the SDD (0.05L).28  Although the SDD is 
not a measure of clinical relevance, this confirms that the changes detected were not due 
to measurement variability.  In future attempts to determine the clinical relevance of the 
changes detected using 3He and 129Xe MRI, we will evaluate the degree of dyspnea and/or 
exercise capacity in study participants.  
Pulmonary Functional Magnetic Resonance Imaging: Asthma Temporal-Spatial Maps 
(Chapter 3) 
In the longitudinal study presented in Chapter 3, we did not obtain well-established clinical 
measurements of asthma or x-ray CT, and therefore questions regarding the clinical 
relevance of our data could not be investigated.  Importantly, between visits we observed 
qualitative regional differences in the distribution of 3He gas within the lung.  These 
temporal differences, termed “intermittent defects” were quantified and visualized using 
the temporal-spatial pulmonary function maps.  Unfortunately, we were unable to ascertain 
whether these asthmatics experienced symptomatic worsening over the two weeks that 
could be attributed to their variable ventilation heterogeneity.  Furthermore, it would have 
been important to investigate the differences in CT-derived airway morphology for airways 
spatially related to intermittent defects, persistent defects and persistently-ventilated lung 
regions.      
The maps generated in this study captured the week-to-week lung function variability in a 
small group of seven asthmatics.  Previous work by de Lange and colleagues have 
demonstrated that the persistence of ventilation defects in asthma decreases with time.20  
Accordingly, it would be very important to evaluate these subjects over a longer period of 
time to determine whether the variability captured over a short two-week period is 
representative of the ventilation variability over longer periods of time, in the absence of 
an exacerbation.  Before these temporal abnormalities are used as therapy targets or as an 
intermediate endpoint, this concept will first need to be investigated.  
Another limitation of this study is that we currently do not know what “type” of ventilation 
defect, if any, is the best target for localized airway treatment in asthma.  For example, in 
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addition to the persistent and intermittent ventilation defects identified in this study, 
dynamic ROI that respond to broncho-provocation (methacholine/exercise) or 
bronchodilation (salbutamol) could potentially be excellent targets for localized treatment.  
It is important to note however that this study provided proof-of-concept results; with this 
segmentation and registration pipeline, the methodology can subsequently be uniquely 
tailored to probe a wide variety of ventilation defect behaviours over time or in response 
to treatment.  For example, the pipeline has been subsequently tailored to regionally 
quantify and visualize the temporal behaviour of ventilation defects in cystic fibrosis 
patients who underwent 3He MRI on two occasions over four years.29    
As a technical limitation, the temporal-spatial pulmonary function maps are susceptible to 
image registration errors that can have an effect on map interpretation.  Scan-to-scan 
variability/differences in lung volume and patient position in the MRI scanner, particularly 
patient tilting, make registration across visits particularly challenging.  Rotations out of 
plane are particularly cumbersome since our voxels have anisotropic dimensions (3.125 
mm x 3.125 mm, slice thickness 15 mm).  However, despite this limitation, we were able 
to achieve sufficient registrations between visits.  We do acknowledge, however, that there 
were a few regions identified along the periphery of the maps with intermittent ventilation 
that may be attributed purely to mismatches in image registration.  However, these 
occurrences were acknowledged and represent a very small percentage of the overall 
thoracic cavity volume.   
What are Ventilation Defects in Asthma? (Chapter 4) 
In the study presented in Chapter 4, we evaluated a relatively broad range of asthmatics 
who were not enrolled based on disease severity or symptoms.  Importantly, however, they 
were patients from an interdisciplinary (Allergy and Respirology) asthma care centre, were 
between 18 and 60 years of age and had a physician diagnosis of asthma and a positive 
methacholine challenge within the past five years.  The strength of this study would have 
been considerably improved if at least severity was documented based on the GINA 
treatment step score.  Furthermore, it would have been advantageous to quantify asthma 
control using one of the many asthma control questionnaires.  Unfortunately, the GINA 
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step score and asthma control questionnaires were not utilized in the asthma care clinic, 
nor the research study, and therefore could not be evaluated in this study. 
Another limitation of this study was the use of partial thoracic CTs that reduced the number 
of airways that could be quantified.  However, we strongly believe that whenever possible, 
lower dose partial CTs should be acquired and be used to quantify airway morphology in 
young subjects, in whom the benefit-risk ratio does not support more extensive CT 
imaging.  In spite of the partial and lower dose CT volume, we were able to generate 
quantitative information and showed there was a significant relationship between CT 
airway measurements and 3He MRI overall, and for specific defects and airways in certain 
cases.   
What do Ventilation Defects Reveal about Asthma Control? (Chapter 5) 
In the study presented in Chapter 5, we evaluated severe asthmatics who were poorly 
controlled but we did not include a control group of patients with less severe asthma but 
with the same degree of poor asthma control.  Accordingly, we could not ascertain the 
relative contribution of asthma severity and asthma control to ventilation defects.  In other 
words, we could not address the important question, "Is the same ventilation heterogeneity 
observed in milder asthmatics who are poorly controlled?"  Future studies are necessary to 
investigate this important question.  
Another limitation of this study was that MRI and MBNW measurements of ventilation 
heterogeneity were obtained in different positions, introducing the potential for postural 
effects.  Imaging was performed supine, whereas MBNW was performed upright and this 
may have influenced the strength of the demonstrated relationships between MRI and 
MBNW measurements of ventilation heterogeneity.  From previous experience, we have 
observed that MBNW measurements of ventilation heterogeneity are significantly worse 
when performed supine as compared to when performed upright.  Regardless, we took 
necessary steps to mitigate and minimize potential postural effects in this study.  
Specifically, imaging was completed within five minutes to limit the time that the patients 
had to remain supine, which has been shown to limit atelectasis.30   
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6.3.2 General Limitations 
One limitation to the studies presented in Chapters 2-5 was the small number of subjects 
evaluated, therefore, caution should be exercised in generalizing these results to the broader 
asthma population.  Importantly, however, hyperpolarized gas MRI measurements are 
quite sensitive and therefore, as demonstrated in these studies and many others, significant 
differences may be detected using small sample sizes.  Moreover, at the time of study 
initiation for the majority of these investigations, there was little prior MRI data in asthma 
available to help generate power calculations and so these were not performed.  Regardless, 
future studies should aim to evaluate larger groups of asthmatics to confirm the results 
observed in these studies.  
Pertinent to both Chapters 2 and 4, we acknowledge that the quantitative measurement of 
ventilation heterogeneity employed here, the COV, is likely affected by partial volumes 
inherent to both 3He and 129Xe MR images.  Errors induced by partial volumes have the 
potential to influence the accuracy of the COV estimations reported in Chapters 2 and 4.  
Our objective was not to develop a novel quantitative metric to evaluate ventilation 
heterogeneity; instead, a previously published method developed by Tzeng and colleagues 
was adopted.27  Edge and/or partial volume effects can be visualized in the cluster and COV 
maps of ventilation (Figure 2-1).  With respect to Chapter 2, in accordance with Tzeng and 
colleagues, we made the assumption that the elevated COV values observed toward the 
edges cancel out when images are compared, as this effect is present both pre- and post-
salbutamol.27  Therefore, although we acknowledge that edge and/or partial volume effects 
likely influence our COV maps, this does not influence or alter our overall conclusions 
which interrogated relative change. 
In Chapters 2-5 our attention was directed towards ventilation defects; however, it is well-
understood that ventilation visualized using hyperpolarized gas MRI is not binary.  The 
studies presented in this thesis have overlooked the potential clinical significance of lung 
regions in asthma that have signal hyper-intensity.  Many of the asthmatics evaluated in 
these studies have had a very heterogeneous MRI gas distribution with regions of hyper-
intense signal intensity in addition to ventilation defects.  We are interested in these regions 
of hyper-intense signal intensity and the physiological mechanisms that may cause them.  
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These regions may be due to hyperinflation and therefore may indicate underlying 
structural abnormalities within the asthmatic lung.  The same semi-automated 
segmentation image analysis software employed in these studies to quantify VDP can be 
used to quantify the gradation of signal intensity observed in hyperpolarized gas MR 
images.28  This analysis method segments static ventilation images using a k-means 
clustering algorithm that classifies voxel signal intensity values into five clusters and is 
therefore able to quantify hyper-intense signal regions.  In future studies, it will be 
important to investigate these regions in addition to ventilation defects.  
Another important limitation to this work in general is the limited 3He access, and the high 
cost of 3He gas that has thus far restricted translation of this imaging method beyond 
specialized MR physics centres.  As previously discussed, this shortage is forcing the noble 
gas MRI community to transition to 129Xe gas, a less expensive and more readily available 
contrast agent.  While both 3He and 129Xe MRI were acquired within a five-minute period 
for the study presented in Chapter 2, the remaining study designs (Chapters 3-5) did not 
include 129Xe MRI.  In Chapter 2, significantly greater 129Xe as compared to 3He ventilation 
defects were observed in asthma, suggesting that 129Xe gas may be more sensitive to airway 
abnormalities than 3He gas.  Although this increased sensitivity is advantageous moving 
forward, the observed difference suggests that our findings presented in Chapters 3-5 using 
3He gas may not be a direct reflection of what would be observed using 129Xe gas.  For 
example, in Chapter 4 we observed that 65% of well-controlled asthmatics had 3He 
ventilation defects.  If this study were to be repeated using 129Xe MRI, one might 
hypothesize that ventilation defects would be visually obvious in nearly 100% of the same 
asthmatics.  Similarly, in Chapter 3, one might hypothesize that 129Xe MRI temporal-spatial 
pulmonary function maps of the same asthmatics would have increased intermittent and 
persistent ventilation defects.  Regardless of this speculation, future 129Xe MRI studies are 
required to validate the results presented here using 3He MRI.  Moreover, future research 
and potential clinical applications of noble gas MRI will most definitely utilize 129Xe gas.  
In accordance with this trajectory, relevant studies that are currently underway at the 
Robarts Research Institute are now using 129Xe MRI.       
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6.4 Future Directions 
6.4.1 Functional MRI of Ventilation in Asthma: Sensitivity, Specificity 
and Comparison with FEV1  
Our results presented in Chapters 4 and 5 indicate that asthmatics with worse MRI 
ventilation, but not FEV1, have worse asthma control, greater airways resistance and 
greater airway hyperresponsiveness.  These results strongly support the notion that MRI 
ventilation defects may be more sensitive than FEV1 to structural and functional changes 
in the asthmatic lung.  Moreover, it is well-understood that FEV1 is relatively insensitive 
to structural and functional changes in the small airways <2mm.31  Taken together, the 
work presented in this thesis and previous work of others using hyperpolarized 3He and 
129Xe MRI provides a strong foundation for the use of MRI in asthma research and clinical 
care.  To accelerate clinical translation and regulatory approval of hyperpolarized gas MRI, 
studies must be performed to validate MRI-derived measurements of ventilation against 
clinical gold-standards, such as FEV1.    
We have performed preliminary analysis in a small proof-of-concept study in which 
spirometry, hyperpolarized 3He MRI and a methacholine challenge were performed in a 
single visit.  We wanted to evaluate and compare the performance of FEV1 and 
3He MRI 
VDP to discriminate: 
1. Patients with a clinical diagnosis of asthma from healthy volunteers 
2. Patients with and without bronchial hyperresponsiveness  
We speculated that MRI ventilation defects may be a more accurate predictor of asthma 
and bronchial hyperresponsiveness than FEV1.  Preliminary data was obtained for 34 
subjects (Asthma: n=25, Healthy: n=9) who performed spirometry, hyperpolarized 3He 
MRI, and a methacholine challenge during a single study visit.  Receiver-operating 
characteristic (ROC) curves were used to characterize the performance of FEV1 and MRI 
VDP as predictors of asthma and bronchial hyperresponsiveness (Figure 6-1).  Optimum 
diagnostic cut-offs were determined according to the maximum Youden’s index value 
(J=sensitivity+specificity-1) and the corresponding sensitivity, specificity, positive and 
negative likelihood ratios were calculated. 
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As shown in Figure 6-1, similar to FEV1, MRI measurements of ventilation discriminated: 
1) patients with a clinical diagnosis of asthma from healthy volunteers (AUCFEV1=0.82, 
p=0.006; AUCMRI VDP=0.79, p=0.01); and 2) patients with and without bronchial 
hyperresponsiveness (AUCFEV1=0.83, p=0.0009; AUCMRI VDP=0.88, p=0.0002).  
Importantly, estimated likelihood ratios suggested that the most accurate diagnosis of 
asthma and bronchial hyperresponsiveness was established using 3He MRI, not FEV1.  
These preliminary results validated functional MRI against FEV1, a clinically-accepted 
measurement of asthma, and this is a necessary step towards clinical translation and 
regulatory approval.  As demonstrated in Chapter 2 of this thesis, 129Xe MRI is more 
sensitive to ventilation abnormalities in asthma than 3He MRI.  Accordingly, next steps 
require a similar but larger scale validation study of 129Xe MRI in asthma.   
 
Figure 6-1  Performance of FEV1 and 
3He MRI VDP as predictors of asthma (left plot) 
and bronchial hyperresponsiveness (right plot). 
Receiver-operating characteristic curves show the sensitivity, specificity and area under 
the curve for FEV1 (solid black line) and
 3He MRI VDP (broken blue line).  
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6.4.2 Efficacy of Functional MRI Guided Bronchial Thermoplasty  
We now have an understanding of the underlying structural determinants of regional 
ventilation defects observed using MRI in asthma.  The proof-of-concept results presented 
in Chapter 4 strongly support the notion that MRI ventilation defects are directly related to 
abnormally remodeled airways that are regionally heterogeneous in the asthmatic lung.  
Therefore, we speculate that abnormally remodeled airways, proximal to MRI ventilation 
defects, may be excellent targets for localized asthma treatment.  In a similar fashion, 
normally functioning airways, proximal to well or normally-ventilated lung regions could 
be avoided during localized treatment.  Current asthma treatments aim to treat all accessible 
airways.   
Bronchial thermoplasty (BT), an established localized asthma treatment, aims to 
permanently reduce smooth muscle mass in the lobar and segmental bronchi with the goal 
of improving symptoms and asthma control.32  To date, the effectiveness and safety of BT 
has been evaluated in four clinical trials,33-36 and this work has demonstrated persistent 
improvement in asthma control, quality-of-life and fewer exacerbations following 
treatment in some patients.  Despite its demonstrated safety and efficacy, BT is a time-
consuming procedure.  The current conventional whole-lung treatment approach targets all 
accessible airways throughout the lungs during three bronchoscopy sessions, each 
separated by approximately three weeks.  Accordingly, the treatment assumes that all 
airways in the asthmatic lung are homogeneously remodeled, which may result in treatment 
of normally functioning airways.  If a personalized, image-guided treatment approach were 
to be adopted that targeted only abnormally functioning airways, treatment time, cost and 
adverse effects might be reduced while patient outcomes may be improved. 
In a study currently underway, we aim to use pulmonary functional MRI to guide BT 
treatment, evaluate BT treatment response and to generate new knowledge required to 
better understand airway-targeted therapy in severe asthma.  All participants will have 
severe asthma and will undergo up to three pre-therapy MRIs to evaluate ventilation 
reproducibility and post-prednisone effects, and there will also be two longitudinal post-
therapy MRIs to evaluate treatment effect.  All participants will be randomized to MRI-
directed or conventional BT and we will measure airway function and treatment response 
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using conventional and imaging tests as well as questionnaires that capture how well 
asthma is controlled and how patients are feeling.   
For those participants randomized to the MRI-directed treatment arm, patient-specific BT 
treatment plans will be developed to identify specific airways to be targeted during a single-
session BT treatment procedure.  Briefly, low-dose thoracic CT will be used to generate a 
detailed three-dimensional model of the airway tree.  Following CT, all subjects will 
undergo further MR imaging following methacholine challenge or salbutamol inhalation.  
As shown for a representative subject in Figure 6-2, the post-challenge MRI will be co-
registered to the low-dose CT with airway rendering to enable spatial comparisons between 
ventilation defects and airways. Patient-specific treatment plans will identify target 
airways, prioritized in order of importance and grouped by lobe to be targeted.  Airways 
demonstrating dynamic or static bronchoconstriction will be targeted based on their spatial 
proximity to ventilation defects. 
 
 
Figure 6-2 Spatial relationship between 3He MRI ventilation (blue), ventilation defects 
(green) and airways (yellow) for a representative subject with severe asthma three days 
prior to BT while on 50 mg of prednisone.  
3He MRI registered to the CT of the thorax (in grey-scale) with the airways segmented in 
yellow to identify airways demonstrating dynamic bronchoconstriction following 
methacholine challenge to be targeted for treatment based on their spatial proximity to 
ventilation defects.  
This study will address the following research questions: 
1) Do regional ventilation defects resolve following BT?  
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2) What is the relationship between ventilation defects and patient outcomes following 
BT? 
3) Can MRI-guided BT treatment to specific abnormal airways result in improved 
asthma control and quality-of-life?  
4) Are patient outcomes related to image-guided BT significantly different than those 
achieved using the conventional treatment approach? 
5) Can MRI identify characteristic ventilation defects that predict BT response? 
One functional MRI study, evaluating seven severe asthmatics, has provided promising 
preliminary evidence supporting the notion that MRI ventilation defects decrease after BT 
treatment.37  Our study will be the first to evaluate the effect of a localized airway 
intervention on regional ventilation visualized using MRI in asthma.  The use of functional 
MRI in this context will provide a better understanding of BT treatment, providing a 
foundation of knowledge for studies aimed at assessing the ability of imaging methods to 
guide localized treatment to only abnormally-functioning airways.  We hypothesize that 
treatment of only specific abnormal airways, proximal to MRI ventilation defects, will 
result in improved MRI gas distribution, airway hyperresponsiveness, asthma control and 
quality-of-life that is not significantly different from patients in the conventional therapy 
group.  We also hypothesize that improved ventilation will be related to improvements in 
well-established clinical measurements of asthma.   
6.4.3 Imaging Exercise-induced and Methacholine-induced 
Bronchoconstriction using Hyperpolarized Gas MRI: Same 
Ventilation Defects or Not?  
Airway hyperresponsiveness is a universal defining feature of asthma.38  It is currently 
measured clinically to aid in the diagnosis and management of asthma, and is often 
employed in clinical trials to evaluate the effectiveness of novel asthma therapies.  Airway 
hyperresponsiveness can be assessed using both direct and indirect stimuli which induce 
bronchoconstriction via different mechanistic pathways; however, these differences are 
poorly understood.39  A better understanding of airway hyper-responsiveness and the 
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mechanisms that contribute to this process in asthma is required to achieve better patient 
outcomes.  
3He MRI has been used to visualize regionally heterogeneous ventilation in response to 
both exercise-23 and methacholine-induced22,23 bronchoconstriction, suggesting that not all 
airways respond to provocation equally.  However, the spatial relationship between 
exercise- and methacholine-induced ventilation defects has not been investigated in the 
same asthmatics.  In other words, it is currently unknown if the same airways in asthma 
respond in a similar manner to both indirect and direct stimuli.  It has been hypothesized 
that clinical assessments of airway hyperresponsiveness induced by indirect methods 
correlate better with the clinical features of asthma.40  This hypothesis has not been tested 
using MRI, therefore it is unknown whether indirect or direct stimuli induced ventilation 
defects correlate more strongly with the clinical features of asthma.  If non-invasive 
imaging measurements are going to be used as intermediate endpoints in clinical trials of 
new therapies, we think future MRI studies should investigate these concepts. 
By acquiring pulmonary CT and well-established clinical measurements of asthma in 
addition to performing MRI following both exercise and methacholine challenge in the 
same asthmatics, the following research questions can be addressed: 
1) Are MRI ventilation defects observed in the same focal lung regions following 
exercise- and methacholine-induced bronchoconstriction in asthma?  
2) Are exercise- or methacholine-induced MRI ventilation defects more strongly 
correlated with well-established clinical measurements of asthma? 
3) Are CT-derived measurements of airway structure different for those airways 
proximal to ventilation defects observed following methacholine and exercise 
induced bronchoconstriction?   
Comparative imaging studies have the potential to provide a better understanding of the 
underlying mechanisms involved in airway hyperresponsiveness, and in turn provide a 
better understanding of potential treatment targets in asthma.  So far at our centre, four 
asthmatics have undergone MR imaging prior to and following both exercise- and 
methacholine-induced bronchoconstriction.  Imaging results from one of the four 
asthmatics is shown in Figure 6-3.  Preliminary data suggests that exercise and 
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methacholine-induced bronchoconstriction will induce a similar decrease in well-
established clinical measurements of asthma; however, visually obvious regional 
differences in gas distribution will be observed using MRI that cannot be detected by 
spirometry.   
 
Figure 6-3  Representative coronal centre slice hyperpolarized 3He MRI of an asthmatic 
subject at baseline and following both methacholine and exercise-induced 
bronchoconstriction.   
3He MRI gas distribution (in blue) registered to the 1H MRI of the thorax (in grey-scale). 
Ventilation abnormalities are present at baseline that become worse following 
methacholine- and exercise-induced bronchoconstriction.  
6.4.4 Functional MRI of Asthma: Alternative Approaches  
It is well-established that direct visualization of the lung airspaces using functional MRI is 
important and that it and provides numerous advantages over clinically available tools.  
Motivating the work presented in Chapter 2, 3He MRI is not well-suited to be a widely 
available clinical tool due to the limited availability of 3He gas.41  This roadblock has 
initiated further development of 129Xe MRI and oxygen enhanced MRI,42 as well as 
motivated the need for alternative approaches to visualize lung function using non-
polarized inhaled gases and 1H MRI.  These emerging methods come with tradeoffs 
regarding cost, access and importantly, image quality.  
Fluorine-19 (19F) MRI of the lungs uses inert fluorinated gases (e.g. tetrafluoromethane 
(CF4), sulfur hexafluoride (SF6), perfluoropropane (C3F8 or PFP)) and may offer 
comparable regional lung function information to hyperpolarized gas MRI, but at a much 
lower cost.43-46  This approach to functional lung imaging has the advantage of using gases 
that are inexpensive, abundant and do not need to be polarized prior to their use.  Halaweish 
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and colleagues have been the first to apply this approach in patients with asthma, 
demonstrating its sensitivity to ventilation defects in two subjects.44   
Free-breathing pulmonary 1H MRI is another approach currently being developed with the 
ability to evaluate lung function.47-50  Fourier decomposition of the 1H signal intensity 
acquired during tidal breathing was introduced by Bauman and colleagues to generate 
ventilation and perfusion images.47  This unique approach does not require a contrast agent 
and can be implemented on the majority of clinical scanners without the requirement for 
specialized multi-nuclear hardware; however, it is limited by cumbersome post-processing.  
Unlike 19F MRI, this approach has not yet been evaluated in patients with asthma.   
With these promising alternative functional MRI approaches in the pipeline, future studies 
are required to investigate their utility in the asthmatic population.  Specifically, initial 
investigations should be focused towards direct qualitative and quantitative comparisons 
of ventilation abnormalities derived from these alternative approaches with those identified 
using hyperpolarized gas MRI.  Such proof-of-concept demonstrations are currently 
underway in COPD51 and should be emulated in asthma.  One major advantage of these 
alternative functional MRI approaches is their direct translational ability as they can be 
implemented in most medical imaging centres with access to a clinical MRI scanner.  This 
advantage is fundamentally important, making these alternative functional MRI 
approaches more likely to find a place in the clinical setting.  
6.5 Significance and Impact 
Even though it is well-understood that FEV1 does not reflect the regional nature of asthma, 
the assessment of novel therapies and disease management continues to depend on this 
global metric.  Using hyperpolarized gas MRI, heterogeneous ventilation defects are 
observed and the regional, patient-specific nature of asthma can be safely and non-
invasively visualized – providing information that is not available using alternative clinical 
methods.  This thesis significantly advances our understanding of the structural 
determinants of MRI ventilation defects identified in asthma and what it means clinically 
to be an asthmatic with ventilation defects.  The studies presented in this thesis provide 
strong evidence that ventilation defects in asthma are not random, but are heterogeneously 
distributed in the lungs, spatially related to airway abnormalities and are related to worse 
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clinical characteristics of asthma including airway hyperresponsiveness, airway 
inflammation, airflow obstruction and disease control.  It is also now well-understood that 
129Xe MRI is more sensitive to airway abnormalities in asthma than 3He MRI, which is 
important for future clinical translation of this imaging method beyond specialized 
academic centres.   
This thesis confirms that regional ventilation defects are a clinically relevant imaging-
based biomarker of asthma and provides a foundation of knowledge supporting the need 
for clinical integration of functional MRI.  Armed with this understanding, there is 
enormous potential for MRI ventilation defects to be used as intermediate endpoints of 
asthma that can be used to evaluate novel treatments and to better inform treatment 
decisions.  Furthermore, the development of novel asthma treatments may be directed 
towards focal ventilation defects.  Hence, there is the potential for functional MRI to guide 
validated localized airway treatments, such as bronchial thermoplasty, to abnormal airways 
that lead to ventilation defects.  These advances in our understanding of asthma may very 
likely impact asthma management and how new treatment will be developed and evaluated.  
By “seeing” asthma and how it regionally responds to treatment and provocation, and how 
it changes over time, there is increased potential for more effective treatments, reduced 
treatment time, and improved patient outcomes.   
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